{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement.pdf",
  "annotations": [
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Sekisui Diagnostics, LLC and its Affiliates",
      "page_number": 0,
      "words": [
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Qualigen, Inc. and its Affiliates",
      "page_number": 0,
      "words": [
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Sekisui",
      "page_number": 0,
      "words": [
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Qualigen",
      "page_number": 0,
      "words": [
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "May 1, 2016",
      "page_number": 0,
      "words": [
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Expiration Date_1",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless earlier terminated pursuant to Section 14 hereof (the \"Term\").",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Renewal Term_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
      "answer_text": "The initial term of this Agreement and any renewal term thereof shall be automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Renewal Term_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
      "answer_text": "The initial term of this Agreement and any renewal term thereof shall be automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Notice Period To Terminate Renewal_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Notice Period To Terminate Renewal\" that should be reviewed by a lawyer. Details: What is the notice period required to terminate renewal?",
      "answer_text": "The initial term of this Agreement and any renewal term thereof shall be automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this Agreement",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Notice Period To Terminate Renewal_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Notice Period To Terminate Renewal\" that should be reviewed by a lawyer. Details: What is the notice period required to terminate renewal?",
      "answer_text": "The initial term of this Agreement and any renewal term thereof shall be automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this Agreement",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Governing Law_0",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, without reference to its conflicts of laws principles.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Exclusivity_0",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Qualigen shall supply Sekisui with all of Sekisui's commercial requirements for the Product in the Applicable Markets.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Exclusivity_0",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the Products exclusively to Sekisui, in each case for the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__No-Solicit Of Customers_0",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Customers\" that should be reviewed by a lawyer. Details: Is a party restricted from contracting or soliciting customers or partners of the counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "Sekisui shall not, and shall cause its subdistributors not to, market, rent or sell any Products to the Qualigen Retained Customers. 3. Supply;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__No-Solicit Of Customers_0",
      "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Customers\" that should be reviewed by a lawyer. Details: Is a party restricted from contracting or soliciting customers or partners of the counterparty, whether during the contract or after the contract ends (or both)?",
      "answer_text": "However, Qualigen shall not engage any distributors (whether exclusive or non-exclusive) other than Sekisui for the Qualigen Retained Customers",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Termination For Convenience_6",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "at any other time upon ninety (90) days' prior written notice of impending termination.",
      "page_number": 6,
      "words": [
        {
          "text": "4.4.",
          "bbox": [
            359.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9998838901519775
        },
        {
          "text": "Sales Expense; Business Plan. For the avoidance of doubt, Sekisui shall be responsible for all sales and related sales expense except",
          "bbox": [
            531.0,
            254.0,
            3029.0,
            300.0
          ],
          "confidence": 0.9895469546318054
        },
        {
          "text": "for Qualigen Retained Customers. The Business Plan sets forth Sekisui's plans for the sale and distribution of the Products, including",
          "bbox": [
            529.0,
            312.0,
            3029.0,
            358.0
          ],
          "confidence": 0.9996442794799805
        },
        {
          "text": "target budget and resource allocations for the marketing and sales of the Products and estimated forecasts of sales to customers.",
          "bbox": [
            531.0,
            371.0,
            3025.0,
            413.0
          ],
          "confidence": 0.9952583909034729
        },
        {
          "text": "Sekisui shall in good faith use commercially reasonable efforts, in conformance with good commercial practice and standards,",
          "bbox": [
            527.0,
            424.0,
            3025.0,
            468.0
          ],
          "confidence": 0.9957903027534485
        },
        {
          "text": "government regulations and other applicable requirements, to promote, market and sell the Products, to execute the Business Plan and.",
          "bbox": [
            527.0,
            477.0,
            3031.0,
            528.0
          ],
          "confidence": 0.9963300824165344
        },
        {
          "text": "to achieve its objectives. Except as set forth in Section 3.2, such forecasts and budgets are intended for guidance purposes only and",
          "bbox": [
            527.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.9968500137329102
        },
        {
          "text": "are not binding obligations. Sekisui shall be responsible for bad debt (customer nonpayment) and credit card merchant fees and",
          "bbox": [
            526.0,
            592.0,
            3029.0,
            638.0
          ],
          "confidence": 0.9950969815254211
        },
        {
          "text": "expenses.",
          "bbox": [
            529.0,
            652.0,
            713.0,
            695.0
          ],
          "confidence": 0.9930500388145447
        },
        {
          "text": "4.5.",
          "bbox": [
            359.0,
            704.0,
            430.0,
            747.0
          ],
          "confidence": 0.9999474287033081
        },
        {
          "text": "Financing Payments; Development Plan. In addition to the payments for the purchase of Products set forth in Section 4.1 above, in",
          "bbox": [
            529.0,
            709.0,
            3025.0,
            746.0
          ],
          "confidence": 0.9943293929100037
        },
        {
          "text": "connection with this Agreement and in furtherance of the Development Plan, Sekisui shall provide to Qualigen up to $6,200,o00 of",
          "bbox": [
            531.0,
            762.0,
            3032.0,
            804.0
          ],
          "confidence": 0.9927346706390381
        },
        {
          "text": "financing in accordance with the timing and other provisions of the Development Plan and the achievement of the applicable",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            861.0
          ],
          "confidence": 0.99497389793396
        },
        {
          "text": "milestones set forth therein (the \"Financing Payments'). All such Financing Payments shall be used in accordance with the",
          "bbox": [
            529.0,
            875.0,
            3029.0,
            917.0
          ],
          "confidence": 0.9900002479553223
        },
        {
          "text": "Development Plan and shall be non-refundable once paid, other than as set off in connection with a Sale Transaction as further",
          "bbox": [
            531.0,
            934.0,
            3027.0,
            970.0
          ],
          "confidence": 0.9940288662910461
        },
        {
          "text": "described below. Time is of the essence for the payment by Sekisui of the resulting Financing Payments upon confirmation of.",
          "bbox": [
            529.0,
            987.0,
            3034.0,
            1031.0
          ],
          "confidence": 0.9924401640892029
        },
        {
          "text": "achievement by Qualigen of the respective Development Plan milestones as set forth in Section 6.2 and the Development Plan.",
          "bbox": [
            529.0,
            1043.0,
            2878.0,
            1085.0
          ],
          "confidence": 0.9938642382621765
        },
        {
          "text": "4.6.",
          "bbox": [
            359.0,
            1096.0,
            428.0,
            1140.0
          ],
          "confidence": 0.9985026121139526
        },
        {
          "text": "Personnel Matters. Sekisui shall offer employment to four Qualigen sales representatives to become employees of Sekisui with",
          "bbox": [
            527.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.9925117492675781
        },
        {
          "text": "primary responsibility for the sale of the Products, and Qualigen hereby consents to and permits such employment. Such offers of",
          "bbox": [
            526.0,
            1151.0,
            3034.0,
            1202.0
          ],
          "confidence": 0.9893380403518677
        },
        {
          "text": "employment are subject to Sekisui's employment policies, including the successful completion of customary background checks, and",
          "bbox": [
            529.0,
            1210.0,
            3029.0,
            1255.0
          ],
          "confidence": 0.998411238193512
        },
        {
          "text": "are not a guarantee of ongoing employment. Upon the expiration or termination of the Term (other than in connection with a Sale",
          "bbox": [
            526.0,
            1266.0,
            3029.0,
            1312.0
          ],
          "confidence": 0.9887347221374512
        },
        {
          "text": "Transaction in which Sekisui acquires Qualigen), Sekisui shall cooperate in permitting Qualigen to offer to rehire any Sekisui sales",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9966340661048889
        },
        {
          "text": "representatives who are primarily responsible for selling the Products. A sales person \"primarily responsible for selling the Products\"",
          "bbox": [
            526.0,
            1378.0,
            3027.0,
            1422.0
          ],
          "confidence": 0.9928828477859497
        },
        {
          "text": "is one that spends more than half of his or her time and receives more than half of his or her commission based compensation based",
          "bbox": [
            527.0,
            1436.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9927029013633728
        },
        {
          "text": "on sales of the Products.",
          "bbox": [
            529.0,
            1491.0,
            991.0,
            1533.0
          ],
          "confidence": 0.9974746704101562
        },
        {
          "text": "4.7.",
          "bbox": [
            356.0,
            1542.0,
            430.0,
            1592.0
          ],
          "confidence": 0.9998869895935059
        },
        {
          "text": "Invoice Terms. Sekisui shall pay for each Product sold by Qualigen within 30 days after Sekisui has received the applicable invoice",
          "bbox": [
            527.0,
            1548.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9901339411735535
        },
        {
          "text": "from Qualigen.",
          "bbox": [
            527.0,
            1606.0,
            801.0,
            1645.0
          ],
          "confidence": 0.9993689656257629
        },
        {
          "text": "4.8.",
          "bbox": [
            359.0,
            1657.0,
            430.0,
            1705.0
          ],
          "confidence": 0.9626007080078125
        },
        {
          "text": "Marketing Claims. Sekisui covenants to Qualigen that Sekisui will not make any written or oral representation or marketing claim",
          "bbox": [
            529.0,
            1661.0,
            3025.0,
            1701.0
          ],
          "confidence": 0.9921669960021973
        },
        {
          "text": "(either formal or informal) about any Product's capabilities or characteristics other than those representations and claims that are fully",
          "bbox": [
            531.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9922473430633545
        },
        {
          "text": "and directly supported by factual materials provided by Qualigen to Sekisui. Sekisui shall not make any false or misleading",
          "bbox": [
            529.0,
            1773.0,
            3029.0,
            1816.0
          ],
          "confidence": 0.9965982437133789
        },
        {
          "text": "representations to customers or others regarding Qualigen or the Products. Sekisui shall not make any representations, warranties or",
          "bbox": [
            527.0,
            1831.0,
            3030.0,
            1873.0
          ],
          "confidence": 0.9925045967102051
        },
        {
          "text": "guarantees with respect to the specifications, features or capabilities of the Products that are not contained within Qualigen's",
          "bbox": [
            527.0,
            1882.0,
            3027.0,
            1932.0
          ],
          "confidence": 0.9993694424629211
        },
        {
          "text": "documentation accompanying the Products or Qualigen's literature describing the Products, including Qualigen's standard limited",
          "bbox": [
            529.0,
            1942.0,
            3029.0,
            1986.0
          ],
          "confidence": 0.9991266131401062
        },
        {
          "text": "warranty and disclaimers.",
          "bbox": [
            531.0,
            1999.0,
            1001.0,
            2039.0
          ],
          "confidence": 0.9992899298667908
        },
        {
          "text": "7",
          "bbox": [
            1638.0,
            2054.0,
            1669.0,
            2090.0
          ],
          "confidence": 0.998302698135376
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938657283782959
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Termination For Convenience_7",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "Sekisui may terminate this Agreement upon prior written notice",
      "page_number": 7,
      "words": [
        {
          "text": "4.9.",
          "bbox": [
            359.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9999215602874756
        },
        {
          "text": "Taxes. Qualigen's stated Product prices do not include any foreign, federal, state or local sales taxes that may be applicable to the",
          "bbox": [
            531.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9932553768157959
        },
        {
          "text": "Products, but in the event that such sales taxes are applicable and Qualigen has the legal obligation to collect such sales taxes (or are",
          "bbox": [
            529.0,
            314.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9822651743888855
        },
        {
          "text": "sales taxes imposed on a seller), Qualigen shall be entitled to add to its invoice the amount of such sales taxes and Sekisui shall pay",
          "bbox": [
            527.0,
            365.0,
            3025.0,
            415.0
          ],
          "confidence": 0.9954785108566284
        },
        {
          "text": "such amount unless Sekisui provides Qualigen with a valid tax exemption certificate authorized by the appropriate taxing authority. As",
          "bbox": [
            529.0,
            428.0,
            3029.0,
            470.0
          ],
          "confidence": 0.9964900016784668
        },
        {
          "text": "between the Parties, all customs duties shall be the responsibility of Sekisui, and all duty expenses will be included as an element of",
          "bbox": [
            527.0,
            479.0,
            3032.0,
            524.0
          ],
          "confidence": 0.9918721318244934
        },
        {
          "text": "COGS as referenced in Exhibit A and will be included as part of the Actual Margin True-Up as defined in Exhibit D. The parties agree",
          "bbox": [
            527.0,
            535.0,
            3027.0,
            581.0
          ],
          "confidence": 0.9950875043869019
        },
        {
          "text": "to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of",
          "bbox": [
            531.0,
            596.0,
            3027.0,
            632.0
          ],
          "confidence": 0.9928668141365051
        },
        {
          "text": "Financing Payments, Product purchase payments, and other payments made by Sekisui to Qualigen under this Agreement. To the",
          "bbox": [
            529.0,
            649.0,
            3025.0,
            693.0
          ],
          "confidence": 0.9906346797943115
        },
        {
          "text": "extent Sekisui is required to withhold taxes on any payment to Qualigen, Sekisui shall pay the amounts of such taxes to the proper",
          "bbox": [
            529.0,
            707.0,
            3029.0,
            751.0
          ],
          "confidence": 0.9893237948417664
        },
        {
          "text": "governmental authority in a timely manner and promptly transmit to Qualigen evidence of such payment and/or an official tax",
          "bbox": [
            527.0,
            758.0,
            3029.0,
            808.0
          ],
          "confidence": 0.9940901398658752
        },
        {
          "text": "certificate, or such other evidence as Qualigen may reasonably request, to establish that such taxes have been paid. Qualigen shall",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            861.0
          ],
          "confidence": 0.9870412349700928
        },
        {
          "text": "provide Sekisui any tax forms that may be reasonably necessary in order for Sekisui to not withhold tax or to withhold tax at a reduced",
          "bbox": [
            529.0,
            870.0,
            3029.0,
            919.0
          ],
          "confidence": 0.9935504198074341
        },
        {
          "text": "rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the",
          "bbox": [
            526.0,
            928.0,
            3029.0,
            974.0
          ],
          "confidence": 0.9866539835929871
        },
        {
          "text": "recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar obligations resulting from payments made",
          "bbox": [
            527.0,
            989.0,
            3029.0,
            1031.0
          ],
          "confidence": 0.9919902682304382
        },
        {
          "text": "under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.",
          "bbox": [
            529.0,
            1043.0,
            2740.0,
            1085.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "4.9.1.",
          "bbox": [
            446.0,
            1098.0,
            546.0,
            1138.0
          ],
          "confidence": 0.9987618923187256
        },
        {
          "text": "Medical Device Tax. The party responsible for paying any applicable medical device excise tax pursuant to Section 4191 of the.",
          "bbox": [
            607.0,
            1095.0,
            3029.0,
            1146.0
          ],
          "confidence": 0.9898098707199097
        },
        {
          "text": "U.S. Internal Revenue Code or any successor thereto will be as determined under such tax provisions. If any, such medical device",
          "bbox": [
            613.0,
            1153.0,
            3027.0,
            1197.0
          ],
          "confidence": 0.9912339448928833
        },
        {
          "text": "excise tax will be treated as a cost element to be included in COGS as referenced in Exhibit A..",
          "bbox": [
            616.0,
            1210.0,
            2333.0,
            1252.0
          ],
          "confidence": 0.989422619342804
        },
        {
          "text": "4.10.",
          "bbox": [
            357.0,
            1263.0,
            450.0,
            1310.0
          ],
          "confidence": 0.9101659655570984
        },
        {
          "text": "Interest. Accrual and payment of interest shall not be deemed to excuse or cure breaches of contract arising from late payment or",
          "bbox": [
            527.0,
            1268.0,
            3029.0,
            1310.0
          ],
          "confidence": 0.9960917234420776
        },
        {
          "text": "nonpayment. Cumulative with and not exclusive of any and all other available remedies, payments that are more than 30 days past due",
          "bbox": [
            527.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9941427111625671
        },
        {
          "text": "hereunder, and which are not otherwise subject to a good faith dispute, shall accrue interest, from the due date until paid, at an annual",
          "bbox": [
            526.0,
            1378.0,
            3029.0,
            1424.0
          ],
          "confidence": 0.9961178302764893
        },
        {
          "text": "rate equal to the prime rate, as reported in The Wall Street Journal, Eastern U.S. Edition, on the date such payment is due, plus an",
          "bbox": [
            526.0,
            1434.0,
            3029.0,
            1480.0
          ],
          "confidence": 0.9957613945007324
        },
        {
          "text": "additional 200 basis points (2%).",
          "bbox": [
            527.0,
            1489.0,
            1137.0,
            1535.0
          ],
          "confidence": 0.9987368583679199
        },
        {
          "text": "4.11.",
          "bbox": [
            359.0,
            1546.0,
            446.0,
            1588.0
          ],
          "confidence": 0.997421145439148
        },
        {
          "text": "Currency. All invoices under this Agreement shall be paid in United States dollars..",
          "bbox": [
            527.0,
            1548.0,
            2061.0,
            1590.0
          ],
          "confidence": 0.9967273473739624
        },
        {
          "text": "5.",
          "bbox": [
            274.0,
            1603.0,
            317.0,
            1645.0
          ],
          "confidence": 0.7983710169792175
        },
        {
          "text": "Manufacturing and Quality Assurance",
          "bbox": [
            446.0,
            1604.0,
            1184.0,
            1645.0
          ],
          "confidence": 0.9868720173835754
        },
        {
          "text": "5.1.",
          "bbox": [
            357.0,
            1656.0,
            431.0,
            1705.0
          ],
          "confidence": 0.9999219179153442
        },
        {
          "text": "Manufacturing Conformance. Qualigen represents and warrants that it shall manufacture all Products in accordance with the",
          "bbox": [
            531.0,
            1661.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9923285841941833
        },
        {
          "text": "applicable product specifications and all applicable federal, state and local laws, regulations, and guidelines. Qualigen represents and",
          "bbox": [
            531.0,
            1716.0,
            3029.0,
            1762.0
          ],
          "confidence": 0.9998115301132202
        },
        {
          "text": "warrants that no Product delivered by Qualigen under this Agreement will be adulterated or misbranded within the meaning of 21",
          "bbox": [
            529.0,
            1773.0,
            3025.0,
            1815.0
          ],
          "confidence": 0.9938739538192749
        },
        {
          "text": "U.S.C. Sections 351-352, or within the meaning of any other applicable law as such laws are constituted and effective at the time of",
          "bbox": [
            527.0,
            1826.0,
            3032.0,
            1871.0
          ],
          "confidence": 0.9836247563362122
        },
        {
          "text": "such shipment or delivery. Qualigen shall maintain appropriate certification status and compliance with the FDA's Quality System",
          "bbox": [
            531.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.999665379524231
        },
        {
          "text": "Regulation, the Directive of 27 October 1998 on In Vitro Diagnostic Medical Devices (IVDD) and/or all other applicable regulations.",
          "bbox": [
            529.0,
            1939.0,
            3020.0,
            1981.0
          ],
          "confidence": 0.9944262504577637
        },
        {
          "text": "Upon request, Qualigen shall furnish to Sekisui any such information required to enable Sekisui to comply with all applicable",
          "bbox": [
            529.0,
            1995.0,
            3027.0,
            2041.0
          ],
          "confidence": 0.9946947693824768
        },
        {
          "text": "regulations and standards that pertain to distributors for the Products..",
          "bbox": [
            527.0,
            2050.0,
            1842.0,
            2096.0
          ],
          "confidence": 0.9838126301765442
        },
        {
          "text": "5.2.",
          "bbox": [
            355.0,
            2103.0,
            430.0,
            2153.0
          ],
          "confidence": 0.9999211430549622
        },
        {
          "text": "Manufacturing Changes. Qualigen shall notify Sekisui in writing no less than 3 months prior to any material changes which affect (i)",
          "bbox": [
            527.0,
            2107.0,
            3025.0,
            2153.0
          ],
          "confidence": 0.9962983727455139
        },
        {
          "text": "the form, fit or function of any Products, or (ii) the labeling or regulatory status of the Products in any of the Applicable Markets.",
          "bbox": [
            529.0,
            2164.0,
            2927.0,
            2209.0
          ],
          "confidence": 0.9934166073799133
        },
        {
          "text": "5.3.",
          "bbox": [
            357.0,
            2218.0,
            428.0,
            2262.0
          ],
          "confidence": 0.999969482421875
        },
        {
          "text": "Manufacturing Site. During the Term, Qualigen shall manufacture all Products using Qualigen's facilities located in Carlsbad.",
          "bbox": [
            529.0,
            2220.0,
            3023.0,
            2262.0
          ],
          "confidence": 0.9907397627830505
        },
        {
          "text": "California. Qualigen shall give at least six (6) months prior written notice to Sekisui of any proposed relocation of the manufacturing of",
          "bbox": [
            531.0,
            2279.0,
            3030.0,
            2321.0
          ],
          "confidence": 0.9922841191291809
        },
        {
          "text": "any Product. Any new facility proposed to be used by Qualigen in manufacturing any Product shall be subject to a new and separate",
          "bbox": [
            527.0,
            2334.0,
            3027.0,
            2377.0
          ],
          "confidence": 0.9995027184486389
        },
        {
          "text": "audit by Sekisui personnel in accordance with Quality Systems Regulations (QSR), as well as ISO 13485..",
          "bbox": [
            527.0,
            2386.0,
            2467.0,
            2432.0
          ],
          "confidence": 0.9848436713218689
        },
        {
          "text": "8",
          "bbox": [
            1638.0,
            2449.0,
            1669.0,
            2483.0
          ],
          "confidence": 0.9997285008430481
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9953641295433044
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Qualigen shall provide Sekisui with at least 30 days prior written notice and access to all due diligence materials provided to any potential acquirer, such 30 day period to commence upon the notification to Sekisui that Qualigen's board of directors has approved such Proposed Sale Transaction (as set forth in a term sheet or draft definitive agreement provided to Sekisui), subject to Sekisui's Right of First Refusal.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Qualigen shall provide Sekisui with at least 30 days prior written notice and access to all due diligence materials provided to any potential acquirer, such 30 day period to commence upon the notification to Sekisui that Qualigen's board of directors has approved such Proposed Sale Transaction (as set forth in a term sheet or draft definitive agreement provided to Sekisui), subject to Sekisui's Right of First Refusal.",
      "page_number": 2,
      "words": [
        {
          "text": "1.21.",
          "bbox": [
            359.0,
            252.0,
            451.0,
            300.0
          ],
          "confidence": 0.9230712652206421
        },
        {
          "text": "Regulatory Authorities shall mean the FDA, each Competent Authority, Health Canada and the Japanese Pharmaceuticals and",
          "bbox": [
            533.0,
            259.0,
            3027.0,
            296.0
          ],
          "confidence": 0.9924156665802002
        },
        {
          "text": "Medical Devices Agency.",
          "bbox": [
            529.0,
            312.0,
            1006.0,
            356.0
          ],
          "confidence": 0.99922776222229
        },
        {
          "text": "1.22.",
          "bbox": [
            359.0,
            364.0,
            450.0,
            413.0
          ],
          "confidence": 0.9985124468803406
        },
        {
          "text": "Revenue Affiliate shall mean any entity of which Sekisui has the direct or indirect power to vote more than fifty percent (50%) of the",
          "bbox": [
            529.0,
            367.0,
            3027.0,
            411.0
          ],
          "confidence": 0.9936479926109314
        },
        {
          "text": "direct or indirect ability to direct or cause the direction of the general management and policies of that entity.",
          "bbox": [
            529.0,
            479.0,
            2545.0,
            526.0
          ],
          "confidence": 0.9983549118041992
        },
        {
          "text": "1.23.",
          "bbox": [
            359.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.9992727041244507
        },
        {
          "text": "Sale Transaction shall mean (i) any transaction in which Qualigen, Qualigen's business or control of Qualigen is acquired, (ii) any",
          "bbox": [
            527.0,
            535.0,
            3025.0,
            583.0
          ],
          "confidence": 0.9933872222900391
        },
        {
          "text": "license, sale, lease, transfer, or other disposition, in a single transaction or series of related transactions, of all or substantially all of",
          "bbox": [
            527.0,
            592.0,
            3031.0,
            636.0
          ],
          "confidence": 0.9962546825408936
        },
        {
          "text": "Qualigen's assets other than in the ordinary course of business, (iii) any sale of a majority of the outstanding shares of capital stock",
          "bbox": [
            533.0,
            651.0,
            3029.0,
            693.0
          ],
          "confidence": 0.9975800514221191
        },
        {
          "text": "of Qualigen, (iv) any sale or license of any rights to any Qualigen products, now or hereafter existing, other than in the ordinary",
          "bbox": [
            531.0,
            707.0,
            3027.0,
            749.0
          ],
          "confidence": 0.9935311079025269
        },
        {
          "text": "course of business, (v) any liquidation or dissolution of Qualigen, (vi) any similar transaction resulting in a change of control of",
          "bbox": [
            531.0,
            764.0,
            3032.0,
            806.0
          ],
          "confidence": 0.9916770458221436
        },
        {
          "text": "Qualigen, or (vii) any of the foregoing with respect to any now or hereafter existing subsidiary of Qualigen which holds, on a",
          "bbox": [
            533.0,
            820.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9889509677886963
        },
        {
          "text": "consolidated basis, all or substantially all of Qualigen's assets (i.e., of the assets of Qualigen and all its Affiliates considered",
          "bbox": [
            529.0,
            875.0,
            3027.0,
            917.0
          ],
          "confidence": 0.9926474690437317
        },
        {
          "text": "together).",
          "bbox": [
            525.0,
            928.0,
            713.0,
            978.0
          ],
          "confidence": 0.9990909695625305
        },
        {
          "text": "1.24.",
          "bbox": [
            359.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9993151426315308
        },
        {
          "text": "Serious Incident shall mean an incident involving the Products, which is reportable to a Competent Authority and as defined in",
          "bbox": [
            531.0,
            990.0,
            3025.0,
            1027.0
          ],
          "confidence": 0.990603506565094
        },
        {
          "text": "Section 5 of Annex III of the IVD Directive, and the European Commission Medical Devices Vigilance Guidelines 2.12-1 or such other",
          "bbox": [
            529.0,
            1043.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9936378002166748
        },
        {
          "text": "Guidelines as may be issued from time to time.",
          "bbox": [
            531.0,
            1102.0,
            1383.0,
            1138.0
          ],
          "confidence": 0.9971452951431274
        },
        {
          "text": "1.25.",
          "bbox": [
            359.0,
            1149.0,
            448.0,
            1199.0
          ],
          "confidence": 0.9999178647994995
        },
        {
          "text": "Territory shall mean worldwide excluding Qualigen Retained Customers.",
          "bbox": [
            529.0,
            1157.0,
            1863.0,
            1199.0
          ],
          "confidence": 0.989960253238678
        },
        {
          "text": "1.26.",
          "bbox": [
            359.0,
            1208.0,
            450.0,
            1255.0
          ],
          "confidence": 0.9994128942489624
        },
        {
          "text": "Third Party shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
          "bbox": [
            527.0,
            1208.0,
            2382.0,
            1254.0
          ],
          "confidence": 0.989874005317688
        },
        {
          "text": "2.",
          "bbox": [
            272.0,
            1265.0,
            317.0,
            1308.0
          ],
          "confidence": 0.9999349117279053
        },
        {
          "text": "Appointment and Term",
          "bbox": [
            450.0,
            1268.0,
            877.0,
            1307.0
          ],
          "confidence": 0.999896228313446
        },
        {
          "text": "2.1.",
          "bbox": [
            359.0,
            1321.0,
            430.0,
            1365.0
          ],
          "confidence": 0.999855101108551
        },
        {
          "text": "Appointment. Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the",
          "bbox": [
            531.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9947742223739624
        },
        {
          "text": "terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory. Sekisui shall be permitted to",
          "bbox": [
            529.0,
            1378.0,
            3025.0,
            1420.0
          ],
          "confidence": 0.9916503429412842
        },
        {
          "text": "appoint sub-distributors in the Territory (including any current Qualigen distributors) with the approval of Qualigen, not to be",
          "bbox": [
            527.0,
            1433.0,
            3027.0,
            1480.0
          ],
          "confidence": 0.9952742457389832
        },
        {
          "text": "unreasonably withheld or delayed. Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the",
          "bbox": [
            529.0,
            1493.0,
            3027.0,
            1535.0
          ],
          "confidence": 0.9905573129653931
        },
        {
          "text": "Products exclusively to Sekisui, in each case for the Territory. Qualigen shall assign to Sekisui Qualigen's agreements with Qualigen's",
          "bbox": [
            527.0,
            1546.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9959052205085754
        },
        {
          "text": "current distributors (such that such current Qualigen distributors shall become Sekisui subdistributors), each of which is set forth on",
          "bbox": [
            527.0,
            1604.0,
            3027.0,
            1646.0
          ],
          "confidence": 0.9941188097000122
        },
        {
          "text": "Schedule 2.1 hereto; if any of such agreements do not allow such assignment and the current distributor declines to consent to such",
          "bbox": [
            531.0,
            1661.0,
            3030.0,
            1703.0
          ],
          "confidence": 0.9969964623451233
        },
        {
          "text": "an assignment to Sekisui, Qualigen shall (if Sekisui so requests) act pursuant to such agreement to terminate such agreement.",
          "bbox": [
            527.0,
            1718.0,
            2862.0,
            1760.0
          ],
          "confidence": 0.9927040338516235
        },
        {
          "text": "2.2.",
          "bbox": [
            355.0,
            1767.0,
            430.0,
            1816.0
          ],
          "confidence": 0.9999159574508667
        },
        {
          "text": "Term. The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless",
          "bbox": [
            529.0,
            1773.0,
            3027.0,
            1815.0
          ],
          "confidence": 0.9939504861831665
        },
        {
          "text": "earlier terminated pursuant to Section 14 hereof (the \"Term'). The initial term of this Agreement and any renewal term thereof shall be",
          "bbox": [
            529.0,
            1829.0,
            3027.0,
            1871.0
          ],
          "confidence": 0.9962239861488342
        },
        {
          "text": "automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9914175271987915
        },
        {
          "text": "Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this",
          "bbox": [
            531.0,
            1942.0,
            3023.0,
            1979.0
          ],
          "confidence": 0.9881066083908081
        },
        {
          "text": "Agreement. References in this Agreement to \"Term\"' shall be deemed to include the initial five (5) year term as well as a reduction or",
          "bbox": [
            533.0,
            1997.0,
            3029.0,
            2039.0
          ],
          "confidence": 0.9924869537353516
        },
        {
          "text": "extension of that time period that may occur as a result of the provision of this Section 0 or the provisions of Section 14.",
          "bbox": [
            531.0,
            2054.0,
            2757.0,
            2096.0
          ],
          "confidence": 0.9920394420623779
        },
        {
          "text": "3",
          "bbox": [
            1638.0,
            2109.0,
            1668.0,
            2147.0
          ],
          "confidence": 0.9998428821563721
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939860105514526
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_2",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term, Sekisui shall have a right of first refusal to match the terms of any arms length, bona fide proposed Sale Transaction with a Third Party (\"Sekisui's Right of First Refusal\").",
      "page_number": 2,
      "words": [
        {
          "text": "1.21.",
          "bbox": [
            359.0,
            252.0,
            451.0,
            300.0
          ],
          "confidence": 0.9230712652206421
        },
        {
          "text": "Regulatory Authorities shall mean the FDA, each Competent Authority, Health Canada and the Japanese Pharmaceuticals and",
          "bbox": [
            533.0,
            259.0,
            3027.0,
            296.0
          ],
          "confidence": 0.9924156665802002
        },
        {
          "text": "Medical Devices Agency.",
          "bbox": [
            529.0,
            312.0,
            1006.0,
            356.0
          ],
          "confidence": 0.99922776222229
        },
        {
          "text": "1.22.",
          "bbox": [
            359.0,
            364.0,
            450.0,
            413.0
          ],
          "confidence": 0.9985124468803406
        },
        {
          "text": "Revenue Affiliate shall mean any entity of which Sekisui has the direct or indirect power to vote more than fifty percent (50%) of the",
          "bbox": [
            529.0,
            367.0,
            3027.0,
            411.0
          ],
          "confidence": 0.9936479926109314
        },
        {
          "text": "direct or indirect ability to direct or cause the direction of the general management and policies of that entity.",
          "bbox": [
            529.0,
            479.0,
            2545.0,
            526.0
          ],
          "confidence": 0.9983549118041992
        },
        {
          "text": "1.23.",
          "bbox": [
            359.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.9992727041244507
        },
        {
          "text": "Sale Transaction shall mean (i) any transaction in which Qualigen, Qualigen's business or control of Qualigen is acquired, (ii) any",
          "bbox": [
            527.0,
            535.0,
            3025.0,
            583.0
          ],
          "confidence": 0.9933872222900391
        },
        {
          "text": "license, sale, lease, transfer, or other disposition, in a single transaction or series of related transactions, of all or substantially all of",
          "bbox": [
            527.0,
            592.0,
            3031.0,
            636.0
          ],
          "confidence": 0.9962546825408936
        },
        {
          "text": "Qualigen's assets other than in the ordinary course of business, (iii) any sale of a majority of the outstanding shares of capital stock",
          "bbox": [
            533.0,
            651.0,
            3029.0,
            693.0
          ],
          "confidence": 0.9975800514221191
        },
        {
          "text": "of Qualigen, (iv) any sale or license of any rights to any Qualigen products, now or hereafter existing, other than in the ordinary",
          "bbox": [
            531.0,
            707.0,
            3027.0,
            749.0
          ],
          "confidence": 0.9935311079025269
        },
        {
          "text": "course of business, (v) any liquidation or dissolution of Qualigen, (vi) any similar transaction resulting in a change of control of",
          "bbox": [
            531.0,
            764.0,
            3032.0,
            806.0
          ],
          "confidence": 0.9916770458221436
        },
        {
          "text": "Qualigen, or (vii) any of the foregoing with respect to any now or hereafter existing subsidiary of Qualigen which holds, on a",
          "bbox": [
            533.0,
            820.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9889509677886963
        },
        {
          "text": "consolidated basis, all or substantially all of Qualigen's assets (i.e., of the assets of Qualigen and all its Affiliates considered",
          "bbox": [
            529.0,
            875.0,
            3027.0,
            917.0
          ],
          "confidence": 0.9926474690437317
        },
        {
          "text": "together).",
          "bbox": [
            525.0,
            928.0,
            713.0,
            978.0
          ],
          "confidence": 0.9990909695625305
        },
        {
          "text": "1.24.",
          "bbox": [
            359.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9993151426315308
        },
        {
          "text": "Serious Incident shall mean an incident involving the Products, which is reportable to a Competent Authority and as defined in",
          "bbox": [
            531.0,
            990.0,
            3025.0,
            1027.0
          ],
          "confidence": 0.990603506565094
        },
        {
          "text": "Section 5 of Annex III of the IVD Directive, and the European Commission Medical Devices Vigilance Guidelines 2.12-1 or such other",
          "bbox": [
            529.0,
            1043.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9936378002166748
        },
        {
          "text": "Guidelines as may be issued from time to time.",
          "bbox": [
            531.0,
            1102.0,
            1383.0,
            1138.0
          ],
          "confidence": 0.9971452951431274
        },
        {
          "text": "1.25.",
          "bbox": [
            359.0,
            1149.0,
            448.0,
            1199.0
          ],
          "confidence": 0.9999178647994995
        },
        {
          "text": "Territory shall mean worldwide excluding Qualigen Retained Customers.",
          "bbox": [
            529.0,
            1157.0,
            1863.0,
            1199.0
          ],
          "confidence": 0.989960253238678
        },
        {
          "text": "1.26.",
          "bbox": [
            359.0,
            1208.0,
            450.0,
            1255.0
          ],
          "confidence": 0.9994128942489624
        },
        {
          "text": "Third Party shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
          "bbox": [
            527.0,
            1208.0,
            2382.0,
            1254.0
          ],
          "confidence": 0.989874005317688
        },
        {
          "text": "2.",
          "bbox": [
            272.0,
            1265.0,
            317.0,
            1308.0
          ],
          "confidence": 0.9999349117279053
        },
        {
          "text": "Appointment and Term",
          "bbox": [
            450.0,
            1268.0,
            877.0,
            1307.0
          ],
          "confidence": 0.999896228313446
        },
        {
          "text": "2.1.",
          "bbox": [
            359.0,
            1321.0,
            430.0,
            1365.0
          ],
          "confidence": 0.999855101108551
        },
        {
          "text": "Appointment. Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the",
          "bbox": [
            531.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9947742223739624
        },
        {
          "text": "terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory. Sekisui shall be permitted to",
          "bbox": [
            529.0,
            1378.0,
            3025.0,
            1420.0
          ],
          "confidence": 0.9916503429412842
        },
        {
          "text": "appoint sub-distributors in the Territory (including any current Qualigen distributors) with the approval of Qualigen, not to be",
          "bbox": [
            527.0,
            1433.0,
            3027.0,
            1480.0
          ],
          "confidence": 0.9952742457389832
        },
        {
          "text": "unreasonably withheld or delayed. Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the",
          "bbox": [
            529.0,
            1493.0,
            3027.0,
            1535.0
          ],
          "confidence": 0.9905573129653931
        },
        {
          "text": "Products exclusively to Sekisui, in each case for the Territory. Qualigen shall assign to Sekisui Qualigen's agreements with Qualigen's",
          "bbox": [
            527.0,
            1546.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9959052205085754
        },
        {
          "text": "current distributors (such that such current Qualigen distributors shall become Sekisui subdistributors), each of which is set forth on",
          "bbox": [
            527.0,
            1604.0,
            3027.0,
            1646.0
          ],
          "confidence": 0.9941188097000122
        },
        {
          "text": "Schedule 2.1 hereto; if any of such agreements do not allow such assignment and the current distributor declines to consent to such",
          "bbox": [
            531.0,
            1661.0,
            3030.0,
            1703.0
          ],
          "confidence": 0.9969964623451233
        },
        {
          "text": "an assignment to Sekisui, Qualigen shall (if Sekisui so requests) act pursuant to such agreement to terminate such agreement.",
          "bbox": [
            527.0,
            1718.0,
            2862.0,
            1760.0
          ],
          "confidence": 0.9927040338516235
        },
        {
          "text": "2.2.",
          "bbox": [
            355.0,
            1767.0,
            430.0,
            1816.0
          ],
          "confidence": 0.9999159574508667
        },
        {
          "text": "Term. The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless",
          "bbox": [
            529.0,
            1773.0,
            3027.0,
            1815.0
          ],
          "confidence": 0.9939504861831665
        },
        {
          "text": "earlier terminated pursuant to Section 14 hereof (the \"Term'). The initial term of this Agreement and any renewal term thereof shall be",
          "bbox": [
            529.0,
            1829.0,
            3027.0,
            1871.0
          ],
          "confidence": 0.9962239861488342
        },
        {
          "text": "automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9914175271987915
        },
        {
          "text": "Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this",
          "bbox": [
            531.0,
            1942.0,
            3023.0,
            1979.0
          ],
          "confidence": 0.9881066083908081
        },
        {
          "text": "Agreement. References in this Agreement to \"Term\"' shall be deemed to include the initial five (5) year term as well as a reduction or",
          "bbox": [
            533.0,
            1997.0,
            3029.0,
            2039.0
          ],
          "confidence": 0.9924869537353516
        },
        {
          "text": "extension of that time period that may occur as a result of the provision of this Section 0 or the provisions of Section 14.",
          "bbox": [
            531.0,
            2054.0,
            2757.0,
            2096.0
          ],
          "confidence": 0.9920394420623779
        },
        {
          "text": "3",
          "bbox": [
            1638.0,
            2109.0,
            1668.0,
            2147.0
          ],
          "confidence": 0.9998428821563721
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939860105514526
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "In the event that Qualigen nonetheless receives an unsolicited offer to engage in a Sale Transaction during such Exclusivity Period, Qualigen may engage with such party to the extent legally required to comply with its fiduciary duties, so long as Qualigen (i) promptly communicates to Sekisui the material terms of any proposal or offer or request for information which it may receive in respect of any such proposed Sale Transaction, including the purchase price, form and timing of consideration and the identity of the acquirer, and (ii) complies with Sekisui's Right of First Refusal (as defined below).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "In the event that Qualigen nonetheless receives an unsolicited offer to engage in a Sale Transaction during such Exclusivity Period, Qualigen may engage with such party to the extent legally required to comply with its fiduciary duties, so long as Qualigen (i) promptly communicates to Sekisui the material terms of any proposal or offer or request for information which it may receive in respect of any such proposed Sale Transaction, including the purchase price, form and timing of consideration and the identity of the acquirer, and (ii) complies with Sekisui's Right of First Refusal (as defined below).",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If the parties do not mutually agree to the terms of such potential acquisition within the Negotiation Period then the Exclusivity Period shall end and, subject to Sekisui's Right of First Refusal, Qualigen shall be free to negotiate the terms of a Sale Transaction with any Third Party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If the parties do not mutually agree to the terms of such potential acquisition within the Negotiation Period then the Exclusivity Period shall end and, subject to Sekisui's Right of First Refusal, Qualigen shall be free to negotiate the terms of a Sale Transaction with any Third Party.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "The Agreement shall not be assigned and is not assignable or delegable by either Party without the written consent of the other, which consent shall not be unreasonably withheld; provided, that Sekisui and Qualigen each may assign this Agreement without the consent of the other to a successor in connection with the merger, consolidation or sale of such Party or of all or substantially all of its assets or the portion of its business to which this Agreement relates.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "The Agreement shall not be assigned and is not assignable or delegable by either Party without the written consent of the other, which consent shall not be unreasonably withheld; provided, that Sekisui and Qualigen each may assign this Agreement without the consent of the other to a successor in connection with the merger, consolidation or sale of such Party or of all or substantially all of its assets or the portion of its business to which this Agreement relates.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "The price that Sekisui shall pay for the Reagent Kits Products shall be based upon a formula intended to ensure that Sekisui will receive 90% of the total Available Margin for all Products during the first 12 months of this Agreement, 70% of the total Available Margin for all Products during months 13-24 of this Agreement, and 65% of the total Available Margin for all Products thereafter.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "The price that Sekisui shall pay for the Reagent Kits Products shall be based upon a formula intended to ensure that Sekisui will receive 90% of the total Available Margin for all Products during the first 12 months of this Agreement, 70% of the total Available Margin for all Products during months 13-24 of this Agreement, and 65% of the total Available Margin for all Products thereafter.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Minimum Commitment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "All Products supplied by Qualigen to Sekisui shall have on the date of shipment by Qualigen a shelf life of not less than a minimum three (3) month shelf life for products shipped within the United States and not less than a minimum four (4) month shelf life for products shipped outside the United States (or such longer shelf-life as may be mutually agreed by Qualigen and a Sekisui customer with respect to a specific customer order).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Minimum Commitment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "All Products supplied by Qualigen to Sekisui shall have on the date of shipment by Qualigen a shelf life of not less than a minimum three (3) month shelf life for products shipped within the United States and not less than a minimum four (4) month shelf life for products shipped outside the United States (or such longer shelf-life as may be mutually agreed by Qualigen and a Sekisui customer with respect to a specific customer order).",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In the event that Qualigen elects not to prosecute or maintain in a particular Applicable Market country any Patent Rights in the jointly developed Development IP (the \"Abandoned Joint IP\"), Sekisui may elect to prosecute such Abandoned Joint IP in such particular Applicable Market country, in which case the Patent Rights for such Abandoned Joint IP in such particular in Applicable Market country shall be owned solely by Sekisui.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "In the event that Qualigen elects not to prosecute or maintain in a particular Applicable Market country any Patent Rights in the jointly developed Development IP (the \"Abandoned Joint IP\"), Sekisui may elect to prosecute such Abandoned Joint IP in such particular Applicable Market country, in which case the Patent Rights for such Abandoned Joint IP in such particular in Applicable Market country shall be owned solely by Sekisui.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Joint Ip Ownership_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "In the event that Qualigen elects not to prosecute or maintain in a particular Applicable Market country any Patent Rights in the jointly developed Development IP (the \"Abandoned Joint IP\"), Sekisui may elect to prosecute such Abandoned Joint IP in such particular Applicable Market country, in which case the Patent Rights for such Abandoned Joint IP in such particular in Applicable Market country shall be owned solely by Sekisui.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "In the event that Qualigen elects not to prosecute or maintain in a particular Applicable Market country any Patent Rights in the jointly developed Development IP (the \"Abandoned Joint IP\"), Sekisui may elect to prosecute such Abandoned Joint IP in such particular Applicable Market country, in which case the Patent Rights for such Abandoned Joint IP in such particular in Applicable Market country shall be owned solely by Sekisui.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Joint Ip Ownership_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "In the event that any Development IP is jointly invented by the Parties in accordance with applicable intellectual property laws, then the ownership of such Development IP that has been jointly invented shall be co-owned by the Parties in accordance with such applicable intellectual property laws; provided, however, that neither Party shall have any duty or obligation to account to the other for any use or exploitation of such jointly invented Development IP and as between the Parties, each Party shall be entitled to retain any and all benefit, financial or otherwise, derived by such Party from such jointly invented Development IP.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "In the event that any Development IP is jointly invented by the Parties in accordance with applicable intellectual property laws, then the ownership of such Development IP that has been jointly invented shall be co-owned by the Parties in accordance with such applicable intellectual property laws; provided, however, that neither Party shall have any duty or obligation to account to the other for any use or exploitation of such jointly invented Development IP and as between the Parties, each Party shall be entitled to retain any and all benefit, financial or otherwise, derived by such Party from such jointly invented Development IP.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "During the Term, Sekisui is hereby permitted to use the Qualigen name and any Qualigen content (including the content of any existing sales collateral and marketing materials) in any sales collateral, marketing materials or other communications used in connection with the marketing and sales of the Product with the prior written consent of Qualigen, which consent shall not be reasonably withheld or delayed.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "During the Term, Sekisui is hereby permitted to use the Qualigen name and any Qualigen content (including the content of any existing sales collateral and marketing materials) in any sales collateral, marketing materials or other communications used in connection with the marketing and sales of the Product with the prior written consent of Qualigen, which consent shall not be reasonably withheld or delayed.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon the expiration or termination of the Term (other than in connection with a Sale Transaction in which Sekisui acquires Qualigen), Sekisui shall cooperate in permitting Qualigen to offer to rehire any Sekisui sales representatives who are primarily responsible for selling the Products. A sales person \"primarily responsible for selling the Products\" is one that spends more than half of his or her time and receives more than half of his or her commission based compensation based on sales of the Products.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon the expiration or termination of the Term (other than in connection with a Sale Transaction in which Sekisui acquires Qualigen), Sekisui shall cooperate in permitting Qualigen to offer to rehire any Sekisui sales representatives who are primarily responsible for selling the Products. A sales person \"primarily responsible for selling the Products\" is one that spends more than half of his or her time and receives more than half of his or her commission based compensation based on sales of the Products.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "If Qualigen does not pass such audit and the reasons for such failure can be remedied within a reasonable period of time (which shall not be less than sixty (60) days), then Sekisui shall provide Qualigen with a list of proposed remedial action items and a proposed timeframe within which to accomplish such action items",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "If Qualigen does not pass such audit and the reasons for such failure can be remedied within a reasonable period of time (which shall not be less than sixty (60) days), then Sekisui shall provide Qualigen with a list of proposed remedial action items and a proposed timeframe within which to accomplish such action items",
      "page_number": 2,
      "words": [
        {
          "text": "1.21.",
          "bbox": [
            359.0,
            252.0,
            451.0,
            300.0
          ],
          "confidence": 0.9230712652206421
        },
        {
          "text": "Regulatory Authorities shall mean the FDA, each Competent Authority, Health Canada and the Japanese Pharmaceuticals and",
          "bbox": [
            533.0,
            259.0,
            3027.0,
            296.0
          ],
          "confidence": 0.9924156665802002
        },
        {
          "text": "Medical Devices Agency.",
          "bbox": [
            529.0,
            312.0,
            1006.0,
            356.0
          ],
          "confidence": 0.99922776222229
        },
        {
          "text": "1.22.",
          "bbox": [
            359.0,
            364.0,
            450.0,
            413.0
          ],
          "confidence": 0.9985124468803406
        },
        {
          "text": "Revenue Affiliate shall mean any entity of which Sekisui has the direct or indirect power to vote more than fifty percent (50%) of the",
          "bbox": [
            529.0,
            367.0,
            3027.0,
            411.0
          ],
          "confidence": 0.9936479926109314
        },
        {
          "text": "direct or indirect ability to direct or cause the direction of the general management and policies of that entity.",
          "bbox": [
            529.0,
            479.0,
            2545.0,
            526.0
          ],
          "confidence": 0.9983549118041992
        },
        {
          "text": "1.23.",
          "bbox": [
            359.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.9992727041244507
        },
        {
          "text": "Sale Transaction shall mean (i) any transaction in which Qualigen, Qualigen's business or control of Qualigen is acquired, (ii) any",
          "bbox": [
            527.0,
            535.0,
            3025.0,
            583.0
          ],
          "confidence": 0.9933872222900391
        },
        {
          "text": "license, sale, lease, transfer, or other disposition, in a single transaction or series of related transactions, of all or substantially all of",
          "bbox": [
            527.0,
            592.0,
            3031.0,
            636.0
          ],
          "confidence": 0.9962546825408936
        },
        {
          "text": "Qualigen's assets other than in the ordinary course of business, (iii) any sale of a majority of the outstanding shares of capital stock",
          "bbox": [
            533.0,
            651.0,
            3029.0,
            693.0
          ],
          "confidence": 0.9975800514221191
        },
        {
          "text": "of Qualigen, (iv) any sale or license of any rights to any Qualigen products, now or hereafter existing, other than in the ordinary",
          "bbox": [
            531.0,
            707.0,
            3027.0,
            749.0
          ],
          "confidence": 0.9935311079025269
        },
        {
          "text": "course of business, (v) any liquidation or dissolution of Qualigen, (vi) any similar transaction resulting in a change of control of",
          "bbox": [
            531.0,
            764.0,
            3032.0,
            806.0
          ],
          "confidence": 0.9916770458221436
        },
        {
          "text": "Qualigen, or (vii) any of the foregoing with respect to any now or hereafter existing subsidiary of Qualigen which holds, on a",
          "bbox": [
            533.0,
            820.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9889509677886963
        },
        {
          "text": "consolidated basis, all or substantially all of Qualigen's assets (i.e., of the assets of Qualigen and all its Affiliates considered",
          "bbox": [
            529.0,
            875.0,
            3027.0,
            917.0
          ],
          "confidence": 0.9926474690437317
        },
        {
          "text": "together).",
          "bbox": [
            525.0,
            928.0,
            713.0,
            978.0
          ],
          "confidence": 0.9990909695625305
        },
        {
          "text": "1.24.",
          "bbox": [
            359.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9993151426315308
        },
        {
          "text": "Serious Incident shall mean an incident involving the Products, which is reportable to a Competent Authority and as defined in",
          "bbox": [
            531.0,
            990.0,
            3025.0,
            1027.0
          ],
          "confidence": 0.990603506565094
        },
        {
          "text": "Section 5 of Annex III of the IVD Directive, and the European Commission Medical Devices Vigilance Guidelines 2.12-1 or such other",
          "bbox": [
            529.0,
            1043.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9936378002166748
        },
        {
          "text": "Guidelines as may be issued from time to time.",
          "bbox": [
            531.0,
            1102.0,
            1383.0,
            1138.0
          ],
          "confidence": 0.9971452951431274
        },
        {
          "text": "1.25.",
          "bbox": [
            359.0,
            1149.0,
            448.0,
            1199.0
          ],
          "confidence": 0.9999178647994995
        },
        {
          "text": "Territory shall mean worldwide excluding Qualigen Retained Customers.",
          "bbox": [
            529.0,
            1157.0,
            1863.0,
            1199.0
          ],
          "confidence": 0.989960253238678
        },
        {
          "text": "1.26.",
          "bbox": [
            359.0,
            1208.0,
            450.0,
            1255.0
          ],
          "confidence": 0.9994128942489624
        },
        {
          "text": "Third Party shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
          "bbox": [
            527.0,
            1208.0,
            2382.0,
            1254.0
          ],
          "confidence": 0.989874005317688
        },
        {
          "text": "2.",
          "bbox": [
            272.0,
            1265.0,
            317.0,
            1308.0
          ],
          "confidence": 0.9999349117279053
        },
        {
          "text": "Appointment and Term",
          "bbox": [
            450.0,
            1268.0,
            877.0,
            1307.0
          ],
          "confidence": 0.999896228313446
        },
        {
          "text": "2.1.",
          "bbox": [
            359.0,
            1321.0,
            430.0,
            1365.0
          ],
          "confidence": 0.999855101108551
        },
        {
          "text": "Appointment. Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the",
          "bbox": [
            531.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9947742223739624
        },
        {
          "text": "terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory. Sekisui shall be permitted to",
          "bbox": [
            529.0,
            1378.0,
            3025.0,
            1420.0
          ],
          "confidence": 0.9916503429412842
        },
        {
          "text": "appoint sub-distributors in the Territory (including any current Qualigen distributors) with the approval of Qualigen, not to be",
          "bbox": [
            527.0,
            1433.0,
            3027.0,
            1480.0
          ],
          "confidence": 0.9952742457389832
        },
        {
          "text": "unreasonably withheld or delayed. Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the",
          "bbox": [
            529.0,
            1493.0,
            3027.0,
            1535.0
          ],
          "confidence": 0.9905573129653931
        },
        {
          "text": "Products exclusively to Sekisui, in each case for the Territory. Qualigen shall assign to Sekisui Qualigen's agreements with Qualigen's",
          "bbox": [
            527.0,
            1546.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9959052205085754
        },
        {
          "text": "current distributors (such that such current Qualigen distributors shall become Sekisui subdistributors), each of which is set forth on",
          "bbox": [
            527.0,
            1604.0,
            3027.0,
            1646.0
          ],
          "confidence": 0.9941188097000122
        },
        {
          "text": "Schedule 2.1 hereto; if any of such agreements do not allow such assignment and the current distributor declines to consent to such",
          "bbox": [
            531.0,
            1661.0,
            3030.0,
            1703.0
          ],
          "confidence": 0.9969964623451233
        },
        {
          "text": "an assignment to Sekisui, Qualigen shall (if Sekisui so requests) act pursuant to such agreement to terminate such agreement.",
          "bbox": [
            527.0,
            1718.0,
            2862.0,
            1760.0
          ],
          "confidence": 0.9927040338516235
        },
        {
          "text": "2.2.",
          "bbox": [
            355.0,
            1767.0,
            430.0,
            1816.0
          ],
          "confidence": 0.9999159574508667
        },
        {
          "text": "Term. The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless",
          "bbox": [
            529.0,
            1773.0,
            3027.0,
            1815.0
          ],
          "confidence": 0.9939504861831665
        },
        {
          "text": "earlier terminated pursuant to Section 14 hereof (the \"Term'). The initial term of this Agreement and any renewal term thereof shall be",
          "bbox": [
            529.0,
            1829.0,
            3027.0,
            1871.0
          ],
          "confidence": 0.9962239861488342
        },
        {
          "text": "automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9914175271987915
        },
        {
          "text": "Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this",
          "bbox": [
            531.0,
            1942.0,
            3023.0,
            1979.0
          ],
          "confidence": 0.9881066083908081
        },
        {
          "text": "Agreement. References in this Agreement to \"Term\"' shall be deemed to include the initial five (5) year term as well as a reduction or",
          "bbox": [
            533.0,
            1997.0,
            3029.0,
            2039.0
          ],
          "confidence": 0.9924869537353516
        },
        {
          "text": "extension of that time period that may occur as a result of the provision of this Section 0 or the provisions of Section 14.",
          "bbox": [
            531.0,
            2054.0,
            2757.0,
            2096.0
          ],
          "confidence": 0.9920394420623779
        },
        {
          "text": "3",
          "bbox": [
            1638.0,
            2109.0,
            1668.0,
            2147.0
          ],
          "confidence": 0.9998428821563721
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939860105514526
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_7",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "As scheduled, Sekisui may perform an audit during reasonable business hours to confirm ongoing compliance with the Quality System Regulations and confirm adequate process controls",
      "page_number": 7,
      "words": [
        {
          "text": "4.9.",
          "bbox": [
            359.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9999215602874756
        },
        {
          "text": "Taxes. Qualigen's stated Product prices do not include any foreign, federal, state or local sales taxes that may be applicable to the",
          "bbox": [
            531.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9932553768157959
        },
        {
          "text": "Products, but in the event that such sales taxes are applicable and Qualigen has the legal obligation to collect such sales taxes (or are",
          "bbox": [
            529.0,
            314.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9822651743888855
        },
        {
          "text": "sales taxes imposed on a seller), Qualigen shall be entitled to add to its invoice the amount of such sales taxes and Sekisui shall pay",
          "bbox": [
            527.0,
            365.0,
            3025.0,
            415.0
          ],
          "confidence": 0.9954785108566284
        },
        {
          "text": "such amount unless Sekisui provides Qualigen with a valid tax exemption certificate authorized by the appropriate taxing authority. As",
          "bbox": [
            529.0,
            428.0,
            3029.0,
            470.0
          ],
          "confidence": 0.9964900016784668
        },
        {
          "text": "between the Parties, all customs duties shall be the responsibility of Sekisui, and all duty expenses will be included as an element of",
          "bbox": [
            527.0,
            479.0,
            3032.0,
            524.0
          ],
          "confidence": 0.9918721318244934
        },
        {
          "text": "COGS as referenced in Exhibit A and will be included as part of the Actual Margin True-Up as defined in Exhibit D. The parties agree",
          "bbox": [
            527.0,
            535.0,
            3027.0,
            581.0
          ],
          "confidence": 0.9950875043869019
        },
        {
          "text": "to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of",
          "bbox": [
            531.0,
            596.0,
            3027.0,
            632.0
          ],
          "confidence": 0.9928668141365051
        },
        {
          "text": "Financing Payments, Product purchase payments, and other payments made by Sekisui to Qualigen under this Agreement. To the",
          "bbox": [
            529.0,
            649.0,
            3025.0,
            693.0
          ],
          "confidence": 0.9906346797943115
        },
        {
          "text": "extent Sekisui is required to withhold taxes on any payment to Qualigen, Sekisui shall pay the amounts of such taxes to the proper",
          "bbox": [
            529.0,
            707.0,
            3029.0,
            751.0
          ],
          "confidence": 0.9893237948417664
        },
        {
          "text": "governmental authority in a timely manner and promptly transmit to Qualigen evidence of such payment and/or an official tax",
          "bbox": [
            527.0,
            758.0,
            3029.0,
            808.0
          ],
          "confidence": 0.9940901398658752
        },
        {
          "text": "certificate, or such other evidence as Qualigen may reasonably request, to establish that such taxes have been paid. Qualigen shall",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            861.0
          ],
          "confidence": 0.9870412349700928
        },
        {
          "text": "provide Sekisui any tax forms that may be reasonably necessary in order for Sekisui to not withhold tax or to withhold tax at a reduced",
          "bbox": [
            529.0,
            870.0,
            3029.0,
            919.0
          ],
          "confidence": 0.9935504198074341
        },
        {
          "text": "rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the",
          "bbox": [
            526.0,
            928.0,
            3029.0,
            974.0
          ],
          "confidence": 0.9866539835929871
        },
        {
          "text": "recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar obligations resulting from payments made",
          "bbox": [
            527.0,
            989.0,
            3029.0,
            1031.0
          ],
          "confidence": 0.9919902682304382
        },
        {
          "text": "under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.",
          "bbox": [
            529.0,
            1043.0,
            2740.0,
            1085.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "4.9.1.",
          "bbox": [
            446.0,
            1098.0,
            546.0,
            1138.0
          ],
          "confidence": 0.9987618923187256
        },
        {
          "text": "Medical Device Tax. The party responsible for paying any applicable medical device excise tax pursuant to Section 4191 of the.",
          "bbox": [
            607.0,
            1095.0,
            3029.0,
            1146.0
          ],
          "confidence": 0.9898098707199097
        },
        {
          "text": "U.S. Internal Revenue Code or any successor thereto will be as determined under such tax provisions. If any, such medical device",
          "bbox": [
            613.0,
            1153.0,
            3027.0,
            1197.0
          ],
          "confidence": 0.9912339448928833
        },
        {
          "text": "excise tax will be treated as a cost element to be included in COGS as referenced in Exhibit A..",
          "bbox": [
            616.0,
            1210.0,
            2333.0,
            1252.0
          ],
          "confidence": 0.989422619342804
        },
        {
          "text": "4.10.",
          "bbox": [
            357.0,
            1263.0,
            450.0,
            1310.0
          ],
          "confidence": 0.9101659655570984
        },
        {
          "text": "Interest. Accrual and payment of interest shall not be deemed to excuse or cure breaches of contract arising from late payment or",
          "bbox": [
            527.0,
            1268.0,
            3029.0,
            1310.0
          ],
          "confidence": 0.9960917234420776
        },
        {
          "text": "nonpayment. Cumulative with and not exclusive of any and all other available remedies, payments that are more than 30 days past due",
          "bbox": [
            527.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9941427111625671
        },
        {
          "text": "hereunder, and which are not otherwise subject to a good faith dispute, shall accrue interest, from the due date until paid, at an annual",
          "bbox": [
            526.0,
            1378.0,
            3029.0,
            1424.0
          ],
          "confidence": 0.9961178302764893
        },
        {
          "text": "rate equal to the prime rate, as reported in The Wall Street Journal, Eastern U.S. Edition, on the date such payment is due, plus an",
          "bbox": [
            526.0,
            1434.0,
            3029.0,
            1480.0
          ],
          "confidence": 0.9957613945007324
        },
        {
          "text": "additional 200 basis points (2%).",
          "bbox": [
            527.0,
            1489.0,
            1137.0,
            1535.0
          ],
          "confidence": 0.9987368583679199
        },
        {
          "text": "4.11.",
          "bbox": [
            359.0,
            1546.0,
            446.0,
            1588.0
          ],
          "confidence": 0.997421145439148
        },
        {
          "text": "Currency. All invoices under this Agreement shall be paid in United States dollars..",
          "bbox": [
            527.0,
            1548.0,
            2061.0,
            1590.0
          ],
          "confidence": 0.9967273473739624
        },
        {
          "text": "5.",
          "bbox": [
            274.0,
            1603.0,
            317.0,
            1645.0
          ],
          "confidence": 0.7983710169792175
        },
        {
          "text": "Manufacturing and Quality Assurance",
          "bbox": [
            446.0,
            1604.0,
            1184.0,
            1645.0
          ],
          "confidence": 0.9868720173835754
        },
        {
          "text": "5.1.",
          "bbox": [
            357.0,
            1656.0,
            431.0,
            1705.0
          ],
          "confidence": 0.9999219179153442
        },
        {
          "text": "Manufacturing Conformance. Qualigen represents and warrants that it shall manufacture all Products in accordance with the",
          "bbox": [
            531.0,
            1661.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9923285841941833
        },
        {
          "text": "applicable product specifications and all applicable federal, state and local laws, regulations, and guidelines. Qualigen represents and",
          "bbox": [
            531.0,
            1716.0,
            3029.0,
            1762.0
          ],
          "confidence": 0.9998115301132202
        },
        {
          "text": "warrants that no Product delivered by Qualigen under this Agreement will be adulterated or misbranded within the meaning of 21",
          "bbox": [
            529.0,
            1773.0,
            3025.0,
            1815.0
          ],
          "confidence": 0.9938739538192749
        },
        {
          "text": "U.S.C. Sections 351-352, or within the meaning of any other applicable law as such laws are constituted and effective at the time of",
          "bbox": [
            527.0,
            1826.0,
            3032.0,
            1871.0
          ],
          "confidence": 0.9836247563362122
        },
        {
          "text": "such shipment or delivery. Qualigen shall maintain appropriate certification status and compliance with the FDA's Quality System",
          "bbox": [
            531.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.999665379524231
        },
        {
          "text": "Regulation, the Directive of 27 October 1998 on In Vitro Diagnostic Medical Devices (IVDD) and/or all other applicable regulations.",
          "bbox": [
            529.0,
            1939.0,
            3020.0,
            1981.0
          ],
          "confidence": 0.9944262504577637
        },
        {
          "text": "Upon request, Qualigen shall furnish to Sekisui any such information required to enable Sekisui to comply with all applicable",
          "bbox": [
            529.0,
            1995.0,
            3027.0,
            2041.0
          ],
          "confidence": 0.9946947693824768
        },
        {
          "text": "regulations and standards that pertain to distributors for the Products..",
          "bbox": [
            527.0,
            2050.0,
            1842.0,
            2096.0
          ],
          "confidence": 0.9838126301765442
        },
        {
          "text": "5.2.",
          "bbox": [
            355.0,
            2103.0,
            430.0,
            2153.0
          ],
          "confidence": 0.9999211430549622
        },
        {
          "text": "Manufacturing Changes. Qualigen shall notify Sekisui in writing no less than 3 months prior to any material changes which affect (i)",
          "bbox": [
            527.0,
            2107.0,
            3025.0,
            2153.0
          ],
          "confidence": 0.9962983727455139
        },
        {
          "text": "the form, fit or function of any Products, or (ii) the labeling or regulatory status of the Products in any of the Applicable Markets.",
          "bbox": [
            529.0,
            2164.0,
            2927.0,
            2209.0
          ],
          "confidence": 0.9934166073799133
        },
        {
          "text": "5.3.",
          "bbox": [
            357.0,
            2218.0,
            428.0,
            2262.0
          ],
          "confidence": 0.999969482421875
        },
        {
          "text": "Manufacturing Site. During the Term, Qualigen shall manufacture all Products using Qualigen's facilities located in Carlsbad.",
          "bbox": [
            529.0,
            2220.0,
            3023.0,
            2262.0
          ],
          "confidence": 0.9907397627830505
        },
        {
          "text": "California. Qualigen shall give at least six (6) months prior written notice to Sekisui of any proposed relocation of the manufacturing of",
          "bbox": [
            531.0,
            2279.0,
            3030.0,
            2321.0
          ],
          "confidence": 0.9922841191291809
        },
        {
          "text": "any Product. Any new facility proposed to be used by Qualigen in manufacturing any Product shall be subject to a new and separate",
          "bbox": [
            527.0,
            2334.0,
            3027.0,
            2377.0
          ],
          "confidence": 0.9995027184486389
        },
        {
          "text": "audit by Sekisui personnel in accordance with Quality Systems Regulations (QSR), as well as ISO 13485..",
          "bbox": [
            527.0,
            2386.0,
            2467.0,
            2432.0
          ],
          "confidence": 0.9848436713218689
        },
        {
          "text": "8",
          "bbox": [
            1638.0,
            2449.0,
            1669.0,
            2483.0
          ],
          "confidence": 0.9997285008430481
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9953641295433044
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_2",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Sekisui shall notify Qualigen at least one month in advance of a planned audit and Qualigen shall make reasonable efforts to accommodate the desired schedule.",
      "page_number": 2,
      "words": [
        {
          "text": "1.21.",
          "bbox": [
            359.0,
            252.0,
            451.0,
            300.0
          ],
          "confidence": 0.9230712652206421
        },
        {
          "text": "Regulatory Authorities shall mean the FDA, each Competent Authority, Health Canada and the Japanese Pharmaceuticals and",
          "bbox": [
            533.0,
            259.0,
            3027.0,
            296.0
          ],
          "confidence": 0.9924156665802002
        },
        {
          "text": "Medical Devices Agency.",
          "bbox": [
            529.0,
            312.0,
            1006.0,
            356.0
          ],
          "confidence": 0.99922776222229
        },
        {
          "text": "1.22.",
          "bbox": [
            359.0,
            364.0,
            450.0,
            413.0
          ],
          "confidence": 0.9985124468803406
        },
        {
          "text": "Revenue Affiliate shall mean any entity of which Sekisui has the direct or indirect power to vote more than fifty percent (50%) of the",
          "bbox": [
            529.0,
            367.0,
            3027.0,
            411.0
          ],
          "confidence": 0.9936479926109314
        },
        {
          "text": "direct or indirect ability to direct or cause the direction of the general management and policies of that entity.",
          "bbox": [
            529.0,
            479.0,
            2545.0,
            526.0
          ],
          "confidence": 0.9983549118041992
        },
        {
          "text": "1.23.",
          "bbox": [
            359.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.9992727041244507
        },
        {
          "text": "Sale Transaction shall mean (i) any transaction in which Qualigen, Qualigen's business or control of Qualigen is acquired, (ii) any",
          "bbox": [
            527.0,
            535.0,
            3025.0,
            583.0
          ],
          "confidence": 0.9933872222900391
        },
        {
          "text": "license, sale, lease, transfer, or other disposition, in a single transaction or series of related transactions, of all or substantially all of",
          "bbox": [
            527.0,
            592.0,
            3031.0,
            636.0
          ],
          "confidence": 0.9962546825408936
        },
        {
          "text": "Qualigen's assets other than in the ordinary course of business, (iii) any sale of a majority of the outstanding shares of capital stock",
          "bbox": [
            533.0,
            651.0,
            3029.0,
            693.0
          ],
          "confidence": 0.9975800514221191
        },
        {
          "text": "of Qualigen, (iv) any sale or license of any rights to any Qualigen products, now or hereafter existing, other than in the ordinary",
          "bbox": [
            531.0,
            707.0,
            3027.0,
            749.0
          ],
          "confidence": 0.9935311079025269
        },
        {
          "text": "course of business, (v) any liquidation or dissolution of Qualigen, (vi) any similar transaction resulting in a change of control of",
          "bbox": [
            531.0,
            764.0,
            3032.0,
            806.0
          ],
          "confidence": 0.9916770458221436
        },
        {
          "text": "Qualigen, or (vii) any of the foregoing with respect to any now or hereafter existing subsidiary of Qualigen which holds, on a",
          "bbox": [
            533.0,
            820.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9889509677886963
        },
        {
          "text": "consolidated basis, all or substantially all of Qualigen's assets (i.e., of the assets of Qualigen and all its Affiliates considered",
          "bbox": [
            529.0,
            875.0,
            3027.0,
            917.0
          ],
          "confidence": 0.9926474690437317
        },
        {
          "text": "together).",
          "bbox": [
            525.0,
            928.0,
            713.0,
            978.0
          ],
          "confidence": 0.9990909695625305
        },
        {
          "text": "1.24.",
          "bbox": [
            359.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9993151426315308
        },
        {
          "text": "Serious Incident shall mean an incident involving the Products, which is reportable to a Competent Authority and as defined in",
          "bbox": [
            531.0,
            990.0,
            3025.0,
            1027.0
          ],
          "confidence": 0.990603506565094
        },
        {
          "text": "Section 5 of Annex III of the IVD Directive, and the European Commission Medical Devices Vigilance Guidelines 2.12-1 or such other",
          "bbox": [
            529.0,
            1043.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9936378002166748
        },
        {
          "text": "Guidelines as may be issued from time to time.",
          "bbox": [
            531.0,
            1102.0,
            1383.0,
            1138.0
          ],
          "confidence": 0.9971452951431274
        },
        {
          "text": "1.25.",
          "bbox": [
            359.0,
            1149.0,
            448.0,
            1199.0
          ],
          "confidence": 0.9999178647994995
        },
        {
          "text": "Territory shall mean worldwide excluding Qualigen Retained Customers.",
          "bbox": [
            529.0,
            1157.0,
            1863.0,
            1199.0
          ],
          "confidence": 0.989960253238678
        },
        {
          "text": "1.26.",
          "bbox": [
            359.0,
            1208.0,
            450.0,
            1255.0
          ],
          "confidence": 0.9994128942489624
        },
        {
          "text": "Third Party shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
          "bbox": [
            527.0,
            1208.0,
            2382.0,
            1254.0
          ],
          "confidence": 0.989874005317688
        },
        {
          "text": "2.",
          "bbox": [
            272.0,
            1265.0,
            317.0,
            1308.0
          ],
          "confidence": 0.9999349117279053
        },
        {
          "text": "Appointment and Term",
          "bbox": [
            450.0,
            1268.0,
            877.0,
            1307.0
          ],
          "confidence": 0.999896228313446
        },
        {
          "text": "2.1.",
          "bbox": [
            359.0,
            1321.0,
            430.0,
            1365.0
          ],
          "confidence": 0.999855101108551
        },
        {
          "text": "Appointment. Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the",
          "bbox": [
            531.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9947742223739624
        },
        {
          "text": "terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory. Sekisui shall be permitted to",
          "bbox": [
            529.0,
            1378.0,
            3025.0,
            1420.0
          ],
          "confidence": 0.9916503429412842
        },
        {
          "text": "appoint sub-distributors in the Territory (including any current Qualigen distributors) with the approval of Qualigen, not to be",
          "bbox": [
            527.0,
            1433.0,
            3027.0,
            1480.0
          ],
          "confidence": 0.9952742457389832
        },
        {
          "text": "unreasonably withheld or delayed. Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the",
          "bbox": [
            529.0,
            1493.0,
            3027.0,
            1535.0
          ],
          "confidence": 0.9905573129653931
        },
        {
          "text": "Products exclusively to Sekisui, in each case for the Territory. Qualigen shall assign to Sekisui Qualigen's agreements with Qualigen's",
          "bbox": [
            527.0,
            1546.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9959052205085754
        },
        {
          "text": "current distributors (such that such current Qualigen distributors shall become Sekisui subdistributors), each of which is set forth on",
          "bbox": [
            527.0,
            1604.0,
            3027.0,
            1646.0
          ],
          "confidence": 0.9941188097000122
        },
        {
          "text": "Schedule 2.1 hereto; if any of such agreements do not allow such assignment and the current distributor declines to consent to such",
          "bbox": [
            531.0,
            1661.0,
            3030.0,
            1703.0
          ],
          "confidence": 0.9969964623451233
        },
        {
          "text": "an assignment to Sekisui, Qualigen shall (if Sekisui so requests) act pursuant to such agreement to terminate such agreement.",
          "bbox": [
            527.0,
            1718.0,
            2862.0,
            1760.0
          ],
          "confidence": 0.9927040338516235
        },
        {
          "text": "2.2.",
          "bbox": [
            355.0,
            1767.0,
            430.0,
            1816.0
          ],
          "confidence": 0.9999159574508667
        },
        {
          "text": "Term. The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless",
          "bbox": [
            529.0,
            1773.0,
            3027.0,
            1815.0
          ],
          "confidence": 0.9939504861831665
        },
        {
          "text": "earlier terminated pursuant to Section 14 hereof (the \"Term'). The initial term of this Agreement and any renewal term thereof shall be",
          "bbox": [
            529.0,
            1829.0,
            3027.0,
            1871.0
          ],
          "confidence": 0.9962239861488342
        },
        {
          "text": "automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9914175271987915
        },
        {
          "text": "Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this",
          "bbox": [
            531.0,
            1942.0,
            3023.0,
            1979.0
          ],
          "confidence": 0.9881066083908081
        },
        {
          "text": "Agreement. References in this Agreement to \"Term\"' shall be deemed to include the initial five (5) year term as well as a reduction or",
          "bbox": [
            533.0,
            1997.0,
            3029.0,
            2039.0
          ],
          "confidence": 0.9924869537353516
        },
        {
          "text": "extension of that time period that may occur as a result of the provision of this Section 0 or the provisions of Section 14.",
          "bbox": [
            531.0,
            2054.0,
            2757.0,
            2096.0
          ],
          "confidence": 0.9920394420623779
        },
        {
          "text": "3",
          "bbox": [
            1638.0,
            2109.0,
            1668.0,
            2147.0
          ],
          "confidence": 0.9998428821563721
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939860105514526
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "As part of Sekisui's supplier approval program, Sekisui will have the option to perform an audit (applying Sekisui's standard supplier criteria for qualification as an \"Approved Supplier\") at Qualigen's Carlsbad, California manufacturing facility annually and at each relocated manufacturing facility at which Qualigen will manufacture the Products within sixty (60) days of Qualigen's notice to Sekisui of the relocation of such manufacturing facility.",
      "page_number": 3,
      "words": [
        {
          "text": "2.3.",
          "bbox": [
            357.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Customer Product Rentals. All instruments placed with customers under a rental program during the Term shall be owned by Sekisui",
          "bbox": [
            533.0,
            258.0,
            3025.0,
            294.0
          ],
          "confidence": 0.9904672503471375
        },
        {
          "text": "(\"Sekisui Instruments'), while Qualigen shall retain ownership of instruments placed with customers under a rental program before the",
          "bbox": [
            529.0,
            312.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9988958835601807
        },
        {
          "text": "execution of this Agreement (\"Qualigen Instruments') and any instruments (including FastPack 2.0) placed by Qualigen to the",
          "bbox": [
            529.0,
            371.0,
            3027.0,
            413.0
          ],
          "confidence": 0.9914922118186951
        },
        {
          "text": "Qualigen Retained Customers.",
          "bbox": [
            535.0,
            429.0,
            1093.0,
            466.0
          ],
          "confidence": 0.9996685981750488
        },
        {
          "text": "2.4.",
          "bbox": [
            357.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.8889804482460022
        },
        {
          "text": "Qualigen Retained Customers. In addition to the retention of the Qualigen Instruments, Qualigen shall be permitted to continue selling",
          "bbox": [
            527.0,
            479.0,
            3027.0,
            526.0
          ],
          "confidence": 0.9955565929412842
        },
        {
          "text": "the existing Qualigen products directly to the Qualigen Retained Customers. However, Qualigen shall not engage any distributors",
          "bbox": [
            527.0,
            537.0,
            3027.0,
            583.0
          ],
          "confidence": 0.9956963062286377
        },
        {
          "text": "(whether exclusive or non-exclusive) other than Sekisui for the Qualigen Retained Customers. Sekisui shall not, and shall cause its",
          "bbox": [
            533.0,
            598.0,
            3025.0,
            634.0
          ],
          "confidence": 0.9922968745231628
        },
        {
          "text": "subdistributors not to, market, rent or sell any Products to the Qualigen Retained Customers.",
          "bbox": [
            529.0,
            651.0,
            2251.0,
            691.0
          ],
          "confidence": 0.9907932281494141
        },
        {
          "text": "3.",
          "bbox": [
            272.0,
            704.0,
            317.0,
            746.0
          ],
          "confidence": 0.9999651312828064
        },
        {
          "text": "Supply; Orders",
          "bbox": [
            450.0,
            707.0,
            741.0,
            746.0
          ],
          "confidence": 0.9901391863822937
        },
        {
          "text": "3.1.",
          "bbox": [
            357.0,
            760.0,
            430.0,
            804.0
          ],
          "confidence": 0.9141092300415039
        },
        {
          "text": "Supply. Qualigen shall supply Sekisui with all of Sekisui's commercial requirements for the Product in the Applicable Markets. All",
          "bbox": [
            529.0,
            758.0,
            3029.0,
            806.0
          ],
          "confidence": 0.9893293976783752
        },
        {
          "text": "Products supplied by Qualigen to Sekisui shall have on the date of shipment by Qualigen a shelf life of not less than a minimum three",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9937877058982849
        },
        {
          "text": "(3) month shelf life for products shipped within the United States and not less than a minimum four (4) month shelf life for products",
          "bbox": [
            531.0,
            875.0,
            3027.0,
            917.0
          ],
          "confidence": 0.9900067448616028
        },
        {
          "text": "shipped outside the United States (or such longer shelf-life as may be mutually agreed by Qualigen and a Sekisui customer with",
          "bbox": [
            531.0,
            932.0,
            3027.0,
            974.0
          ],
          "confidence": 0.99024897813797
        },
        {
          "text": "respect to a specific customer order). Qualigen shall use reasonable efforts to assure that the Products, as manufactured by Qualigen,",
          "bbox": [
            527.0,
            989.0,
            3025.0,
            1031.0
          ],
          "confidence": 0.9897968769073486
        },
        {
          "text": "conform to the applicable product specifications and requirements of the Regulatory Authorities in, and are manufactured in",
          "bbox": [
            529.0,
            1043.0,
            3025.0,
            1084.0
          ],
          "confidence": 0.9916502833366394
        },
        {
          "text": "accordance with all Regulatory Approvals, laws and regulations applicable to the Products in the Applicable Markets. Qualigen shall",
          "bbox": [
            529.0,
            1100.0,
            3029.0,
            1144.0
          ],
          "confidence": 0.9925655722618103
        },
        {
          "text": "maintain the necessary records to comply with all Regulatory Approvals and other applicable rules and regulations in the Applicable",
          "bbox": [
            527.0,
            1157.0,
            3029.0,
            1199.0
          ],
          "confidence": 0.9983315467834473
        },
        {
          "text": "Markets.",
          "bbox": [
            529.0,
            1212.0,
            698.0,
            1250.0
          ],
          "confidence": 0.999404788017273
        },
        {
          "text": "3.2.",
          "bbox": [
            357.0,
            1265.0,
            428.0,
            1308.0
          ],
          "confidence": 0.9999250173568726
        },
        {
          "text": "Forecast. Sekisui shall submit to Qualigen by the fifth day of each calendar month a rolling twelve (12) month (month-by-month)",
          "bbox": [
            526.0,
            1265.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9970149993896484
        },
        {
          "text": "forecast of the quantity of each Product that Sekisui anticipates selling during the following twelve (12) months (the \"Forecast'). A s",
          "bbox": [
            526.0,
            1321.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9838274717330933
        },
        {
          "text": "to Reagent Kits each respective Forecast shall represent reasonable estimates to be used for planning and inventory stocking",
          "bbox": [
            527.0,
            1378.0,
            3027.0,
            1424.0
          ],
          "confidence": 0.9944573640823364
        },
        {
          "text": "purposes as indicated in Exhibit D, and shall not be binding on Sekisui; provided, however, that as to Instruments the quantities for",
          "bbox": [
            527.0,
            1433.0,
            3029.0,
            1480.0
          ],
          "confidence": 0.9939049482345581
        },
        {
          "text": "each of the first three months of each respective Forecast shall be deemed to constitute and shall constitute firm, binding orders for",
          "bbox": [
            529.0,
            1493.0,
            3027.0,
            1535.0
          ],
          "confidence": 0.9949345588684082
        },
        {
          "text": "such quantities of Instruments in such respective months (but in no event for a lesser quantity for a month than the quantity for such",
          "bbox": [
            531.0,
            1550.0,
            3027.0,
            1592.0
          ],
          "confidence": 0.9874935746192932
        },
        {
          "text": "month which, pursuant to an earlier Forecast, had already become a firm, binding order).",
          "bbox": [
            527.0,
            1603.0,
            2164.0,
            1646.0
          ],
          "confidence": 0.9950923323631287
        },
        {
          "text": "4",
          "bbox": [
            1638.0,
            1665.0,
            1669.0,
            1698.0
          ],
          "confidence": 0.9995495676994324
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9941825866699219
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "As part of Sekisui's supplier approval program, Sekisui will have the option to perform an audit (applying Sekisui's standard supplier criteria for qualification as an \"Approved Supplier\") at Qualigen's Carlsbad, California manufacturing facility annually and at each relocated manufacturing facility at which Qualigen will manufacture the Products within sixty (60) days of Qualigen's notice to Sekisui of the relocation of such manufacturing facility.",
      "page_number": 4,
      "words": [
        {
          "text": "3.3.",
          "bbox": [
            355.0,
            252.0,
            430.0,
            302.0
          ],
          "confidence": 0.9240008592605591
        },
        {
          "text": "Orders. Orders shall be processed as set forth in Exhibit F. Each purchase order shall be governed by the terms and conditions of this",
          "bbox": [
            533.0,
            258.0,
            3023.0,
            294.0
          ],
          "confidence": 0.9986158013343811
        },
        {
          "text": "Agreement (regardless of whether such purchase order references the Agreement). Sekisui shall be allowed to, for convenience,",
          "bbox": [
            529.0,
            312.0,
            3027.0,
            358.0
          ],
          "confidence": 0.9976808428764343
        },
        {
          "text": "document its purchase orders by using Sekisui's standard form of purchase order, but in no event shall anything in such purchase",
          "bbox": [
            529.0,
            371.0,
            3027.0,
            413.0
          ],
          "confidence": 0.9932072162628174
        },
        {
          "text": "order vary, contradict or augment the terms of this Agreement, and the parties agree that any \"preprinted\" provisions in the purchase",
          "bbox": [
            529.0,
            428.0,
            3027.0,
            470.0
          ],
          "confidence": 0.9944770932197571
        },
        {
          "text": "orders shall, if they are inconsistent with or additive to this Agreement, simply be disregarded and shall be deemed inapplicable",
          "bbox": [
            531.0,
            482.0,
            3027.0,
            524.0
          ],
          "confidence": 0.9979562759399414
        },
        {
          "text": "and/or rejected (regardless of acceptance, performance or apparent acquiescence, none of which shall constitute or be construed to",
          "bbox": [
            529.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.986576497554779
        },
        {
          "text": "constitute Qualigen's or Sekisui's consent to or recognition of terms, conditions or provisions that are different from or are not.",
          "bbox": [
            527.0,
            592.0,
            3031.0,
            638.0
          ],
          "confidence": 0.9969212412834167
        },
        {
          "text": "3.3 Qualigen agrees to accept such \"preprinted\" term. Similarly, Qualigen shall be allowed to, for convenience, document its",
          "bbox": [
            533.0,
            707.0,
            3029.0,
            749.0
          ],
          "confidence": 0.9938979744911194
        },
        {
          "text": "acknowledgements, confirmations and similar instruments by using Qualigen's standard form of acknowledgement, confirmation and.",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.9829728603363037
        },
        {
          "text": "similar instruments, but in no event shall anything in such acknowledgements, confirmations and similar instruments vary, contradict.",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            859.0
          ],
          "confidence": 0.9940021634101868
        },
        {
          "text": "or augment the terms of this Agreement, and the Parties agree that any \"preprinted\" provisions in the acknowledgements,",
          "bbox": [
            527.0,
            875.0,
            3025.0,
            919.0
          ],
          "confidence": 0.9900205135345459
        },
        {
          "text": "confirmations and similar instruments shall, if they are inconsistent with or additive to this Agreement, simply be disregarded and be",
          "bbox": [
            531.0,
            932.0,
            3027.0,
            974.0
          ],
          "confidence": 0.997846782207489
        },
        {
          "text": "deemed inapplicable and/or rejected (regardless of acceptance, performance or apparent acquiescence, none of which shall constitute",
          "bbox": [
            531.0,
            989.0,
            3029.0,
            1031.0
          ],
          "confidence": 0.9957342743873596
        },
        {
          "text": "or be construed to constitute Qualigen's or Sekisui's consent to or recognition of terms, conditions or provisions that are different",
          "bbox": [
            529.0,
            1043.0,
            3029.0,
            1085.0
          ],
          "confidence": 0.9977991580963135
        },
        {
          "text": "from or are not contained in this Agreement), unless in a separate and nonboilerplate agreement which expressly identifies and waives.",
          "bbox": [
            527.0,
            1096.0,
            3029.0,
            1142.0
          ],
          "confidence": 0.9943267107009888
        },
        {
          "text": "this Section 3.3 Sekisui agrees to accept such \"preprinted\"' term.",
          "bbox": [
            527.0,
            1153.0,
            1724.0,
            1199.0
          ],
          "confidence": 0.988237202167511
        },
        {
          "text": "3.4.",
          "bbox": [
            355.0,
            1206.0,
            431.0,
            1255.0
          ],
          "confidence": 0.9999426603317261
        },
        {
          "text": "Product Records. Qualigen shall test or cause to be tested each lot of Product purchased by Sekisui. Qualigen shall provide Sekisui",
          "bbox": [
            529.0,
            1212.0,
            3029.0,
            1254.0
          ],
          "confidence": 0.998099148273468
        },
        {
          "text": "with copies of any Product test records requested or Sekisui may audit Qualigen to review the Product test records..",
          "bbox": [
            531.0,
            1268.0,
            2677.0,
            1310.0
          ],
          "confidence": 0.9985233545303345
        },
        {
          "text": "3.5.",
          "bbox": [
            355.0,
            1318.0,
            431.0,
            1367.0
          ],
          "confidence": 0.9999627470970154
        },
        {
          "text": "No Alterations or Mishandling. Sekisui shall not, and shall also cause its subdistributors not to, alter or modify (or add to or subtract",
          "bbox": [
            531.0,
            1327.0,
            3029.0,
            1363.0
          ],
          "confidence": 0.9904143810272217
        },
        {
          "text": "from) in any way any Products delivered by Qualigen hereunder. Sekisui shall, and shall also cause its subdistributors to, handle,",
          "bbox": [
            527.0,
            1378.0,
            3025.0,
            1422.0
          ],
          "confidence": 0.9852206707000732
        },
        {
          "text": "store and transport the Products in accordance with Qualigen's guidelines and shall not, and shall also cause its subdistributors not",
          "bbox": [
            529.0,
            1436.0,
            3030.0,
            1478.0
          ],
          "confidence": 0.9993420243263245
        },
        {
          "text": "to, subject such Products to abuse, mishandling or unusual physical, thermal, chemical or electrical stress or sell any Product after its",
          "bbox": [
            529.0,
            1493.0,
            3029.0,
            1535.0
          ],
          "confidence": 0.9960097670555115
        },
        {
          "text": "expiration date.",
          "bbox": [
            529.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9999659061431885
        },
        {
          "text": "3.6.",
          "bbox": [
            357.0,
            1601.0,
            428.0,
            1645.0
          ],
          "confidence": 0.9161304831504822
        },
        {
          "text": "Packaging and Labeling. The Products shall be delivered by Qualigen, and Sekisui shall cause the Products to be delivered to end",
          "bbox": [
            529.0,
            1604.0,
            3030.0,
            1646.0
          ],
          "confidence": 0.9958147406578064
        },
        {
          "text": "users, in Qualigen packaging and with Qualigen labeling, all as intended to be received by the end user. Such packaging and labeling.",
          "bbox": [
            527.0,
            1659.0,
            3027.0,
            1705.0
          ],
          "confidence": 0.9934335350990295
        },
        {
          "text": "(and the Products themselves) (and \"product inserts,\" which Qualigen may provide online so long as it is done in compliance with all",
          "bbox": [
            529.0,
            1718.0,
            3030.0,
            1760.0
          ],
          "confidence": 0.9961274862289429
        },
        {
          "text": "legal requirements of the applicable jurisdiction) shall include such Qualigen trade names, brand names, trademarks and logos (and.",
          "bbox": [
            527.0,
            1773.0,
            3030.0,
            1815.0
          ],
          "confidence": 0.99114990234375
        },
        {
          "text": "patent notices) as Qualigen shall select and with such size, colors, positioning and prominence as Qualigen shall select in its sole",
          "bbox": [
            527.0,
            1827.0,
            3029.0,
            1873.0
          ],
          "confidence": 0.9902817606925964
        },
        {
          "text": "discretion, and shall not include any Sekisui trade names, brand names, trademarks or logos (except that, if so required by applicable",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9992655515670776
        },
        {
          "text": "law, Qualigen shall include a statement that Sekisui is the distributor and/or that Sekisui is the importer). Sekisui shall not imprint or.",
          "bbox": [
            531.0,
            1944.0,
            3027.0,
            1981.0
          ],
          "confidence": 0.9904691576957703
        },
        {
          "text": "affix any of its (or any non-Qualigen person's) trade names, brand names, trademarks or logos to any Product or its packaging or",
          "bbox": [
            529.0,
            1997.0,
            3027.0,
            2041.0
          ],
          "confidence": 0.9889706373214722
        },
        {
          "text": "labeling, and shall also cause its subdistributors not to do so. Sekisui shall not deface, cover, obscure, erase, alter or remove any.",
          "bbox": [
            527.0,
            2052.0,
            3027.0,
            2098.0
          ],
          "confidence": 0.997536301612854
        },
        {
          "text": "Qualigen trade names, brand names, trademarks or logos (or patent notices) applied by Qualigen to the Products or to the Products'",
          "bbox": [
            533.0,
            2111.0,
            3023.0,
            2153.0
          ],
          "confidence": 0.9949026107788086
        },
        {
          "text": "packaging or labeling, and shall also cause its subdistributors not to do so..",
          "bbox": [
            529.0,
            2164.0,
            1930.0,
            2209.0
          ],
          "confidence": 0.9871931076049805
        },
        {
          "text": "5",
          "bbox": [
            1638.0,
            2222.0,
            1669.0,
            2259.0
          ],
          "confidence": 0.9999334812164307
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9931644201278687
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Any new facility proposed to be used by Qualigen in manufacturing any Product shall be subject to a new and separate audit by Sekisui personnel in accordance with Quality Systems Regulations (QSR), as well as ISO 13485.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Any new facility proposed to be used by Qualigen in manufacturing any Product shall be subject to a new and separate audit by Sekisui personnel in accordance with Quality Systems Regulations (QSR), as well as ISO 13485.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable written notice (and no more often than once every 150 days), the auditing Party shall have the right, during normal business hours, to audit the books and records maintained by the audited Party pursuant to this Agreement to ensure the accuracy of all reports and payments made hereunder.",
      "page_number": 4,
      "words": [
        {
          "text": "3.3.",
          "bbox": [
            355.0,
            252.0,
            430.0,
            302.0
          ],
          "confidence": 0.9240008592605591
        },
        {
          "text": "Orders. Orders shall be processed as set forth in Exhibit F. Each purchase order shall be governed by the terms and conditions of this",
          "bbox": [
            533.0,
            258.0,
            3023.0,
            294.0
          ],
          "confidence": 0.9986158013343811
        },
        {
          "text": "Agreement (regardless of whether such purchase order references the Agreement). Sekisui shall be allowed to, for convenience,",
          "bbox": [
            529.0,
            312.0,
            3027.0,
            358.0
          ],
          "confidence": 0.9976808428764343
        },
        {
          "text": "document its purchase orders by using Sekisui's standard form of purchase order, but in no event shall anything in such purchase",
          "bbox": [
            529.0,
            371.0,
            3027.0,
            413.0
          ],
          "confidence": 0.9932072162628174
        },
        {
          "text": "order vary, contradict or augment the terms of this Agreement, and the parties agree that any \"preprinted\" provisions in the purchase",
          "bbox": [
            529.0,
            428.0,
            3027.0,
            470.0
          ],
          "confidence": 0.9944770932197571
        },
        {
          "text": "orders shall, if they are inconsistent with or additive to this Agreement, simply be disregarded and shall be deemed inapplicable",
          "bbox": [
            531.0,
            482.0,
            3027.0,
            524.0
          ],
          "confidence": 0.9979562759399414
        },
        {
          "text": "and/or rejected (regardless of acceptance, performance or apparent acquiescence, none of which shall constitute or be construed to",
          "bbox": [
            529.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.986576497554779
        },
        {
          "text": "constitute Qualigen's or Sekisui's consent to or recognition of terms, conditions or provisions that are different from or are not.",
          "bbox": [
            527.0,
            592.0,
            3031.0,
            638.0
          ],
          "confidence": 0.9969212412834167
        },
        {
          "text": "3.3 Qualigen agrees to accept such \"preprinted\" term. Similarly, Qualigen shall be allowed to, for convenience, document its",
          "bbox": [
            533.0,
            707.0,
            3029.0,
            749.0
          ],
          "confidence": 0.9938979744911194
        },
        {
          "text": "acknowledgements, confirmations and similar instruments by using Qualigen's standard form of acknowledgement, confirmation and.",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.9829728603363037
        },
        {
          "text": "similar instruments, but in no event shall anything in such acknowledgements, confirmations and similar instruments vary, contradict.",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            859.0
          ],
          "confidence": 0.9940021634101868
        },
        {
          "text": "or augment the terms of this Agreement, and the Parties agree that any \"preprinted\" provisions in the acknowledgements,",
          "bbox": [
            527.0,
            875.0,
            3025.0,
            919.0
          ],
          "confidence": 0.9900205135345459
        },
        {
          "text": "confirmations and similar instruments shall, if they are inconsistent with or additive to this Agreement, simply be disregarded and be",
          "bbox": [
            531.0,
            932.0,
            3027.0,
            974.0
          ],
          "confidence": 0.997846782207489
        },
        {
          "text": "deemed inapplicable and/or rejected (regardless of acceptance, performance or apparent acquiescence, none of which shall constitute",
          "bbox": [
            531.0,
            989.0,
            3029.0,
            1031.0
          ],
          "confidence": 0.9957342743873596
        },
        {
          "text": "or be construed to constitute Qualigen's or Sekisui's consent to or recognition of terms, conditions or provisions that are different",
          "bbox": [
            529.0,
            1043.0,
            3029.0,
            1085.0
          ],
          "confidence": 0.9977991580963135
        },
        {
          "text": "from or are not contained in this Agreement), unless in a separate and nonboilerplate agreement which expressly identifies and waives.",
          "bbox": [
            527.0,
            1096.0,
            3029.0,
            1142.0
          ],
          "confidence": 0.9943267107009888
        },
        {
          "text": "this Section 3.3 Sekisui agrees to accept such \"preprinted\"' term.",
          "bbox": [
            527.0,
            1153.0,
            1724.0,
            1199.0
          ],
          "confidence": 0.988237202167511
        },
        {
          "text": "3.4.",
          "bbox": [
            355.0,
            1206.0,
            431.0,
            1255.0
          ],
          "confidence": 0.9999426603317261
        },
        {
          "text": "Product Records. Qualigen shall test or cause to be tested each lot of Product purchased by Sekisui. Qualigen shall provide Sekisui",
          "bbox": [
            529.0,
            1212.0,
            3029.0,
            1254.0
          ],
          "confidence": 0.998099148273468
        },
        {
          "text": "with copies of any Product test records requested or Sekisui may audit Qualigen to review the Product test records..",
          "bbox": [
            531.0,
            1268.0,
            2677.0,
            1310.0
          ],
          "confidence": 0.9985233545303345
        },
        {
          "text": "3.5.",
          "bbox": [
            355.0,
            1318.0,
            431.0,
            1367.0
          ],
          "confidence": 0.9999627470970154
        },
        {
          "text": "No Alterations or Mishandling. Sekisui shall not, and shall also cause its subdistributors not to, alter or modify (or add to or subtract",
          "bbox": [
            531.0,
            1327.0,
            3029.0,
            1363.0
          ],
          "confidence": 0.9904143810272217
        },
        {
          "text": "from) in any way any Products delivered by Qualigen hereunder. Sekisui shall, and shall also cause its subdistributors to, handle,",
          "bbox": [
            527.0,
            1378.0,
            3025.0,
            1422.0
          ],
          "confidence": 0.9852206707000732
        },
        {
          "text": "store and transport the Products in accordance with Qualigen's guidelines and shall not, and shall also cause its subdistributors not",
          "bbox": [
            529.0,
            1436.0,
            3030.0,
            1478.0
          ],
          "confidence": 0.9993420243263245
        },
        {
          "text": "to, subject such Products to abuse, mishandling or unusual physical, thermal, chemical or electrical stress or sell any Product after its",
          "bbox": [
            529.0,
            1493.0,
            3029.0,
            1535.0
          ],
          "confidence": 0.9960097670555115
        },
        {
          "text": "expiration date.",
          "bbox": [
            529.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9999659061431885
        },
        {
          "text": "3.6.",
          "bbox": [
            357.0,
            1601.0,
            428.0,
            1645.0
          ],
          "confidence": 0.9161304831504822
        },
        {
          "text": "Packaging and Labeling. The Products shall be delivered by Qualigen, and Sekisui shall cause the Products to be delivered to end",
          "bbox": [
            529.0,
            1604.0,
            3030.0,
            1646.0
          ],
          "confidence": 0.9958147406578064
        },
        {
          "text": "users, in Qualigen packaging and with Qualigen labeling, all as intended to be received by the end user. Such packaging and labeling.",
          "bbox": [
            527.0,
            1659.0,
            3027.0,
            1705.0
          ],
          "confidence": 0.9934335350990295
        },
        {
          "text": "(and the Products themselves) (and \"product inserts,\" which Qualigen may provide online so long as it is done in compliance with all",
          "bbox": [
            529.0,
            1718.0,
            3030.0,
            1760.0
          ],
          "confidence": 0.9961274862289429
        },
        {
          "text": "legal requirements of the applicable jurisdiction) shall include such Qualigen trade names, brand names, trademarks and logos (and.",
          "bbox": [
            527.0,
            1773.0,
            3030.0,
            1815.0
          ],
          "confidence": 0.99114990234375
        },
        {
          "text": "patent notices) as Qualigen shall select and with such size, colors, positioning and prominence as Qualigen shall select in its sole",
          "bbox": [
            527.0,
            1827.0,
            3029.0,
            1873.0
          ],
          "confidence": 0.9902817606925964
        },
        {
          "text": "discretion, and shall not include any Sekisui trade names, brand names, trademarks or logos (except that, if so required by applicable",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9992655515670776
        },
        {
          "text": "law, Qualigen shall include a statement that Sekisui is the distributor and/or that Sekisui is the importer). Sekisui shall not imprint or.",
          "bbox": [
            531.0,
            1944.0,
            3027.0,
            1981.0
          ],
          "confidence": 0.9904691576957703
        },
        {
          "text": "affix any of its (or any non-Qualigen person's) trade names, brand names, trademarks or logos to any Product or its packaging or",
          "bbox": [
            529.0,
            1997.0,
            3027.0,
            2041.0
          ],
          "confidence": 0.9889706373214722
        },
        {
          "text": "labeling, and shall also cause its subdistributors not to do so. Sekisui shall not deface, cover, obscure, erase, alter or remove any.",
          "bbox": [
            527.0,
            2052.0,
            3027.0,
            2098.0
          ],
          "confidence": 0.997536301612854
        },
        {
          "text": "Qualigen trade names, brand names, trademarks or logos (or patent notices) applied by Qualigen to the Products or to the Products'",
          "bbox": [
            533.0,
            2111.0,
            3023.0,
            2153.0
          ],
          "confidence": 0.9949026107788086
        },
        {
          "text": "packaging or labeling, and shall also cause its subdistributors not to do so..",
          "bbox": [
            529.0,
            2164.0,
            1930.0,
            2209.0
          ],
          "confidence": 0.9871931076049805
        },
        {
          "text": "5",
          "bbox": [
            1638.0,
            2222.0,
            1669.0,
            2259.0
          ],
          "confidence": 0.9999334812164307
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9931644201278687
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable written notice (and no more often than once every 150 days), the auditing Party shall have the right, during normal business hours, to audit the books and records maintained by the audited Party pursuant to this Agreement to ensure the accuracy of all reports and payments made hereunder.",
      "page_number": 5,
      "words": [
        {
          "text": "4.",
          "bbox": [
            277.0,
            258.0,
            312.0,
            292.0
          ],
          "confidence": 0.9997537136077881
        },
        {
          "text": "Price, Shipment and Payment",
          "bbox": [
            448.0,
            258.0,
            1008.0,
            296.0
          ],
          "confidence": 0.9979109764099121
        },
        {
          "text": "4.1.",
          "bbox": [
            356.0,
            308.0,
            430.0,
            355.0
          ],
          "confidence": 0.9998072385787964
        },
        {
          "text": "Price. The price that Sekisui shall pay for the Products shall be established separately for the Reagent Kits and for the products other",
          "bbox": [
            527.0,
            312.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9889334440231323
        },
        {
          "text": "than Reagent Kits. The price that Sekisui shall pay for the Reagent Kits Products shall be based upon a formula intended to ensure",
          "bbox": [
            529.0,
            371.0,
            3029.0,
            413.0
          ],
          "confidence": 0.9914680123329163
        },
        {
          "text": "that Sekisui will receive 90% of the total Available Margin for all Products during the first 12 months of this Agreement, 70% of the",
          "bbox": [
            529.0,
            424.0,
            3025.0,
            468.0
          ],
          "confidence": 0.9925817251205444
        },
        {
          "text": "total Available Margin for all Products during months 13-24 of this Agreement, and 65% of the total Available Margin for all Products",
          "bbox": [
            529.0,
            481.0,
            3029.0,
            523.0
          ],
          "confidence": 0.9938228130340576
        },
        {
          "text": "thereafter. Accordingly, the prices (established separately for the Reagent Kits and for the products other than Reagent Kits) to be",
          "bbox": [
            527.0,
            537.0,
            3027.0,
            581.0
          ],
          "confidence": 0.9919881820678711
        },
        {
          "text": "paid by Sekisui for the Products shall be fixed (subject to a later lookback true up) for each respective prospective six month period in",
          "bbox": [
            529.0,
            596.0,
            3027.0,
            638.0
          ],
          "confidence": 0.9898732900619507
        },
        {
          "text": "the manner set forth in Exhibit D. The initial prices Sekisui agrees to pay for the respective Products for the first such prospective \"six",
          "bbox": [
            529.0,
            651.0,
            3029.0,
            693.0
          ],
          "confidence": 0.9969068765640259
        },
        {
          "text": "month period\" (in this instance actually a five month period: May-September 2016) shall be fixed (subject to a later lookback true up)",
          "bbox": [
            529.0,
            707.0,
            3025.0,
            749.0
          ],
          "confidence": 0.991199791431427
        },
        {
          "text": "in the manner set forth in Exhibit D. Thereafter such prices shall be revisited and recalculated (prospectively) every six months in the",
          "bbox": [
            526.0,
            760.0,
            3027.0,
            806.0
          ],
          "confidence": 0.996826708316803
        },
        {
          "text": "manner set forth in Exhibit D (i.e., for purposes of such calculations for establishing the new prospective prices for the reagent",
          "bbox": [
            526.0,
            817.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9992964267730713
        },
        {
          "text": "products, the applicable Net Revenue, COGS and Available Margin shall be the Net Revenue, COGS and Available Margin for the",
          "bbox": [
            527.0,
            872.0,
            3029.0,
            919.0
          ],
          "confidence": 0.9942246675491333
        },
        {
          "text": "applicable historical 6-month period as defined in Exhibit D). In addition, on a semi-annual basis, such amount shall be reviewed based",
          "bbox": [
            529.0,
            926.0,
            3029.0,
            976.0
          ],
          "confidence": 0.9986409544944763
        },
        {
          "text": "on the actual Net Revenue, COGS and Available Margin for the 6 months then ended. In the event that such review results in a",
          "bbox": [
            529.0,
            987.0,
            3030.0,
            1029.0
          ],
          "confidence": 0.9881531000137329
        },
        {
          "text": "difference from the intended share of Available Margin between the Parties as contemplated above, the Parties shall make a true up",
          "bbox": [
            527.0,
            1036.0,
            3031.0,
            1091.0
          ],
          "confidence": 0.998327374458313
        },
        {
          "text": "payment between them in order to compensate for such overpayment or shortfall, all as provided in Exhibit D. Any true-up payments",
          "bbox": [
            529.0,
            1100.0,
            3030.0,
            1144.0
          ],
          "confidence": 0.995193600654602
        },
        {
          "text": "shall be paid by the applicable Party within 30 days of the receipt of an invoice for the agreed to true up amount.",
          "bbox": [
            529.0,
            1155.0,
            2617.0,
            1199.0
          ],
          "confidence": 0.9920356273651123
        },
        {
          "text": "Sekisui shall set the customer selling prices in good faith and in a commercially reasonable manner.",
          "bbox": [
            531.0,
            1212.0,
            2365.0,
            1255.0
          ],
          "confidence": 0.9999339580535889
        },
        {
          "text": "4.2.",
          "bbox": [
            359.0,
            1265.0,
            428.0,
            1308.0
          ],
          "confidence": 0.8984659910202026
        },
        {
          "text": "Shipment. The shipment of orders to Sekisui's customers shall be subject to the ability of Sekisui and Qualigen to obtain all required",
          "bbox": [
            533.0,
            1268.0,
            3029.0,
            1310.0
          ],
          "confidence": 0.9926885366439819
        },
        {
          "text": "licenses and permits then in effect. Qualigen agrees (i) to assist Sekisui in obtaining such required licenses or permits, (ii) to comply",
          "bbox": [
            527.0,
            1323.0,
            3025.0,
            1369.0
          ],
          "confidence": 0.995852530002594
        },
        {
          "text": "with all Regulatory Approvals in, including all approvals and licenses necessary to import the Product into, the Applicable Markets,",
          "bbox": [
            527.0,
            1378.0,
            3025.0,
            1424.0
          ],
          "confidence": 0.9957587718963623
        },
        {
          "text": "and (iii) to maintain the necessary records to comply with all Regulatory Approvals and other applicable rules and regulations in the",
          "bbox": [
            529.0,
            1436.0,
            3027.0,
            1478.0
          ],
          "confidence": 0.9890313148498535
        },
        {
          "text": "Applicable Markets. Qualigen shall not be subject to unreasonable requests for assistance in applying for Regulatory Approvals",
          "bbox": [
            531.0,
            1491.0,
            3029.0,
            1537.0
          ],
          "confidence": 0.9920080304145813
        },
        {
          "text": "such as providing original or proprietary documents, submitting free product samples or extensive translations. All Product ordered",
          "bbox": [
            529.0,
            1550.0,
            3029.0,
            1592.0
          ],
          "confidence": 0.9944561719894409
        },
        {
          "text": "by Sekisui's customers shall be suitably packed for shipment and storage by Qualigen on behalf of Sekisui in accordance with",
          "bbox": [
            529.0,
            1604.0,
            3027.0,
            1646.0
          ],
          "confidence": 0.9927265644073486
        },
        {
          "text": "Qualigen's standard commercial shipping practices. Each order shall be shipped as designated by Sekisui's customers in the order. If",
          "bbox": [
            531.0,
            1661.0,
            3034.0,
            1703.0
          ],
          "confidence": 0.9977225065231323
        },
        {
          "text": "the carrier noted on the Sekisui customer's purchase order is not available, or if the purchase order does not designate a carrier, then",
          "bbox": [
            529.0,
            1718.0,
            3029.0,
            1760.0
          ],
          "confidence": 0.998767077922821
        },
        {
          "text": "Sekisui shall select the mode of shipment or, if Sekisui does not select the mode of shipment, Qualigen shall select the mode of",
          "bbox": [
            529.0,
            1773.0,
            3032.0,
            1815.0
          ],
          "confidence": 0.9924181699752808
        },
        {
          "text": "shipment. Qualigen's responsibility shall be to deposit the ordered goods with the designated carrier within the shipping periods",
          "bbox": [
            529.0,
            1827.0,
            3029.0,
            1873.0
          ],
          "confidence": 0.9897130727767944
        },
        {
          "text": "specified, and Qualigen shall not be liable for late delivery if so accomplished.",
          "bbox": [
            529.0,
            1884.0,
            1977.0,
            1930.0
          ],
          "confidence": 0.9980674982070923
        },
        {
          "text": "4.3.",
          "bbox": [
            359.0,
            1939.0,
            428.0,
            1983.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "Delivery Terms. Qualigen shall deliver Products ordered by Sekisui, FCA (Incoterms 2010) Qualigen's facility in Carlsbad, California.",
          "bbox": [
            527.0,
            1939.0,
            3023.0,
            1983.0
          ],
          "confidence": 0.9894762635231018
        },
        {
          "text": "Title to Products ordered by Sekisui shall pass to Sekisui upon delivery to the designated Sekisui storeroom at Qualigen's facility",
          "bbox": [
            531.0,
            1997.0,
            3021.0,
            2037.0
          ],
          "confidence": 0.9903566837310791
        },
        {
          "text": "While held at the Sekisui storeroom, any physical inventory loss will be the responsibility of Qualigen. Sekisui undertakes that all",
          "bbox": [
            531.0,
            2050.0,
            3029.0,
            2096.0
          ],
          "confidence": 0.988981306552887
        },
        {
          "text": "Sekisui inventory of Products shall be kept at such designated Sekisui storeroom at Qualigen's facility, until resale to Sekisui's",
          "bbox": [
            527.0,
            2107.0,
            3029.0,
            2153.0
          ],
          "confidence": 0.994454026222229
        },
        {
          "text": "customers.",
          "bbox": [
            529.0,
            2169.0,
            732.0,
            2206.0
          ],
          "confidence": 0.9999099969863892
        },
        {
          "text": "6",
          "bbox": [
            1638.0,
            2222.0,
            1669.0,
            2260.0
          ],
          "confidence": 0.9988355040550232
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9937501549720764
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "7.2.3. as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 7.2.4. as soon as practicable, but in any event within forty five (45) days after the end of each quarter of each fiscal year of Qualigen, a progress report setting forth Qualigen's business results and progress against the Development Plan; and 7.2.5. as soon as practicable, but in any event no later than sixty (60) days before the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets and income statements.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "7.2.3. as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 7.2.4. as soon as practicable, but in any event within forty five (45) days after the end of each quarter of each fiscal year of Qualigen, a progress report setting forth Qualigen's business results and progress against the Development Plan; and 7.2.5. as soon as practicable, but in any event no later than sixty (60) days before the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets and income statements.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "If Qualigen does not pass such audit and the reasons for such failure cannot be remedied within a reasonable period of time or Qualigen fails or elects not to complete any remedial actions reasonably suggested by Sekisui, then Sekisui's sole and exclusive remedy shall be to terminate this Agreement in accordance with the provisions of Section 14 of this Agreement, with such termination to be effective upon receipt of a termination notice by Qualigen sent by Sekisui at any time after the sixty day remedy period described in this Section 5.4 has passed",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "If Qualigen does not pass such audit and the reasons for such failure cannot be remedied within a reasonable period of time or Qualigen fails or elects not to complete any remedial actions reasonably suggested by Sekisui, then Sekisui's sole and exclusive remedy shall be to terminate this Agreement in accordance with the provisions of Section 14 of this Agreement, with such termination to be effective upon receipt of a termination notice by Qualigen sent by Sekisui at any time after the sixty day remedy period described in this Section 5.4 has passed",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_0",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Qualigen shall provide Sekisui with copies of any Product test records requested or Sekisui may audit Qualigen to review the Product test records.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Qualigen shall deliver to Sekisui: 7.2.1. as soon as practicable, but in any event within one-hundred eighty (180) days after the end of each fiscal year of Qualigen (i) a balance sheet as of the end of such year, (ii) a statement of income for such year, and (iii) a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in Qualigen's budget for such year, with an explanation of any material differences between such amounts, all such financial statements in the form of a compilation prepared by independent public accountants; 7.2.2. as soon as practicable, but in any event within thirty (30) days after the end of each quarter of each fiscal year of Qualigen, an unaudited statement of income for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Qualigen shall deliver to Sekisui: 7.2.1. as soon as practicable, but in any event within one-hundred eighty (180) days after the end of each fiscal year of Qualigen (i) a balance sheet as of the end of such year, (ii) a statement of income for such year, and (iii) a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in Qualigen's budget for such year, with an explanation of any material differences between such amounts, all such financial statements in the form of a compilation prepared by independent public accountants; 7.2.2. as soon as practicable, but in any event within thirty (30) days after the end of each quarter of each fiscal year of Qualigen, an unaudited statement of income for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Liquidated Damages_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
      "answer_text": "In the event of any breach of Sections 9.1 through 9.3, including without limitation, any actions by stockholders of Qualigen that result in a Sale Transaction without complying with Sections 9.1 through 9.3 above, or otherwise hinder the intent and purpose of the provisions of Sections 9.1 through 9.3 above, in addition to any other remedies available to Sekisui under the terms of this Agreement, including the right to specific performance and other equitable remedies, Sekisui shall be entitled to liquidated damages in the amount of three times any and all Financing Payments made to date.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Liquidated Damages_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
      "answer_text": "In the event of any breach of Sections 9.1 through 9.3, including without limitation, any actions by stockholders of Qualigen that result in a Sale Transaction without complying with Sections 9.1 through 9.3 above, or otherwise hinder the intent and purpose of the provisions of Sections 9.1 through 9.3 above, in addition to any other remedies available to Sekisui under the terms of this Agreement, including the right to specific performance and other equitable remedies, Sekisui shall be entitled to liquidated damages in the amount of three times any and all Financing Payments made to date.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Warranty Duration_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Warranty Duration\" that should be reviewed by a lawyer. Details: What is the duration of any  warranty against defects or errors in technology, products, or services  provided under the contract?",
      "answer_text": "Qualigen shall provide to Sekisui and for the benefit of Sekisui's customers of Products a standard commercial written warranty that the Products will be free of defects in materials or workmanship starting from the date the Product has been received by Sekisui's customer and ending after the length of time stated for the applicable Product on Exhibit D hereto (the \"User Warranty\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Warranty Duration_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Warranty Duration\" that should be reviewed by a lawyer. Details: What is the duration of any  warranty against defects or errors in technology, products, or services  provided under the contract?",
      "answer_text": "Qualigen shall provide to Sekisui and for the benefit of Sekisui's customers of Products a standard commercial written warranty that the Products will be free of defects in materials or workmanship starting from the date the Product has been received by Sekisui's customer and ending after the length of time stated for the applicable Product on Exhibit D hereto (the \"User Warranty\").",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "The Insurance shall be primary for all purposes to other insurance coverage, whether such other insurance is stated to be primary, contributory, excess, contingent or otherwise, without recourse to or contribution from any Sekisui-owned coverage.",
      "page_number": 6,
      "words": [
        {
          "text": "4.4.",
          "bbox": [
            359.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9998838901519775
        },
        {
          "text": "Sales Expense; Business Plan. For the avoidance of doubt, Sekisui shall be responsible for all sales and related sales expense except",
          "bbox": [
            531.0,
            254.0,
            3029.0,
            300.0
          ],
          "confidence": 0.9895469546318054
        },
        {
          "text": "for Qualigen Retained Customers. The Business Plan sets forth Sekisui's plans for the sale and distribution of the Products, including",
          "bbox": [
            529.0,
            312.0,
            3029.0,
            358.0
          ],
          "confidence": 0.9996442794799805
        },
        {
          "text": "target budget and resource allocations for the marketing and sales of the Products and estimated forecasts of sales to customers.",
          "bbox": [
            531.0,
            371.0,
            3025.0,
            413.0
          ],
          "confidence": 0.9952583909034729
        },
        {
          "text": "Sekisui shall in good faith use commercially reasonable efforts, in conformance with good commercial practice and standards,",
          "bbox": [
            527.0,
            424.0,
            3025.0,
            468.0
          ],
          "confidence": 0.9957903027534485
        },
        {
          "text": "government regulations and other applicable requirements, to promote, market and sell the Products, to execute the Business Plan and.",
          "bbox": [
            527.0,
            477.0,
            3031.0,
            528.0
          ],
          "confidence": 0.9963300824165344
        },
        {
          "text": "to achieve its objectives. Except as set forth in Section 3.2, such forecasts and budgets are intended for guidance purposes only and",
          "bbox": [
            527.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.9968500137329102
        },
        {
          "text": "are not binding obligations. Sekisui shall be responsible for bad debt (customer nonpayment) and credit card merchant fees and",
          "bbox": [
            526.0,
            592.0,
            3029.0,
            638.0
          ],
          "confidence": 0.9950969815254211
        },
        {
          "text": "expenses.",
          "bbox": [
            529.0,
            652.0,
            713.0,
            695.0
          ],
          "confidence": 0.9930500388145447
        },
        {
          "text": "4.5.",
          "bbox": [
            359.0,
            704.0,
            430.0,
            747.0
          ],
          "confidence": 0.9999474287033081
        },
        {
          "text": "Financing Payments; Development Plan. In addition to the payments for the purchase of Products set forth in Section 4.1 above, in",
          "bbox": [
            529.0,
            709.0,
            3025.0,
            746.0
          ],
          "confidence": 0.9943293929100037
        },
        {
          "text": "connection with this Agreement and in furtherance of the Development Plan, Sekisui shall provide to Qualigen up to $6,200,o00 of",
          "bbox": [
            531.0,
            762.0,
            3032.0,
            804.0
          ],
          "confidence": 0.9927346706390381
        },
        {
          "text": "financing in accordance with the timing and other provisions of the Development Plan and the achievement of the applicable",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            861.0
          ],
          "confidence": 0.99497389793396
        },
        {
          "text": "milestones set forth therein (the \"Financing Payments'). All such Financing Payments shall be used in accordance with the",
          "bbox": [
            529.0,
            875.0,
            3029.0,
            917.0
          ],
          "confidence": 0.9900002479553223
        },
        {
          "text": "Development Plan and shall be non-refundable once paid, other than as set off in connection with a Sale Transaction as further",
          "bbox": [
            531.0,
            934.0,
            3027.0,
            970.0
          ],
          "confidence": 0.9940288662910461
        },
        {
          "text": "described below. Time is of the essence for the payment by Sekisui of the resulting Financing Payments upon confirmation of.",
          "bbox": [
            529.0,
            987.0,
            3034.0,
            1031.0
          ],
          "confidence": 0.9924401640892029
        },
        {
          "text": "achievement by Qualigen of the respective Development Plan milestones as set forth in Section 6.2 and the Development Plan.",
          "bbox": [
            529.0,
            1043.0,
            2878.0,
            1085.0
          ],
          "confidence": 0.9938642382621765
        },
        {
          "text": "4.6.",
          "bbox": [
            359.0,
            1096.0,
            428.0,
            1140.0
          ],
          "confidence": 0.9985026121139526
        },
        {
          "text": "Personnel Matters. Sekisui shall offer employment to four Qualigen sales representatives to become employees of Sekisui with",
          "bbox": [
            527.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.9925117492675781
        },
        {
          "text": "primary responsibility for the sale of the Products, and Qualigen hereby consents to and permits such employment. Such offers of",
          "bbox": [
            526.0,
            1151.0,
            3034.0,
            1202.0
          ],
          "confidence": 0.9893380403518677
        },
        {
          "text": "employment are subject to Sekisui's employment policies, including the successful completion of customary background checks, and",
          "bbox": [
            529.0,
            1210.0,
            3029.0,
            1255.0
          ],
          "confidence": 0.998411238193512
        },
        {
          "text": "are not a guarantee of ongoing employment. Upon the expiration or termination of the Term (other than in connection with a Sale",
          "bbox": [
            526.0,
            1266.0,
            3029.0,
            1312.0
          ],
          "confidence": 0.9887347221374512
        },
        {
          "text": "Transaction in which Sekisui acquires Qualigen), Sekisui shall cooperate in permitting Qualigen to offer to rehire any Sekisui sales",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9966340661048889
        },
        {
          "text": "representatives who are primarily responsible for selling the Products. A sales person \"primarily responsible for selling the Products\"",
          "bbox": [
            526.0,
            1378.0,
            3027.0,
            1422.0
          ],
          "confidence": 0.9928828477859497
        },
        {
          "text": "is one that spends more than half of his or her time and receives more than half of his or her commission based compensation based",
          "bbox": [
            527.0,
            1436.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9927029013633728
        },
        {
          "text": "on sales of the Products.",
          "bbox": [
            529.0,
            1491.0,
            991.0,
            1533.0
          ],
          "confidence": 0.9974746704101562
        },
        {
          "text": "4.7.",
          "bbox": [
            356.0,
            1542.0,
            430.0,
            1592.0
          ],
          "confidence": 0.9998869895935059
        },
        {
          "text": "Invoice Terms. Sekisui shall pay for each Product sold by Qualigen within 30 days after Sekisui has received the applicable invoice",
          "bbox": [
            527.0,
            1548.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9901339411735535
        },
        {
          "text": "from Qualigen.",
          "bbox": [
            527.0,
            1606.0,
            801.0,
            1645.0
          ],
          "confidence": 0.9993689656257629
        },
        {
          "text": "4.8.",
          "bbox": [
            359.0,
            1657.0,
            430.0,
            1705.0
          ],
          "confidence": 0.9626007080078125
        },
        {
          "text": "Marketing Claims. Sekisui covenants to Qualigen that Sekisui will not make any written or oral representation or marketing claim",
          "bbox": [
            529.0,
            1661.0,
            3025.0,
            1701.0
          ],
          "confidence": 0.9921669960021973
        },
        {
          "text": "(either formal or informal) about any Product's capabilities or characteristics other than those representations and claims that are fully",
          "bbox": [
            531.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9922473430633545
        },
        {
          "text": "and directly supported by factual materials provided by Qualigen to Sekisui. Sekisui shall not make any false or misleading",
          "bbox": [
            529.0,
            1773.0,
            3029.0,
            1816.0
          ],
          "confidence": 0.9965982437133789
        },
        {
          "text": "representations to customers or others regarding Qualigen or the Products. Sekisui shall not make any representations, warranties or",
          "bbox": [
            527.0,
            1831.0,
            3030.0,
            1873.0
          ],
          "confidence": 0.9925045967102051
        },
        {
          "text": "guarantees with respect to the specifications, features or capabilities of the Products that are not contained within Qualigen's",
          "bbox": [
            527.0,
            1882.0,
            3027.0,
            1932.0
          ],
          "confidence": 0.9993694424629211
        },
        {
          "text": "documentation accompanying the Products or Qualigen's literature describing the Products, including Qualigen's standard limited",
          "bbox": [
            529.0,
            1942.0,
            3029.0,
            1986.0
          ],
          "confidence": 0.9991266131401062
        },
        {
          "text": "warranty and disclaimers.",
          "bbox": [
            531.0,
            1999.0,
            1001.0,
            2039.0
          ],
          "confidence": 0.9992899298667908
        },
        {
          "text": "7",
          "bbox": [
            1638.0,
            2054.0,
            1669.0,
            2090.0
          ],
          "confidence": 0.998302698135376
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938657283782959
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "The Insurance shall be primary for all purposes to other insurance coverage, whether such other insurance is stated to be primary, contributory, excess, contingent or otherwise, without recourse to or contribution from any Sekisui-owned coverage.",
      "page_number": 7,
      "words": [
        {
          "text": "4.9.",
          "bbox": [
            359.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9999215602874756
        },
        {
          "text": "Taxes. Qualigen's stated Product prices do not include any foreign, federal, state or local sales taxes that may be applicable to the",
          "bbox": [
            531.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9932553768157959
        },
        {
          "text": "Products, but in the event that such sales taxes are applicable and Qualigen has the legal obligation to collect such sales taxes (or are",
          "bbox": [
            529.0,
            314.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9822651743888855
        },
        {
          "text": "sales taxes imposed on a seller), Qualigen shall be entitled to add to its invoice the amount of such sales taxes and Sekisui shall pay",
          "bbox": [
            527.0,
            365.0,
            3025.0,
            415.0
          ],
          "confidence": 0.9954785108566284
        },
        {
          "text": "such amount unless Sekisui provides Qualigen with a valid tax exemption certificate authorized by the appropriate taxing authority. As",
          "bbox": [
            529.0,
            428.0,
            3029.0,
            470.0
          ],
          "confidence": 0.9964900016784668
        },
        {
          "text": "between the Parties, all customs duties shall be the responsibility of Sekisui, and all duty expenses will be included as an element of",
          "bbox": [
            527.0,
            479.0,
            3032.0,
            524.0
          ],
          "confidence": 0.9918721318244934
        },
        {
          "text": "COGS as referenced in Exhibit A and will be included as part of the Actual Margin True-Up as defined in Exhibit D. The parties agree",
          "bbox": [
            527.0,
            535.0,
            3027.0,
            581.0
          ],
          "confidence": 0.9950875043869019
        },
        {
          "text": "to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of",
          "bbox": [
            531.0,
            596.0,
            3027.0,
            632.0
          ],
          "confidence": 0.9928668141365051
        },
        {
          "text": "Financing Payments, Product purchase payments, and other payments made by Sekisui to Qualigen under this Agreement. To the",
          "bbox": [
            529.0,
            649.0,
            3025.0,
            693.0
          ],
          "confidence": 0.9906346797943115
        },
        {
          "text": "extent Sekisui is required to withhold taxes on any payment to Qualigen, Sekisui shall pay the amounts of such taxes to the proper",
          "bbox": [
            529.0,
            707.0,
            3029.0,
            751.0
          ],
          "confidence": 0.9893237948417664
        },
        {
          "text": "governmental authority in a timely manner and promptly transmit to Qualigen evidence of such payment and/or an official tax",
          "bbox": [
            527.0,
            758.0,
            3029.0,
            808.0
          ],
          "confidence": 0.9940901398658752
        },
        {
          "text": "certificate, or such other evidence as Qualigen may reasonably request, to establish that such taxes have been paid. Qualigen shall",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            861.0
          ],
          "confidence": 0.9870412349700928
        },
        {
          "text": "provide Sekisui any tax forms that may be reasonably necessary in order for Sekisui to not withhold tax or to withhold tax at a reduced",
          "bbox": [
            529.0,
            870.0,
            3029.0,
            919.0
          ],
          "confidence": 0.9935504198074341
        },
        {
          "text": "rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the",
          "bbox": [
            526.0,
            928.0,
            3029.0,
            974.0
          ],
          "confidence": 0.9866539835929871
        },
        {
          "text": "recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar obligations resulting from payments made",
          "bbox": [
            527.0,
            989.0,
            3029.0,
            1031.0
          ],
          "confidence": 0.9919902682304382
        },
        {
          "text": "under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.",
          "bbox": [
            529.0,
            1043.0,
            2740.0,
            1085.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "4.9.1.",
          "bbox": [
            446.0,
            1098.0,
            546.0,
            1138.0
          ],
          "confidence": 0.9987618923187256
        },
        {
          "text": "Medical Device Tax. The party responsible for paying any applicable medical device excise tax pursuant to Section 4191 of the.",
          "bbox": [
            607.0,
            1095.0,
            3029.0,
            1146.0
          ],
          "confidence": 0.9898098707199097
        },
        {
          "text": "U.S. Internal Revenue Code or any successor thereto will be as determined under such tax provisions. If any, such medical device",
          "bbox": [
            613.0,
            1153.0,
            3027.0,
            1197.0
          ],
          "confidence": 0.9912339448928833
        },
        {
          "text": "excise tax will be treated as a cost element to be included in COGS as referenced in Exhibit A..",
          "bbox": [
            616.0,
            1210.0,
            2333.0,
            1252.0
          ],
          "confidence": 0.989422619342804
        },
        {
          "text": "4.10.",
          "bbox": [
            357.0,
            1263.0,
            450.0,
            1310.0
          ],
          "confidence": 0.9101659655570984
        },
        {
          "text": "Interest. Accrual and payment of interest shall not be deemed to excuse or cure breaches of contract arising from late payment or",
          "bbox": [
            527.0,
            1268.0,
            3029.0,
            1310.0
          ],
          "confidence": 0.9960917234420776
        },
        {
          "text": "nonpayment. Cumulative with and not exclusive of any and all other available remedies, payments that are more than 30 days past due",
          "bbox": [
            527.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9941427111625671
        },
        {
          "text": "hereunder, and which are not otherwise subject to a good faith dispute, shall accrue interest, from the due date until paid, at an annual",
          "bbox": [
            526.0,
            1378.0,
            3029.0,
            1424.0
          ],
          "confidence": 0.9961178302764893
        },
        {
          "text": "rate equal to the prime rate, as reported in The Wall Street Journal, Eastern U.S. Edition, on the date such payment is due, plus an",
          "bbox": [
            526.0,
            1434.0,
            3029.0,
            1480.0
          ],
          "confidence": 0.9957613945007324
        },
        {
          "text": "additional 200 basis points (2%).",
          "bbox": [
            527.0,
            1489.0,
            1137.0,
            1535.0
          ],
          "confidence": 0.9987368583679199
        },
        {
          "text": "4.11.",
          "bbox": [
            359.0,
            1546.0,
            446.0,
            1588.0
          ],
          "confidence": 0.997421145439148
        },
        {
          "text": "Currency. All invoices under this Agreement shall be paid in United States dollars..",
          "bbox": [
            527.0,
            1548.0,
            2061.0,
            1590.0
          ],
          "confidence": 0.9967273473739624
        },
        {
          "text": "5.",
          "bbox": [
            274.0,
            1603.0,
            317.0,
            1645.0
          ],
          "confidence": 0.7983710169792175
        },
        {
          "text": "Manufacturing and Quality Assurance",
          "bbox": [
            446.0,
            1604.0,
            1184.0,
            1645.0
          ],
          "confidence": 0.9868720173835754
        },
        {
          "text": "5.1.",
          "bbox": [
            357.0,
            1656.0,
            431.0,
            1705.0
          ],
          "confidence": 0.9999219179153442
        },
        {
          "text": "Manufacturing Conformance. Qualigen represents and warrants that it shall manufacture all Products in accordance with the",
          "bbox": [
            531.0,
            1661.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9923285841941833
        },
        {
          "text": "applicable product specifications and all applicable federal, state and local laws, regulations, and guidelines. Qualigen represents and",
          "bbox": [
            531.0,
            1716.0,
            3029.0,
            1762.0
          ],
          "confidence": 0.9998115301132202
        },
        {
          "text": "warrants that no Product delivered by Qualigen under this Agreement will be adulterated or misbranded within the meaning of 21",
          "bbox": [
            529.0,
            1773.0,
            3025.0,
            1815.0
          ],
          "confidence": 0.9938739538192749
        },
        {
          "text": "U.S.C. Sections 351-352, or within the meaning of any other applicable law as such laws are constituted and effective at the time of",
          "bbox": [
            527.0,
            1826.0,
            3032.0,
            1871.0
          ],
          "confidence": 0.9836247563362122
        },
        {
          "text": "such shipment or delivery. Qualigen shall maintain appropriate certification status and compliance with the FDA's Quality System",
          "bbox": [
            531.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.999665379524231
        },
        {
          "text": "Regulation, the Directive of 27 October 1998 on In Vitro Diagnostic Medical Devices (IVDD) and/or all other applicable regulations.",
          "bbox": [
            529.0,
            1939.0,
            3020.0,
            1981.0
          ],
          "confidence": 0.9944262504577637
        },
        {
          "text": "Upon request, Qualigen shall furnish to Sekisui any such information required to enable Sekisui to comply with all applicable",
          "bbox": [
            529.0,
            1995.0,
            3027.0,
            2041.0
          ],
          "confidence": 0.9946947693824768
        },
        {
          "text": "regulations and standards that pertain to distributors for the Products..",
          "bbox": [
            527.0,
            2050.0,
            1842.0,
            2096.0
          ],
          "confidence": 0.9838126301765442
        },
        {
          "text": "5.2.",
          "bbox": [
            355.0,
            2103.0,
            430.0,
            2153.0
          ],
          "confidence": 0.9999211430549622
        },
        {
          "text": "Manufacturing Changes. Qualigen shall notify Sekisui in writing no less than 3 months prior to any material changes which affect (i)",
          "bbox": [
            527.0,
            2107.0,
            3025.0,
            2153.0
          ],
          "confidence": 0.9962983727455139
        },
        {
          "text": "the form, fit or function of any Products, or (ii) the labeling or regulatory status of the Products in any of the Applicable Markets.",
          "bbox": [
            529.0,
            2164.0,
            2927.0,
            2209.0
          ],
          "confidence": 0.9934166073799133
        },
        {
          "text": "5.3.",
          "bbox": [
            357.0,
            2218.0,
            428.0,
            2262.0
          ],
          "confidence": 0.999969482421875
        },
        {
          "text": "Manufacturing Site. During the Term, Qualigen shall manufacture all Products using Qualigen's facilities located in Carlsbad.",
          "bbox": [
            529.0,
            2220.0,
            3023.0,
            2262.0
          ],
          "confidence": 0.9907397627830505
        },
        {
          "text": "California. Qualigen shall give at least six (6) months prior written notice to Sekisui of any proposed relocation of the manufacturing of",
          "bbox": [
            531.0,
            2279.0,
            3030.0,
            2321.0
          ],
          "confidence": 0.9922841191291809
        },
        {
          "text": "any Product. Any new facility proposed to be used by Qualigen in manufacturing any Product shall be subject to a new and separate",
          "bbox": [
            527.0,
            2334.0,
            3027.0,
            2377.0
          ],
          "confidence": 0.9995027184486389
        },
        {
          "text": "audit by Sekisui personnel in accordance with Quality Systems Regulations (QSR), as well as ISO 13485..",
          "bbox": [
            527.0,
            2386.0,
            2467.0,
            2432.0
          ],
          "confidence": 0.9848436713218689
        },
        {
          "text": "8",
          "bbox": [
            1638.0,
            2449.0,
            1669.0,
            2483.0
          ],
          "confidence": 0.9997285008430481
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9953641295433044
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_0",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "All Qualigen's Insurance shall be placed with an insurer that (a) has an A.M. Best rating of A- or better or (b) is a qualified self- insurance program that is approved by Sekisui.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_0",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Sekisui shall be named as an additional insured with respect to the Insurance.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_5",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "insurance program that is approved by Sekisui. Qualigen shall provide Sekisui, upon request, with written evidence of the Insurance, including where it is provided through qualified self-insurance.",
      "page_number": 5,
      "words": [
        {
          "text": "4.",
          "bbox": [
            277.0,
            258.0,
            312.0,
            292.0
          ],
          "confidence": 0.9997537136077881
        },
        {
          "text": "Price, Shipment and Payment",
          "bbox": [
            448.0,
            258.0,
            1008.0,
            296.0
          ],
          "confidence": 0.9979109764099121
        },
        {
          "text": "4.1.",
          "bbox": [
            356.0,
            308.0,
            430.0,
            355.0
          ],
          "confidence": 0.9998072385787964
        },
        {
          "text": "Price. The price that Sekisui shall pay for the Products shall be established separately for the Reagent Kits and for the products other",
          "bbox": [
            527.0,
            312.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9889334440231323
        },
        {
          "text": "than Reagent Kits. The price that Sekisui shall pay for the Reagent Kits Products shall be based upon a formula intended to ensure",
          "bbox": [
            529.0,
            371.0,
            3029.0,
            413.0
          ],
          "confidence": 0.9914680123329163
        },
        {
          "text": "that Sekisui will receive 90% of the total Available Margin for all Products during the first 12 months of this Agreement, 70% of the",
          "bbox": [
            529.0,
            424.0,
            3025.0,
            468.0
          ],
          "confidence": 0.9925817251205444
        },
        {
          "text": "total Available Margin for all Products during months 13-24 of this Agreement, and 65% of the total Available Margin for all Products",
          "bbox": [
            529.0,
            481.0,
            3029.0,
            523.0
          ],
          "confidence": 0.9938228130340576
        },
        {
          "text": "thereafter. Accordingly, the prices (established separately for the Reagent Kits and for the products other than Reagent Kits) to be",
          "bbox": [
            527.0,
            537.0,
            3027.0,
            581.0
          ],
          "confidence": 0.9919881820678711
        },
        {
          "text": "paid by Sekisui for the Products shall be fixed (subject to a later lookback true up) for each respective prospective six month period in",
          "bbox": [
            529.0,
            596.0,
            3027.0,
            638.0
          ],
          "confidence": 0.9898732900619507
        },
        {
          "text": "the manner set forth in Exhibit D. The initial prices Sekisui agrees to pay for the respective Products for the first such prospective \"six",
          "bbox": [
            529.0,
            651.0,
            3029.0,
            693.0
          ],
          "confidence": 0.9969068765640259
        },
        {
          "text": "month period\" (in this instance actually a five month period: May-September 2016) shall be fixed (subject to a later lookback true up)",
          "bbox": [
            529.0,
            707.0,
            3025.0,
            749.0
          ],
          "confidence": 0.991199791431427
        },
        {
          "text": "in the manner set forth in Exhibit D. Thereafter such prices shall be revisited and recalculated (prospectively) every six months in the",
          "bbox": [
            526.0,
            760.0,
            3027.0,
            806.0
          ],
          "confidence": 0.996826708316803
        },
        {
          "text": "manner set forth in Exhibit D (i.e., for purposes of such calculations for establishing the new prospective prices for the reagent",
          "bbox": [
            526.0,
            817.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9992964267730713
        },
        {
          "text": "products, the applicable Net Revenue, COGS and Available Margin shall be the Net Revenue, COGS and Available Margin for the",
          "bbox": [
            527.0,
            872.0,
            3029.0,
            919.0
          ],
          "confidence": 0.9942246675491333
        },
        {
          "text": "applicable historical 6-month period as defined in Exhibit D). In addition, on a semi-annual basis, such amount shall be reviewed based",
          "bbox": [
            529.0,
            926.0,
            3029.0,
            976.0
          ],
          "confidence": 0.9986409544944763
        },
        {
          "text": "on the actual Net Revenue, COGS and Available Margin for the 6 months then ended. In the event that such review results in a",
          "bbox": [
            529.0,
            987.0,
            3030.0,
            1029.0
          ],
          "confidence": 0.9881531000137329
        },
        {
          "text": "difference from the intended share of Available Margin between the Parties as contemplated above, the Parties shall make a true up",
          "bbox": [
            527.0,
            1036.0,
            3031.0,
            1091.0
          ],
          "confidence": 0.998327374458313
        },
        {
          "text": "payment between them in order to compensate for such overpayment or shortfall, all as provided in Exhibit D. Any true-up payments",
          "bbox": [
            529.0,
            1100.0,
            3030.0,
            1144.0
          ],
          "confidence": 0.995193600654602
        },
        {
          "text": "shall be paid by the applicable Party within 30 days of the receipt of an invoice for the agreed to true up amount.",
          "bbox": [
            529.0,
            1155.0,
            2617.0,
            1199.0
          ],
          "confidence": 0.9920356273651123
        },
        {
          "text": "Sekisui shall set the customer selling prices in good faith and in a commercially reasonable manner.",
          "bbox": [
            531.0,
            1212.0,
            2365.0,
            1255.0
          ],
          "confidence": 0.9999339580535889
        },
        {
          "text": "4.2.",
          "bbox": [
            359.0,
            1265.0,
            428.0,
            1308.0
          ],
          "confidence": 0.8984659910202026
        },
        {
          "text": "Shipment. The shipment of orders to Sekisui's customers shall be subject to the ability of Sekisui and Qualigen to obtain all required",
          "bbox": [
            533.0,
            1268.0,
            3029.0,
            1310.0
          ],
          "confidence": 0.9926885366439819
        },
        {
          "text": "licenses and permits then in effect. Qualigen agrees (i) to assist Sekisui in obtaining such required licenses or permits, (ii) to comply",
          "bbox": [
            527.0,
            1323.0,
            3025.0,
            1369.0
          ],
          "confidence": 0.995852530002594
        },
        {
          "text": "with all Regulatory Approvals in, including all approvals and licenses necessary to import the Product into, the Applicable Markets,",
          "bbox": [
            527.0,
            1378.0,
            3025.0,
            1424.0
          ],
          "confidence": 0.9957587718963623
        },
        {
          "text": "and (iii) to maintain the necessary records to comply with all Regulatory Approvals and other applicable rules and regulations in the",
          "bbox": [
            529.0,
            1436.0,
            3027.0,
            1478.0
          ],
          "confidence": 0.9890313148498535
        },
        {
          "text": "Applicable Markets. Qualigen shall not be subject to unreasonable requests for assistance in applying for Regulatory Approvals",
          "bbox": [
            531.0,
            1491.0,
            3029.0,
            1537.0
          ],
          "confidence": 0.9920080304145813
        },
        {
          "text": "such as providing original or proprietary documents, submitting free product samples or extensive translations. All Product ordered",
          "bbox": [
            529.0,
            1550.0,
            3029.0,
            1592.0
          ],
          "confidence": 0.9944561719894409
        },
        {
          "text": "by Sekisui's customers shall be suitably packed for shipment and storage by Qualigen on behalf of Sekisui in accordance with",
          "bbox": [
            529.0,
            1604.0,
            3027.0,
            1646.0
          ],
          "confidence": 0.9927265644073486
        },
        {
          "text": "Qualigen's standard commercial shipping practices. Each order shall be shipped as designated by Sekisui's customers in the order. If",
          "bbox": [
            531.0,
            1661.0,
            3034.0,
            1703.0
          ],
          "confidence": 0.9977225065231323
        },
        {
          "text": "the carrier noted on the Sekisui customer's purchase order is not available, or if the purchase order does not designate a carrier, then",
          "bbox": [
            529.0,
            1718.0,
            3029.0,
            1760.0
          ],
          "confidence": 0.998767077922821
        },
        {
          "text": "Sekisui shall select the mode of shipment or, if Sekisui does not select the mode of shipment, Qualigen shall select the mode of",
          "bbox": [
            529.0,
            1773.0,
            3032.0,
            1815.0
          ],
          "confidence": 0.9924181699752808
        },
        {
          "text": "shipment. Qualigen's responsibility shall be to deposit the ordered goods with the designated carrier within the shipping periods",
          "bbox": [
            529.0,
            1827.0,
            3029.0,
            1873.0
          ],
          "confidence": 0.9897130727767944
        },
        {
          "text": "specified, and Qualigen shall not be liable for late delivery if so accomplished.",
          "bbox": [
            529.0,
            1884.0,
            1977.0,
            1930.0
          ],
          "confidence": 0.9980674982070923
        },
        {
          "text": "4.3.",
          "bbox": [
            359.0,
            1939.0,
            428.0,
            1983.0
          ],
          "confidence": 0.9999516606330872
        },
        {
          "text": "Delivery Terms. Qualigen shall deliver Products ordered by Sekisui, FCA (Incoterms 2010) Qualigen's facility in Carlsbad, California.",
          "bbox": [
            527.0,
            1939.0,
            3023.0,
            1983.0
          ],
          "confidence": 0.9894762635231018
        },
        {
          "text": "Title to Products ordered by Sekisui shall pass to Sekisui upon delivery to the designated Sekisui storeroom at Qualigen's facility",
          "bbox": [
            531.0,
            1997.0,
            3021.0,
            2037.0
          ],
          "confidence": 0.9903566837310791
        },
        {
          "text": "While held at the Sekisui storeroom, any physical inventory loss will be the responsibility of Qualigen. Sekisui undertakes that all",
          "bbox": [
            531.0,
            2050.0,
            3029.0,
            2096.0
          ],
          "confidence": 0.988981306552887
        },
        {
          "text": "Sekisui inventory of Products shall be kept at such designated Sekisui storeroom at Qualigen's facility, until resale to Sekisui's",
          "bbox": [
            527.0,
            2107.0,
            3029.0,
            2153.0
          ],
          "confidence": 0.994454026222229
        },
        {
          "text": "customers.",
          "bbox": [
            529.0,
            2169.0,
            732.0,
            2206.0
          ],
          "confidence": 0.9999099969863892
        },
        {
          "text": "6",
          "bbox": [
            1638.0,
            2222.0,
            1669.0,
            2260.0
          ],
          "confidence": 0.9988355040550232
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9937501549720764
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_16_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Combined single limit for bodily and property damage of not less than $1,000,000 for each occurrence and $2,000,000 annual aggregate providing: ● Assault and Battery coverage, ● Broad form property damage coverage, ● Broad form contractual liability coverage, ● Products and completed operations coverage, and ● Personal and advertising injury coverage.",
      "page_number": 16,
      "words": [
        {
          "text": "11.3.",
          "bbox": [
            359.0,
            252.0,
            446.0,
            300.0
          ],
          "confidence": 0.9815950393676758
        },
        {
          "text": "Patent Indemnity. Qualigen and Sekisui shall notify each other promptly in writing of any action (and all prior claims relating to such",
          "bbox": [
            531.0,
            258.0,
            3029.0,
            300.0
          ],
          "confidence": 0.9860003590583801
        },
        {
          "text": "action) brought against Qualigen or Sekisui alleging that the manufacture, marketing, import, offer for sale, sale or use of a Product",
          "bbox": [
            529.0,
            312.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9954747557640076
        },
        {
          "text": "constitute infringement of the intellectual property rights of a Third Party, and (provided that such a Claim does not arise from",
          "bbox": [
            529.0,
            371.0,
            3029.0,
            413.0
          ],
          "confidence": 0.9887493252754211
        },
        {
          "text": "Sekisui's noncompliance with Sections 3.6, 8.4, 10.2(b), 10.2(c), 10.2(e) or 10.2(f) of this Agreement (e.g., Sekisui has altered a Product",
          "bbox": [
            531.0,
            426.0,
            3029.0,
            470.0
          ],
          "confidence": 0.9962202310562134
        },
        {
          "text": "or has used a Sekisui trademark in connection with a Product)) Qualigen agrees to defend Sekisui in such action at its expense and",
          "bbox": [
            529.0,
            482.0,
            3029.0,
            524.0
          ],
          "confidence": 0.996284008026123
        },
        {
          "text": "shall pay any costs or damages finally awarded against Sekisui in any such action; provided, that Qualigen shall have had sole",
          "bbox": [
            529.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.9884932041168213
        },
        {
          "text": "control of the defense of any such action and all negotiations for its settlement or compromise and provided further that no settlement",
          "bbox": [
            531.0,
            596.0,
            3030.0,
            638.0
          ],
          "confidence": 0.9909276962280273
        },
        {
          "text": "or compromise shall be binding on a Party hereto without its prior written consent, which consent shall not be unreasonably withheld.",
          "bbox": [
            529.0,
            651.0,
            3023.0,
            693.0
          ],
          "confidence": 0.989925742149353
        },
        {
          "text": "In the event a lawsuit is filed against Sekisui or Qualigen alleging that the manufacture, marketing, import, offer for sale, sale or use of",
          "bbox": [
            527.0,
            707.0,
            3030.0,
            749.0
          ],
          "confidence": 0.9910100698471069
        },
        {
          "text": "a Product constitute infringement of the intellectual property rights of a Third Party, or Qualigen files an action for declaratory.",
          "bbox": [
            526.0,
            760.0,
            3027.0,
            808.0
          ],
          "confidence": 0.9910844564437866
        },
        {
          "text": "judgment because of a serious threat of such a lawsuit, or if in Qualigen's reasonable business judgment a Product is likely to become",
          "bbox": [
            526.0,
            819.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9931852221488953
        },
        {
          "text": "the subject of a claim of infringement of a patent or other intellectual property right; then Qualigen may, at its expense, and may",
          "bbox": [
            527.0,
            872.0,
            3025.0,
            919.0
          ],
          "confidence": 0.9935116171836853
        },
        {
          "text": "request Sekisui's assistance to, attempt to obtain a license to such patent or other intellectual property right.",
          "bbox": [
            529.0,
            932.0,
            2545.0,
            974.0
          ],
          "confidence": 0.9978859424591064
        },
        {
          "text": "11.4.",
          "bbox": [
            361.0,
            985.0,
            444.0,
            1027.0
          ],
          "confidence": 0.9171080589294434
        },
        {
          "text": "Indemnification Procedures. The Party or other Indemnitee intending to claim indemnification under this Section 11 (an \"Indemnified",
          "bbox": [
            529.0,
            990.0,
            3025.0,
            1027.0
          ],
          "confidence": 0.9899179935455322
        },
        {
          "text": "Party') shall promptly notify the other Party (the \"Indemnifying Party') of any Claim in respect of which the Indemnified Party intends",
          "bbox": [
            527.0,
            1042.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9900816679000854
        },
        {
          "text": "to claim such indemnification (provided, that no delay or deficiency on the part of the Indemnified Party in so notifying the",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1144.0
          ],
          "confidence": 0.9942113161087036
        },
        {
          "text": "Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the.",
          "bbox": [
            527.0,
            1153.0,
            3029.0,
            1199.0
          ],
          "confidence": 0.9978135824203491
        },
        {
          "text": "Indemnifying Party has suffered actual prejudice directly caused by the delay or other deficiency), and the Indemnifying Party shall",
          "bbox": [
            529.0,
            1212.0,
            3030.0,
            1254.0
          ],
          "confidence": 0.9992060661315918
        },
        {
          "text": "assume the defense thereof (with counsel selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party)",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9879560470581055
        },
        {
          "text": "whether or not such Claim is rightfully brought; provided, however, that an Indemnified Party shall have the right to retain its own",
          "bbox": [
            531.0,
            1325.0,
            3029.0,
            1367.0
          ],
          "confidence": 0.9928699731826782
        },
        {
          "text": "counsel and participate in the defense thereof, with the fees and expenses to be paid by the Indemnified Party, unless the",
          "bbox": [
            531.0,
            1380.0,
            3027.0,
            1422.0
          ],
          "confidence": 0.9939807057380676
        },
        {
          "text": "Indemnifying Party does not assume the defense or unless a representation of both the Indemnified Party and the Indemnifying Party",
          "bbox": [
            527.0,
            1434.0,
            3025.0,
            1480.0
          ],
          "confidence": 0.994968593120575
        },
        {
          "text": "by the same counsel would be inappropriate due to the actual or potential differing interests between them, in which case the",
          "bbox": [
            531.0,
            1493.0,
            3025.0,
            1535.0
          ],
          "confidence": 0.9984760880470276
        },
        {
          "text": "reasonable fees and expenses of counsel retained by the Indemnified Party shall be paid by the Indemnifying Party. Notwithstanding",
          "bbox": [
            526.0,
            1546.0,
            3027.0,
            1592.0
          ],
          "confidence": 0.9920616745948792
        },
        {
          "text": "the previous sentence, in no event shall the Indemnifying Party be required to pay for more than one separate counsel no matter the",
          "bbox": [
            529.0,
            1604.0,
            3029.0,
            1646.0
          ],
          "confidence": 0.9806979894638062
        },
        {
          "text": "number or circumstances of all Indemnified Parties. If the Indemnifying Party shall fail to timely assume the defense of and reasonably",
          "bbox": [
            526.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9940850138664246
        },
        {
          "text": "defend such Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party",
          "bbox": [
            529.0,
            1714.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9941278100013733
        },
        {
          "text": "shall pay (as incurred and on demand) the fees and expenses of counsel retained by the Indemnified Party and all other expenses of",
          "bbox": [
            527.0,
            1771.0,
            3034.0,
            1815.0
          ],
          "confidence": 0.9944397211074829
        },
        {
          "text": "with the Indemnifying Party and its legal representatives in the investigations of any Claim. The Indemnifying Party shall not be liable",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9955669641494751
        },
        {
          "text": "for the indemnification of any Claim settled (or resolved by consent to the entry of judgment) without the written consent of the",
          "bbox": [
            527.0,
            1939.0,
            3027.0,
            1985.0
          ],
          "confidence": 0.9966848492622375
        },
        {
          "text": "Indemnifying Party. Also, if the Indemnifying Party shall control the defense of any such Claim, the Indemnifying Party shall have the",
          "bbox": [
            527.0,
            1995.0,
            3027.0,
            2039.0
          ],
          "confidence": 0.9892342686653137
        },
        {
          "text": "right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior written consent (which shall not be",
          "bbox": [
            527.0,
            2054.0,
            3027.0,
            2096.0
          ],
          "confidence": 0.9871853590011597
        },
        {
          "text": "unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the",
          "bbox": [
            529.0,
            2109.0,
            3025.0,
            2151.0
          ],
          "confidence": 0.9933958053588867
        },
        {
          "text": "entry of judgment upon) such Claim unless (A) there is no finding or admission of any violation of law or any violation of the rights of",
          "bbox": [
            529.0,
            2165.0,
            3032.0,
            2209.0
          ],
          "confidence": 0.9923961758613586
        },
        {
          "text": "any person or entity by an Indemnified Party, no requirement that the Indemnified Party admit fault or culpability, and no adverse.",
          "bbox": [
            527.0,
            2220.0,
            3027.0,
            2266.0
          ],
          "confidence": 0.9911665320396423
        },
        {
          "text": "effect on any other claims that may be made by or against the Indemnified Party and (B) the sole relief provided is monetary damages",
          "bbox": [
            529.0,
            2277.0,
            3027.0,
            2323.0
          ],
          "confidence": 0.9996267557144165
        },
        {
          "text": "that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from",
          "bbox": [
            529.0,
            2335.0,
            3029.0,
            2377.0
          ],
          "confidence": 0.9952800273895264
        },
        {
          "text": "taking) any action.",
          "bbox": [
            531.0,
            2394.0,
            875.0,
            2432.0
          ],
          "confidence": 0.9978508353233337
        },
        {
          "text": "17",
          "bbox": [
            1629.0,
            2443.0,
            1677.0,
            2485.0
          ],
          "confidence": 0.9977062344551086
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939860105514526
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_17_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Combined single limit for bodily and property damage of not less than $1,000,000 for each occurrence and $2,000,000 annual aggregate providing: ● Assault and Battery coverage, ● Broad form property damage coverage, ● Broad form contractual liability coverage, ● Products and completed operations coverage, and ● Personal and advertising injury coverage.",
      "page_number": 17,
      "words": [
        {
          "text": "Regardless of who controls the defense, the other Party hereto shall reasonably cooperate in the defense as may be requested.",
          "bbox": [
            531.0,
            259.0,
            3023.0,
            296.0
          ],
          "confidence": 0.9953616857528687
        },
        {
          "text": "Without limitation, the Party hereto which is not the Indemnifying Party and (if different) the Indemnified Party, and their respective",
          "bbox": [
            533.0,
            314.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9978629946708679
        },
        {
          "text": "directors, officers, advisers, agents and employees, shall cooperate fully with the Indemnifying Party and its legal representatives in.",
          "bbox": [
            529.0,
            367.0,
            3029.0,
            413.0
          ],
          "confidence": 0.9934097528457642
        },
        {
          "text": "the investigation and defense of any Claim..",
          "bbox": [
            531.0,
            429.0,
            1338.0,
            466.0
          ],
          "confidence": 0.9640095233917236
        },
        {
          "text": "11.5.",
          "bbox": [
            361.0,
            477.0,
            446.0,
            524.0
          ],
          "confidence": 0.9999017715454102
        },
        {
          "text": "Section 11 shall also be reimbursed by the Indemnifying Party except as otherwise set forth in Section 11.4..",
          "bbox": [
            527.0,
            535.0,
            2509.0,
            581.0
          ],
          "confidence": 0.9810970425605774
        },
        {
          "text": "11.6.",
          "bbox": [
            356.0,
            584.0,
            447.0,
            638.0
          ],
          "confidence": 0.9999011158943176
        },
        {
          "text": "set forth below (\"Insurance'). Sekisui shall be named as an additional insured with respect to the Insurance. The Insurance shall be",
          "bbox": [
            529.0,
            651.0,
            3027.0,
            693.0
          ],
          "confidence": 0.9920510053634644
        },
        {
          "text": "primary for all purposes to other insurance coverage, whether such other insurance is stated to be primary, contributory, excess,",
          "bbox": [
            529.0,
            707.0,
            3025.0,
            749.0
          ],
          "confidence": 0.9984265565872192
        },
        {
          "text": "contingent or otherwise, without recourse to or contribution from any Sekisui-owned coverage..",
          "bbox": [
            529.0,
            762.0,
            2304.0,
            806.0
          ],
          "confidence": 0.9951342940330505
        },
        {
          "text": "a)",
          "bbox": [
            453.0,
            826.0,
            495.0,
            855.0
          ],
          "confidence": 0.7500269412994385
        },
        {
          "text": "Commercial General Liability Insurance - Combined single limit for bodily and property damage of not less than $1,ooo,o0o for each.",
          "bbox": [
            526.0,
            817.0,
            3027.0,
            863.0
          ],
          "confidence": 0.977998673915863
        },
        {
          "text": "occurrence and $2,000,000 annual aggregate providing:",
          "bbox": [
            526.0,
            873.0,
            1553.0,
            919.0
          ],
          "confidence": 0.9911948442459106
        },
        {
          "text": "Assault and Battery coverage,",
          "bbox": [
            643.0,
            926.0,
            1213.0,
            978.0
          ],
          "confidence": 0.9728929996490479
        },
        {
          "text": "Broad form property damage coverage,",
          "bbox": [
            643.0,
            989.0,
            1369.0,
            1031.0
          ],
          "confidence": 0.9986250400543213
        },
        {
          "text": "Broad form contractual liability coverage,",
          "bbox": [
            641.0,
            1038.0,
            1412.0,
            1089.0
          ],
          "confidence": 0.9995808601379395
        },
        {
          "text": "Products and completed operations coverage, and.",
          "bbox": [
            643.0,
            1100.0,
            1582.0,
            1142.0
          ],
          "confidence": 0.989491879940033
        },
        {
          "text": "Personal and advertising injury coverage.",
          "bbox": [
            641.0,
            1151.0,
            1416.0,
            1203.0
          ],
          "confidence": 0.9957625865936279
        },
        {
          "text": "(b)  Workers' Compensation and Employer's Liability Insurance - With limits of liability for:.",
          "bbox": [
            448.0,
            1210.0,
            2168.0,
            1252.0
          ],
          "confidence": 0.9783419966697693
        },
        {
          "text": "Workers' compensation as required by statute;",
          "bbox": [
            645.0,
            1266.0,
            1523.0,
            1310.0
          ],
          "confidence": 0.9785932898521423
        },
        {
          "text": "Employer's liability for bodily injury by accident: $500,o00 each accident; bodily injury by disease: $500,o00 policy limit; and.",
          "bbox": [
            645.0,
            1323.0,
            3029.0,
            1367.0
          ],
          "confidence": 0.9904770255088806
        },
        {
          "text": "bodily injury by disease: $500,000 each employee.",
          "bbox": [
            645.0,
            1380.0,
            1573.0,
            1424.0
          ],
          "confidence": 0.9864776730537415
        },
        {
          "text": "All Qualigen's Insurance shall be placed with an insurer that (a) has an A.M. Best rating of A- or better or (b) is a qualified self-",
          "bbox": [
            535.0,
            1438.0,
            3021.0,
            1475.0
          ],
          "confidence": 0.9945136904716492
        },
        {
          "text": "insurance program that is approved by Sekisui. Qualigen shall provide Sekisui, upon request, with written evidence of the Insurance,",
          "bbox": [
            526.0,
            1491.0,
            3025.0,
            1537.0
          ],
          "confidence": 0.9933100342750549
        },
        {
          "text": "including where it is provided through qualified self-insurance. Nothing in this Section shall be deemed to limit Qualigen's",
          "bbox": [
            527.0,
            1550.0,
            3027.0,
            1592.0
          ],
          "confidence": 0.9917309880256653
        },
        {
          "text": "responsibility to the amounts stated above or to any limits of Qualigen's insurance policies.",
          "bbox": [
            527.0,
            1604.0,
            2233.0,
            1646.0
          ],
          "confidence": 0.9961390495300293
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1656.0,
            341.0,
            1701.0
          ],
          "confidence": 0.9999504089355469
        },
        {
          "text": "Regulatory Matters",
          "bbox": [
            446.0,
            1661.0,
            823.0,
            1701.0
          ],
          "confidence": 0.9998922348022461
        },
        {
          "text": "12.1.",
          "bbox": [
            364.0,
            1714.0,
            450.0,
            1756.0
          ],
          "confidence": 0.9998953938484192
        },
        {
          "text": "Regulatory Approval. Qualigen shall be responsible for maintaining, at its sole cost, the Regulatory Approvals required for the",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9864863157272339
        },
        {
          "text": "marketing and sale of the Products in the Applicable Markets. Qualigen shall hold in its name all Regulatory Approvals required for.",
          "bbox": [
            527.0,
            1769.0,
            3029.0,
            1816.0
          ],
          "confidence": 0.9870142936706543
        },
        {
          "text": "good standing all existing Regulatory Approvals. Qualigen and Sekisui shall provide reasonable advice and assistance to each other.",
          "bbox": [
            529.0,
            1882.0,
            3029.0,
            1932.0
          ],
          "confidence": 0.9919559359550476
        },
        {
          "text": "as may be necessary to maintain required Regulatory Approvals. In addition, Qualigen shall use commercially reasonable efforts to",
          "bbox": [
            529.0,
            1942.0,
            3025.0,
            1983.0
          ],
          "confidence": 0.9951932430267334
        },
        {
          "text": "obtain Regulatory Approval for any additional territories upon Sekisui's commercially reasonable request..",
          "bbox": [
            531.0,
            1999.0,
            2499.0,
            2041.0
          ],
          "confidence": 0.9896303415298462
        },
        {
          "text": "18",
          "bbox": [
            1629.0,
            2048.0,
            1680.0,
            2096.0
          ],
          "confidence": 0.999865710735321
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939543604850769
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_16_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Workers' Compensation and Employer's Liability Insurance - With limits of liability for: ● Workers' compensation as required by statute; ● Employer's liability for bodily injury by accident: $500,000 each accident; bodily injury by disease: $500,000 policy limit; and bodily injury by disease: $500,000 each employee.",
      "page_number": 16,
      "words": [
        {
          "text": "11.3.",
          "bbox": [
            359.0,
            252.0,
            446.0,
            300.0
          ],
          "confidence": 0.9815950393676758
        },
        {
          "text": "Patent Indemnity. Qualigen and Sekisui shall notify each other promptly in writing of any action (and all prior claims relating to such",
          "bbox": [
            531.0,
            258.0,
            3029.0,
            300.0
          ],
          "confidence": 0.9860003590583801
        },
        {
          "text": "action) brought against Qualigen or Sekisui alleging that the manufacture, marketing, import, offer for sale, sale or use of a Product",
          "bbox": [
            529.0,
            312.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9954747557640076
        },
        {
          "text": "constitute infringement of the intellectual property rights of a Third Party, and (provided that such a Claim does not arise from",
          "bbox": [
            529.0,
            371.0,
            3029.0,
            413.0
          ],
          "confidence": 0.9887493252754211
        },
        {
          "text": "Sekisui's noncompliance with Sections 3.6, 8.4, 10.2(b), 10.2(c), 10.2(e) or 10.2(f) of this Agreement (e.g., Sekisui has altered a Product",
          "bbox": [
            531.0,
            426.0,
            3029.0,
            470.0
          ],
          "confidence": 0.9962202310562134
        },
        {
          "text": "or has used a Sekisui trademark in connection with a Product)) Qualigen agrees to defend Sekisui in such action at its expense and",
          "bbox": [
            529.0,
            482.0,
            3029.0,
            524.0
          ],
          "confidence": 0.996284008026123
        },
        {
          "text": "shall pay any costs or damages finally awarded against Sekisui in any such action; provided, that Qualigen shall have had sole",
          "bbox": [
            529.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.9884932041168213
        },
        {
          "text": "control of the defense of any such action and all negotiations for its settlement or compromise and provided further that no settlement",
          "bbox": [
            531.0,
            596.0,
            3030.0,
            638.0
          ],
          "confidence": 0.9909276962280273
        },
        {
          "text": "or compromise shall be binding on a Party hereto without its prior written consent, which consent shall not be unreasonably withheld.",
          "bbox": [
            529.0,
            651.0,
            3023.0,
            693.0
          ],
          "confidence": 0.989925742149353
        },
        {
          "text": "In the event a lawsuit is filed against Sekisui or Qualigen alleging that the manufacture, marketing, import, offer for sale, sale or use of",
          "bbox": [
            527.0,
            707.0,
            3030.0,
            749.0
          ],
          "confidence": 0.9910100698471069
        },
        {
          "text": "a Product constitute infringement of the intellectual property rights of a Third Party, or Qualigen files an action for declaratory.",
          "bbox": [
            526.0,
            760.0,
            3027.0,
            808.0
          ],
          "confidence": 0.9910844564437866
        },
        {
          "text": "judgment because of a serious threat of such a lawsuit, or if in Qualigen's reasonable business judgment a Product is likely to become",
          "bbox": [
            526.0,
            819.0,
            3029.0,
            863.0
          ],
          "confidence": 0.9931852221488953
        },
        {
          "text": "the subject of a claim of infringement of a patent or other intellectual property right; then Qualigen may, at its expense, and may",
          "bbox": [
            527.0,
            872.0,
            3025.0,
            919.0
          ],
          "confidence": 0.9935116171836853
        },
        {
          "text": "request Sekisui's assistance to, attempt to obtain a license to such patent or other intellectual property right.",
          "bbox": [
            529.0,
            932.0,
            2545.0,
            974.0
          ],
          "confidence": 0.9978859424591064
        },
        {
          "text": "11.4.",
          "bbox": [
            361.0,
            985.0,
            444.0,
            1027.0
          ],
          "confidence": 0.9171080589294434
        },
        {
          "text": "Indemnification Procedures. The Party or other Indemnitee intending to claim indemnification under this Section 11 (an \"Indemnified",
          "bbox": [
            529.0,
            990.0,
            3025.0,
            1027.0
          ],
          "confidence": 0.9899179935455322
        },
        {
          "text": "Party') shall promptly notify the other Party (the \"Indemnifying Party') of any Claim in respect of which the Indemnified Party intends",
          "bbox": [
            527.0,
            1042.0,
            3027.0,
            1085.0
          ],
          "confidence": 0.9900816679000854
        },
        {
          "text": "to claim such indemnification (provided, that no delay or deficiency on the part of the Indemnified Party in so notifying the",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1144.0
          ],
          "confidence": 0.9942113161087036
        },
        {
          "text": "Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the.",
          "bbox": [
            527.0,
            1153.0,
            3029.0,
            1199.0
          ],
          "confidence": 0.9978135824203491
        },
        {
          "text": "Indemnifying Party has suffered actual prejudice directly caused by the delay or other deficiency), and the Indemnifying Party shall",
          "bbox": [
            529.0,
            1212.0,
            3030.0,
            1254.0
          ],
          "confidence": 0.9992060661315918
        },
        {
          "text": "assume the defense thereof (with counsel selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party)",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9879560470581055
        },
        {
          "text": "whether or not such Claim is rightfully brought; provided, however, that an Indemnified Party shall have the right to retain its own",
          "bbox": [
            531.0,
            1325.0,
            3029.0,
            1367.0
          ],
          "confidence": 0.9928699731826782
        },
        {
          "text": "counsel and participate in the defense thereof, with the fees and expenses to be paid by the Indemnified Party, unless the",
          "bbox": [
            531.0,
            1380.0,
            3027.0,
            1422.0
          ],
          "confidence": 0.9939807057380676
        },
        {
          "text": "Indemnifying Party does not assume the defense or unless a representation of both the Indemnified Party and the Indemnifying Party",
          "bbox": [
            527.0,
            1434.0,
            3025.0,
            1480.0
          ],
          "confidence": 0.994968593120575
        },
        {
          "text": "by the same counsel would be inappropriate due to the actual or potential differing interests between them, in which case the",
          "bbox": [
            531.0,
            1493.0,
            3025.0,
            1535.0
          ],
          "confidence": 0.9984760880470276
        },
        {
          "text": "reasonable fees and expenses of counsel retained by the Indemnified Party shall be paid by the Indemnifying Party. Notwithstanding",
          "bbox": [
            526.0,
            1546.0,
            3027.0,
            1592.0
          ],
          "confidence": 0.9920616745948792
        },
        {
          "text": "the previous sentence, in no event shall the Indemnifying Party be required to pay for more than one separate counsel no matter the",
          "bbox": [
            529.0,
            1604.0,
            3029.0,
            1646.0
          ],
          "confidence": 0.9806979894638062
        },
        {
          "text": "number or circumstances of all Indemnified Parties. If the Indemnifying Party shall fail to timely assume the defense of and reasonably",
          "bbox": [
            526.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9940850138664246
        },
        {
          "text": "defend such Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party",
          "bbox": [
            529.0,
            1714.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9941278100013733
        },
        {
          "text": "shall pay (as incurred and on demand) the fees and expenses of counsel retained by the Indemnified Party and all other expenses of",
          "bbox": [
            527.0,
            1771.0,
            3034.0,
            1815.0
          ],
          "confidence": 0.9944397211074829
        },
        {
          "text": "with the Indemnifying Party and its legal representatives in the investigations of any Claim. The Indemnifying Party shall not be liable",
          "bbox": [
            529.0,
            1886.0,
            3027.0,
            1928.0
          ],
          "confidence": 0.9955669641494751
        },
        {
          "text": "for the indemnification of any Claim settled (or resolved by consent to the entry of judgment) without the written consent of the",
          "bbox": [
            527.0,
            1939.0,
            3027.0,
            1985.0
          ],
          "confidence": 0.9966848492622375
        },
        {
          "text": "Indemnifying Party. Also, if the Indemnifying Party shall control the defense of any such Claim, the Indemnifying Party shall have the",
          "bbox": [
            527.0,
            1995.0,
            3027.0,
            2039.0
          ],
          "confidence": 0.9892342686653137
        },
        {
          "text": "right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior written consent (which shall not be",
          "bbox": [
            527.0,
            2054.0,
            3027.0,
            2096.0
          ],
          "confidence": 0.9871853590011597
        },
        {
          "text": "unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the",
          "bbox": [
            529.0,
            2109.0,
            3025.0,
            2151.0
          ],
          "confidence": 0.9933958053588867
        },
        {
          "text": "entry of judgment upon) such Claim unless (A) there is no finding or admission of any violation of law or any violation of the rights of",
          "bbox": [
            529.0,
            2165.0,
            3032.0,
            2209.0
          ],
          "confidence": 0.9923961758613586
        },
        {
          "text": "any person or entity by an Indemnified Party, no requirement that the Indemnified Party admit fault or culpability, and no adverse.",
          "bbox": [
            527.0,
            2220.0,
            3027.0,
            2266.0
          ],
          "confidence": 0.9911665320396423
        },
        {
          "text": "effect on any other claims that may be made by or against the Indemnified Party and (B) the sole relief provided is monetary damages",
          "bbox": [
            529.0,
            2277.0,
            3027.0,
            2323.0
          ],
          "confidence": 0.9996267557144165
        },
        {
          "text": "that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from",
          "bbox": [
            529.0,
            2335.0,
            3029.0,
            2377.0
          ],
          "confidence": 0.9952800273895264
        },
        {
          "text": "taking) any action.",
          "bbox": [
            531.0,
            2394.0,
            875.0,
            2432.0
          ],
          "confidence": 0.9978508353233337
        },
        {
          "text": "17",
          "bbox": [
            1629.0,
            2443.0,
            1677.0,
            2485.0
          ],
          "confidence": 0.9977062344551086
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939860105514526
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_17_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Workers' Compensation and Employer's Liability Insurance - With limits of liability for: ● Workers' compensation as required by statute; ● Employer's liability for bodily injury by accident: $500,000 each accident; bodily injury by disease: $500,000 policy limit; and bodily injury by disease: $500,000 each employee.",
      "page_number": 17,
      "words": [
        {
          "text": "Regardless of who controls the defense, the other Party hereto shall reasonably cooperate in the defense as may be requested.",
          "bbox": [
            531.0,
            259.0,
            3023.0,
            296.0
          ],
          "confidence": 0.9953616857528687
        },
        {
          "text": "Without limitation, the Party hereto which is not the Indemnifying Party and (if different) the Indemnified Party, and their respective",
          "bbox": [
            533.0,
            314.0,
            3027.0,
            356.0
          ],
          "confidence": 0.9978629946708679
        },
        {
          "text": "directors, officers, advisers, agents and employees, shall cooperate fully with the Indemnifying Party and its legal representatives in.",
          "bbox": [
            529.0,
            367.0,
            3029.0,
            413.0
          ],
          "confidence": 0.9934097528457642
        },
        {
          "text": "the investigation and defense of any Claim..",
          "bbox": [
            531.0,
            429.0,
            1338.0,
            466.0
          ],
          "confidence": 0.9640095233917236
        },
        {
          "text": "11.5.",
          "bbox": [
            361.0,
            477.0,
            446.0,
            524.0
          ],
          "confidence": 0.9999017715454102
        },
        {
          "text": "Section 11 shall also be reimbursed by the Indemnifying Party except as otherwise set forth in Section 11.4..",
          "bbox": [
            527.0,
            535.0,
            2509.0,
            581.0
          ],
          "confidence": 0.9810970425605774
        },
        {
          "text": "11.6.",
          "bbox": [
            356.0,
            584.0,
            447.0,
            638.0
          ],
          "confidence": 0.9999011158943176
        },
        {
          "text": "set forth below (\"Insurance'). Sekisui shall be named as an additional insured with respect to the Insurance. The Insurance shall be",
          "bbox": [
            529.0,
            651.0,
            3027.0,
            693.0
          ],
          "confidence": 0.9920510053634644
        },
        {
          "text": "primary for all purposes to other insurance coverage, whether such other insurance is stated to be primary, contributory, excess,",
          "bbox": [
            529.0,
            707.0,
            3025.0,
            749.0
          ],
          "confidence": 0.9984265565872192
        },
        {
          "text": "contingent or otherwise, without recourse to or contribution from any Sekisui-owned coverage..",
          "bbox": [
            529.0,
            762.0,
            2304.0,
            806.0
          ],
          "confidence": 0.9951342940330505
        },
        {
          "text": "a)",
          "bbox": [
            453.0,
            826.0,
            495.0,
            855.0
          ],
          "confidence": 0.7500269412994385
        },
        {
          "text": "Commercial General Liability Insurance - Combined single limit for bodily and property damage of not less than $1,ooo,o0o for each.",
          "bbox": [
            526.0,
            817.0,
            3027.0,
            863.0
          ],
          "confidence": 0.977998673915863
        },
        {
          "text": "occurrence and $2,000,000 annual aggregate providing:",
          "bbox": [
            526.0,
            873.0,
            1553.0,
            919.0
          ],
          "confidence": 0.9911948442459106
        },
        {
          "text": "Assault and Battery coverage,",
          "bbox": [
            643.0,
            926.0,
            1213.0,
            978.0
          ],
          "confidence": 0.9728929996490479
        },
        {
          "text": "Broad form property damage coverage,",
          "bbox": [
            643.0,
            989.0,
            1369.0,
            1031.0
          ],
          "confidence": 0.9986250400543213
        },
        {
          "text": "Broad form contractual liability coverage,",
          "bbox": [
            641.0,
            1038.0,
            1412.0,
            1089.0
          ],
          "confidence": 0.9995808601379395
        },
        {
          "text": "Products and completed operations coverage, and.",
          "bbox": [
            643.0,
            1100.0,
            1582.0,
            1142.0
          ],
          "confidence": 0.989491879940033
        },
        {
          "text": "Personal and advertising injury coverage.",
          "bbox": [
            641.0,
            1151.0,
            1416.0,
            1203.0
          ],
          "confidence": 0.9957625865936279
        },
        {
          "text": "(b)  Workers' Compensation and Employer's Liability Insurance - With limits of liability for:.",
          "bbox": [
            448.0,
            1210.0,
            2168.0,
            1252.0
          ],
          "confidence": 0.9783419966697693
        },
        {
          "text": "Workers' compensation as required by statute;",
          "bbox": [
            645.0,
            1266.0,
            1523.0,
            1310.0
          ],
          "confidence": 0.9785932898521423
        },
        {
          "text": "Employer's liability for bodily injury by accident: $500,o00 each accident; bodily injury by disease: $500,o00 policy limit; and.",
          "bbox": [
            645.0,
            1323.0,
            3029.0,
            1367.0
          ],
          "confidence": 0.9904770255088806
        },
        {
          "text": "bodily injury by disease: $500,000 each employee.",
          "bbox": [
            645.0,
            1380.0,
            1573.0,
            1424.0
          ],
          "confidence": 0.9864776730537415
        },
        {
          "text": "All Qualigen's Insurance shall be placed with an insurer that (a) has an A.M. Best rating of A- or better or (b) is a qualified self-",
          "bbox": [
            535.0,
            1438.0,
            3021.0,
            1475.0
          ],
          "confidence": 0.9945136904716492
        },
        {
          "text": "insurance program that is approved by Sekisui. Qualigen shall provide Sekisui, upon request, with written evidence of the Insurance,",
          "bbox": [
            526.0,
            1491.0,
            3025.0,
            1537.0
          ],
          "confidence": 0.9933100342750549
        },
        {
          "text": "including where it is provided through qualified self-insurance. Nothing in this Section shall be deemed to limit Qualigen's",
          "bbox": [
            527.0,
            1550.0,
            3027.0,
            1592.0
          ],
          "confidence": 0.9917309880256653
        },
        {
          "text": "responsibility to the amounts stated above or to any limits of Qualigen's insurance policies.",
          "bbox": [
            527.0,
            1604.0,
            2233.0,
            1646.0
          ],
          "confidence": 0.9961390495300293
        },
        {
          "text": "12.",
          "bbox": [
            274.0,
            1656.0,
            341.0,
            1701.0
          ],
          "confidence": 0.9999504089355469
        },
        {
          "text": "Regulatory Matters",
          "bbox": [
            446.0,
            1661.0,
            823.0,
            1701.0
          ],
          "confidence": 0.9998922348022461
        },
        {
          "text": "12.1.",
          "bbox": [
            364.0,
            1714.0,
            450.0,
            1756.0
          ],
          "confidence": 0.9998953938484192
        },
        {
          "text": "Regulatory Approval. Qualigen shall be responsible for maintaining, at its sole cost, the Regulatory Approvals required for the",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9864863157272339
        },
        {
          "text": "marketing and sale of the Products in the Applicable Markets. Qualigen shall hold in its name all Regulatory Approvals required for.",
          "bbox": [
            527.0,
            1769.0,
            3029.0,
            1816.0
          ],
          "confidence": 0.9870142936706543
        },
        {
          "text": "good standing all existing Regulatory Approvals. Qualigen and Sekisui shall provide reasonable advice and assistance to each other.",
          "bbox": [
            529.0,
            1882.0,
            3029.0,
            1932.0
          ],
          "confidence": 0.9919559359550476
        },
        {
          "text": "as may be necessary to maintain required Regulatory Approvals. In addition, Qualigen shall use commercially reasonable efforts to",
          "bbox": [
            529.0,
            1942.0,
            3025.0,
            1983.0
          ],
          "confidence": 0.9951932430267334
        },
        {
          "text": "obtain Regulatory Approval for any additional territories upon Sekisui's commercially reasonable request..",
          "bbox": [
            531.0,
            1999.0,
            2499.0,
            2041.0
          ],
          "confidence": 0.9896303415298462
        },
        {
          "text": "18",
          "bbox": [
            1629.0,
            2048.0,
            1680.0,
            2096.0
          ],
          "confidence": 0.999865710735321
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9939543604850769
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Insurance_6",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Qualigen, at its own expense, shall procure and maintain during the Term, insurance policies with the minimum coverages set forth below (\"Insurance\").",
      "page_number": 6,
      "words": [
        {
          "text": "4.4.",
          "bbox": [
            359.0,
            254.0,
            428.0,
            298.0
          ],
          "confidence": 0.9998838901519775
        },
        {
          "text": "Sales Expense; Business Plan. For the avoidance of doubt, Sekisui shall be responsible for all sales and related sales expense except",
          "bbox": [
            531.0,
            254.0,
            3029.0,
            300.0
          ],
          "confidence": 0.9895469546318054
        },
        {
          "text": "for Qualigen Retained Customers. The Business Plan sets forth Sekisui's plans for the sale and distribution of the Products, including",
          "bbox": [
            529.0,
            312.0,
            3029.0,
            358.0
          ],
          "confidence": 0.9996442794799805
        },
        {
          "text": "target budget and resource allocations for the marketing and sales of the Products and estimated forecasts of sales to customers.",
          "bbox": [
            531.0,
            371.0,
            3025.0,
            413.0
          ],
          "confidence": 0.9952583909034729
        },
        {
          "text": "Sekisui shall in good faith use commercially reasonable efforts, in conformance with good commercial practice and standards,",
          "bbox": [
            527.0,
            424.0,
            3025.0,
            468.0
          ],
          "confidence": 0.9957903027534485
        },
        {
          "text": "government regulations and other applicable requirements, to promote, market and sell the Products, to execute the Business Plan and.",
          "bbox": [
            527.0,
            477.0,
            3031.0,
            528.0
          ],
          "confidence": 0.9963300824165344
        },
        {
          "text": "to achieve its objectives. Except as set forth in Section 3.2, such forecasts and budgets are intended for guidance purposes only and",
          "bbox": [
            527.0,
            539.0,
            3029.0,
            581.0
          ],
          "confidence": 0.9968500137329102
        },
        {
          "text": "are not binding obligations. Sekisui shall be responsible for bad debt (customer nonpayment) and credit card merchant fees and",
          "bbox": [
            526.0,
            592.0,
            3029.0,
            638.0
          ],
          "confidence": 0.9950969815254211
        },
        {
          "text": "expenses.",
          "bbox": [
            529.0,
            652.0,
            713.0,
            695.0
          ],
          "confidence": 0.9930500388145447
        },
        {
          "text": "4.5.",
          "bbox": [
            359.0,
            704.0,
            430.0,
            747.0
          ],
          "confidence": 0.9999474287033081
        },
        {
          "text": "Financing Payments; Development Plan. In addition to the payments for the purchase of Products set forth in Section 4.1 above, in",
          "bbox": [
            529.0,
            709.0,
            3025.0,
            746.0
          ],
          "confidence": 0.9943293929100037
        },
        {
          "text": "connection with this Agreement and in furtherance of the Development Plan, Sekisui shall provide to Qualigen up to $6,200,o00 of",
          "bbox": [
            531.0,
            762.0,
            3032.0,
            804.0
          ],
          "confidence": 0.9927346706390381
        },
        {
          "text": "financing in accordance with the timing and other provisions of the Development Plan and the achievement of the applicable",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            861.0
          ],
          "confidence": 0.99497389793396
        },
        {
          "text": "milestones set forth therein (the \"Financing Payments'). All such Financing Payments shall be used in accordance with the",
          "bbox": [
            529.0,
            875.0,
            3029.0,
            917.0
          ],
          "confidence": 0.9900002479553223
        },
        {
          "text": "Development Plan and shall be non-refundable once paid, other than as set off in connection with a Sale Transaction as further",
          "bbox": [
            531.0,
            934.0,
            3027.0,
            970.0
          ],
          "confidence": 0.9940288662910461
        },
        {
          "text": "described below. Time is of the essence for the payment by Sekisui of the resulting Financing Payments upon confirmation of.",
          "bbox": [
            529.0,
            987.0,
            3034.0,
            1031.0
          ],
          "confidence": 0.9924401640892029
        },
        {
          "text": "achievement by Qualigen of the respective Development Plan milestones as set forth in Section 6.2 and the Development Plan.",
          "bbox": [
            529.0,
            1043.0,
            2878.0,
            1085.0
          ],
          "confidence": 0.9938642382621765
        },
        {
          "text": "4.6.",
          "bbox": [
            359.0,
            1096.0,
            428.0,
            1140.0
          ],
          "confidence": 0.9985026121139526
        },
        {
          "text": "Personnel Matters. Sekisui shall offer employment to four Qualigen sales representatives to become employees of Sekisui with",
          "bbox": [
            527.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.9925117492675781
        },
        {
          "text": "primary responsibility for the sale of the Products, and Qualigen hereby consents to and permits such employment. Such offers of",
          "bbox": [
            526.0,
            1151.0,
            3034.0,
            1202.0
          ],
          "confidence": 0.9893380403518677
        },
        {
          "text": "employment are subject to Sekisui's employment policies, including the successful completion of customary background checks, and",
          "bbox": [
            529.0,
            1210.0,
            3029.0,
            1255.0
          ],
          "confidence": 0.998411238193512
        },
        {
          "text": "are not a guarantee of ongoing employment. Upon the expiration or termination of the Term (other than in connection with a Sale",
          "bbox": [
            526.0,
            1266.0,
            3029.0,
            1312.0
          ],
          "confidence": 0.9887347221374512
        },
        {
          "text": "Transaction in which Sekisui acquires Qualigen), Sekisui shall cooperate in permitting Qualigen to offer to rehire any Sekisui sales",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9966340661048889
        },
        {
          "text": "representatives who are primarily responsible for selling the Products. A sales person \"primarily responsible for selling the Products\"",
          "bbox": [
            526.0,
            1378.0,
            3027.0,
            1422.0
          ],
          "confidence": 0.9928828477859497
        },
        {
          "text": "is one that spends more than half of his or her time and receives more than half of his or her commission based compensation based",
          "bbox": [
            527.0,
            1436.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9927029013633728
        },
        {
          "text": "on sales of the Products.",
          "bbox": [
            529.0,
            1491.0,
            991.0,
            1533.0
          ],
          "confidence": 0.9974746704101562
        },
        {
          "text": "4.7.",
          "bbox": [
            356.0,
            1542.0,
            430.0,
            1592.0
          ],
          "confidence": 0.9998869895935059
        },
        {
          "text": "Invoice Terms. Sekisui shall pay for each Product sold by Qualigen within 30 days after Sekisui has received the applicable invoice",
          "bbox": [
            527.0,
            1548.0,
            3027.0,
            1590.0
          ],
          "confidence": 0.9901339411735535
        },
        {
          "text": "from Qualigen.",
          "bbox": [
            527.0,
            1606.0,
            801.0,
            1645.0
          ],
          "confidence": 0.9993689656257629
        },
        {
          "text": "4.8.",
          "bbox": [
            359.0,
            1657.0,
            430.0,
            1705.0
          ],
          "confidence": 0.9626007080078125
        },
        {
          "text": "Marketing Claims. Sekisui covenants to Qualigen that Sekisui will not make any written or oral representation or marketing claim",
          "bbox": [
            529.0,
            1661.0,
            3025.0,
            1701.0
          ],
          "confidence": 0.9921669960021973
        },
        {
          "text": "(either formal or informal) about any Product's capabilities or characteristics other than those representations and claims that are fully",
          "bbox": [
            531.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9922473430633545
        },
        {
          "text": "and directly supported by factual materials provided by Qualigen to Sekisui. Sekisui shall not make any false or misleading",
          "bbox": [
            529.0,
            1773.0,
            3029.0,
            1816.0
          ],
          "confidence": 0.9965982437133789
        },
        {
          "text": "representations to customers or others regarding Qualigen or the Products. Sekisui shall not make any representations, warranties or",
          "bbox": [
            527.0,
            1831.0,
            3030.0,
            1873.0
          ],
          "confidence": 0.9925045967102051
        },
        {
          "text": "guarantees with respect to the specifications, features or capabilities of the Products that are not contained within Qualigen's",
          "bbox": [
            527.0,
            1882.0,
            3027.0,
            1932.0
          ],
          "confidence": 0.9993694424629211
        },
        {
          "text": "documentation accompanying the Products or Qualigen's literature describing the Products, including Qualigen's standard limited",
          "bbox": [
            529.0,
            1942.0,
            3029.0,
            1986.0
          ],
          "confidence": 0.9991266131401062
        },
        {
          "text": "warranty and disclaimers.",
          "bbox": [
            531.0,
            1999.0,
            1001.0,
            2039.0
          ],
          "confidence": 0.9992899298667908
        },
        {
          "text": "7",
          "bbox": [
            1638.0,
            2054.0,
            1669.0,
            2090.0
          ],
          "confidence": 0.998302698135376
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938657283782959
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Covenant Not To Sue_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "During and after the Term, neither Party shall register, use or claim ownership or other rights in any logo, trade name, brand name or trademark of the other Party in existence during the Term (nor any logo, trade name, brand name or trademark confusingly similar to any logo, trade name, brand name or trademark of the other Party in existence during the Term), nor assist anyone else to do so, nor make or assist in any challenge to any logo, trade name, brand name or trademark of the other Party in existence during the Term.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.54",
          "bbox": [
            2775.0,
            285.0,
            3029.0,
            322.0
          ],
          "confidence": 0.9907796382904053
        },
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ],
          "confidence": 0.9993387460708618
        },
        {
          "text": "This Distribution and Development Agreement (this \"Agreement') is made and entered into as of May 1, 2016 by and between Sekisui",
          "bbox": [
            446.0,
            397.0,
            3029.0,
            440.0
          ],
          "confidence": 0.9882326722145081
        },
        {
          "text": "Diagnostics, LLC and its Affiliates, a Delaware limited liability company with principal offices at 4 Hartwell Place, Lexington, Massachusetts 02421",
          "bbox": [
            277.0,
            451.0,
            3023.0,
            497.0
          ],
          "confidence": 0.9923726916313171
        },
        {
          "text": "(\"Sekisui'), and Qualigen, Inc. and its Affiliates, a Delaware corporation with principal offices at 2042 Corte Del Nogal, Carlsbad, California 92011",
          "bbox": [
            281.0,
            510.0,
            3025.0,
            552.0
          ],
          "confidence": 0.9927595257759094
        },
        {
          "text": "(\"Qualigen'' and together with Sekisui, each a \"Party\"' and together the \"Parties\").",
          "bbox": [
            281.0,
            566.0,
            1798.0,
            609.0
          ],
          "confidence": 0.9820629954338074
        },
        {
          "text": "WHEREAS, Qualigen is engaged in the manufacture, supply and development of certain clinical rapid diagnostic test devices and",
          "bbox": [
            446.0,
            621.0,
            3029.0,
            665.0
          ],
          "confidence": 0.995762825012207
        },
        {
          "text": "controls; and",
          "bbox": [
            279.0,
            680.0,
            527.0,
            718.0
          ],
          "confidence": 0.9980675578117371
        },
        {
          "text": "WHEREAS, Qualigen wishes to appoint Sekisui as its exclusive distributor for such products in the Territory (as defined below); and",
          "bbox": [
            446.0,
            731.0,
            2915.0,
            777.0
          ],
          "confidence": 0.9991511106491089
        },
        {
          "text": "WHEREAS, Sekisui wishes to be appointed as the exclusive distributor of such products and to fund the development of certain future",
          "bbox": [
            446.0,
            788.0,
            3027.0,
            833.0
          ],
          "confidence": 0.9955896139144897
        },
        {
          "text": "products.",
          "bbox": [
            279.0,
            850.0,
            453.0,
            888.0
          ],
          "confidence": 0.9996678829193115
        },
        {
          "text": "NOw, THEREFORE, in consideration of the mutual covenants hereinafter contained, the parties hereto agree as follows:",
          "bbox": [
            442.0,
            903.0,
            2679.0,
            945.0
          ],
          "confidence": 0.9935966730117798
        },
        {
          "text": "1.",
          "bbox": [
            274.0,
            956.0,
            319.0,
            1000.0
          ],
          "confidence": 0.7900614142417908
        },
        {
          "text": "Definitions",
          "bbox": [
            444.0,
            957.0,
            660.0,
            1000.0
          ],
          "confidence": 0.9999024868011475
        },
        {
          "text": "1.1.",
          "bbox": [
            359.0,
            1012.0,
            430.0,
            1056.0
          ],
          "confidence": 0.9995684623718262
        },
        {
          "text": "Adverse Event shall mean an incident in which the Product was alleged to have caused or contributed to the death or serious injury",
          "bbox": [
            531.0,
            1012.0,
            3025.0,
            1060.0
          ],
          "confidence": 0.994376540184021
        },
        {
          "text": "of a patient or operator and would require submitting a Medical Devices Report to the FDA (as hereinafter defined) as per 21 CFR 803,",
          "bbox": [
            529.0,
            1073.0,
            3025.0,
            1115.0
          ],
          "confidence": 0.9922464489936829
        },
        {
          "text": "or a similar report to a Competent Authority (as hereinafter defined) as per Vigilance Guidance MEDDEV 2.12-1.",
          "bbox": [
            529.0,
            1126.0,
            2594.0,
            1170.0
          ],
          "confidence": 0.991019606590271
        },
        {
          "text": "1.2.",
          "bbox": [
            357.0,
            1177.0,
            431.0,
            1226.0
          ],
          "confidence": 0.9998720288276672
        },
        {
          "text": "Affiliate shall mean, (i) with respect to Qualigen, any corporation or other form of business organization, which directly or indirectly",
          "bbox": [
            531.0,
            1184.0,
            3023.0,
            1228.0
          ],
          "confidence": 0.9940222501754761
        },
        {
          "text": "owns, controls, is controlled by, or is under common control with Qualigen, and (ii), with respect to Sekisui, shall mean Sekisui",
          "bbox": [
            529.0,
            1243.0,
            3027.0,
            1279.0
          ],
          "confidence": 0.9940464496612549
        },
        {
          "text": "Diagnostics (UK) Ltd., Sekisui Diagnostics PEI, Inc., SEKISUI MEDICAL CO., LTD., and Sekisui Diagnostics GmbH. An entity shall",
          "bbox": [
            527.0,
            1296.0,
            3029.0,
            1338.0
          ],
          "confidence": 0.9943324327468872
        },
        {
          "text": "be regarded as being in control of another entity if the former entity has the direct or indirect power to vote more than fifty percent",
          "bbox": [
            527.0,
            1350.0,
            3029.0,
            1396.0
          ],
          "confidence": 0.988784670829773
        },
        {
          "text": "(50%) of the outstanding voting securities (or other ownership interest for a business organization other than a corporation) of that",
          "bbox": [
            531.0,
            1407.0,
            3029.0,
            1449.0
          ],
          "confidence": 0.9877817034721375
        },
        {
          "text": "entity, or the direct or indirect ability to direct or cause the direction of the general management and policies of the other entity.",
          "bbox": [
            531.0,
            1466.0,
            2886.0,
            1508.0
          ],
          "confidence": 0.9933804273605347
        },
        {
          "text": "1.3.",
          "bbox": [
            359.0,
            1517.0,
            428.0,
            1561.0
          ],
          "confidence": 0.9999538064002991
        },
        {
          "text": "Applicable Markets shall mean the United States, Canada, the European Union, Japan and other additional geographies that are",
          "bbox": [
            533.0,
            1520.0,
            3027.0,
            1562.0
          ],
          "confidence": 0.9970231056213379
        },
        {
          "text": "added from time to time at the request of Sekisui, but only to the extent that it is commercially reasonable for Qualigen to expand to",
          "bbox": [
            529.0,
            1577.0,
            3025.0,
            1619.0
          ],
          "confidence": 0.9942214488983154
        },
        {
          "text": "such additional geographies.",
          "bbox": [
            529.0,
            1634.0,
            1068.0,
            1676.0
          ],
          "confidence": 0.9972877502441406
        },
        {
          "text": "1.4.",
          "bbox": [
            357.0,
            1685.0,
            428.0,
            1729.0
          ],
          "confidence": 0.9999471306800842
        },
        {
          "text": "Available Margin is defined on Exhibit A.",
          "bbox": [
            536.0,
            1694.0,
            1289.0,
            1725.0
          ],
          "confidence": 0.9849425554275513
        },
        {
          "text": "1.5.",
          "bbox": [
            359.0,
            1741.0,
            430.0,
            1785.0
          ],
          "confidence": 0.9999499320983887
        },
        {
          "text": "Business Plan shall mean the business plan attached as Exhibit B hereto, which business plan may be amended from time to time by",
          "bbox": [
            527.0,
            1741.0,
            3025.0,
            1787.0
          ],
          "confidence": 0.993672788143158
        },
        {
          "text": "mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            1802.0,
            1320.0,
            1842.0
          ],
          "confidence": 0.9912546873092651
        },
        {
          "text": "1.6.",
          "bbox": [
            357.0,
            1855.0,
            428.0,
            1899.0
          ],
          "confidence": 0.9683603048324585
        },
        {
          "text": "COGS is defined on Exhibit A..",
          "bbox": [
            531.0,
            1857.0,
            1084.0,
            1897.0
          ],
          "confidence": 0.9848209619522095
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938068389892578
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTION AND DEVELOPMENT AGREEMENT",
          "page": 0,
          "bbox": [
            1138.0,
            342.0,
            2170.0,
            378.0
          ]
        }
      ]
    },
    {
      "id": "RitterPharmaceuticalsInc_20200313_S-4A_EX-10.54_12055220_EX-10.54_Development Agreement__Covenant Not To Sue_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "During and after the Term, neither Party shall register, use or claim ownership or other rights in any logo, trade name, brand name or trademark of the other Party in existence during the Term (nor any logo, trade name, brand name or trademark confusingly similar to any logo, trade name, brand name or trademark of the other Party in existence during the Term), nor assist anyone else to do so, nor make or assist in any challenge to any logo, trade name, brand name or trademark of the other Party in existence during the Term.",
      "page_number": 1,
      "words": [
        {
          "text": "1.7.",
          "bbox": [
            357.0,
            252.0,
            431.0,
            302.0
          ],
          "confidence": 0.9999446272850037
        },
        {
          "text": "Competent Authority shall mean the governmental authority in a member state of the European Union which has competence in.",
          "bbox": [
            533.0,
            259.0,
            3025.0,
            296.0
          ],
          "confidence": 0.9858279228210449
        },
        {
          "text": "relation to the Products.",
          "bbox": [
            529.0,
            316.0,
            975.0,
            353.0
          ],
          "confidence": 0.9976170063018799
        },
        {
          "text": "1.8.",
          "bbox": [
            359.0,
            367.0,
            428.0,
            411.0
          ],
          "confidence": 0.9999740123748779
        },
        {
          "text": "Development Plan shall mean the development plan attached as Exhibit C hereto, which development plan may be amended from time",
          "bbox": [
            531.0,
            373.0,
            3025.0,
            409.0
          ],
          "confidence": 0.9967420697212219
        },
        {
          "text": "to time by mutual agreement of Qualigen and Sekisui..",
          "bbox": [
            529.0,
            424.0,
            1515.0,
            468.0
          ],
          "confidence": 0.9820897579193115
        },
        {
          "text": "1.9.",
          "bbox": [
            359.0,
            479.0,
            428.0,
            523.0
          ],
          "confidence": 0.9999629259109497
        },
        {
          "text": "Effective Date shall mean May 1, 2016.",
          "bbox": [
            531.0,
            484.0,
            1243.0,
            521.0
          ],
          "confidence": 0.9914774894714355
        },
        {
          "text": "1.10.",
          "bbox": [
            357.0,
            534.0,
            450.0,
            581.0
          ],
          "confidence": 0.999906063079834
        },
        {
          "text": "European Union shall mean the countries in Europe that are under the CE mark regulatory regime",
          "bbox": [
            527.0,
            535.0,
            2329.0,
            581.0
          ],
          "confidence": 0.9942074418067932
        },
        {
          "text": "1.11.",
          "bbox": [
            361.0,
            592.0,
            446.0,
            634.0
          ],
          "confidence": 0.9997264742851257
        },
        {
          "text": "Exclusivity Period shall mean the period from the Effective Date until December 31, 2018.",
          "bbox": [
            529.0,
            594.0,
            2166.0,
            636.0
          ],
          "confidence": 0.9869322180747986
        },
        {
          "text": "1.12.",
          "bbox": [
            361.0,
            649.0,
            448.0,
            691.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "FDA shall mean the U.S. Food and Drug Administration or any successor agency.",
          "bbox": [
            527.0,
            647.0,
            2052.0,
            694.0
          ],
          "confidence": 0.9935176968574524
        },
        {
          "text": "1.13.",
          "bbox": [
            361.0,
            704.0,
            448.0,
            746.0
          ],
          "confidence": 0.9996975660324097
        },
        {
          "text": "Health Canada shall mean the department of the government of Canada with responsibility for national public health",
          "bbox": [
            529.0,
            704.0,
            2695.0,
            747.0
          ],
          "confidence": 0.9990750551223755
        },
        {
          "text": "1.14.",
          "bbox": [
            361.0,
            760.0,
            448.0,
            802.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "Intellectual Property Rights means all intellectual property rights in any jurisdiction worldwide, including, without limitation: (a) Patent",
          "bbox": [
            527.0,
            760.0,
            3029.0,
            806.0
          ],
          "confidence": 0.99346923828125
        },
        {
          "text": "Rights; (b) rights associated with works of authorship including copyrights, copyright applications, and copyright registrations; (c)",
          "bbox": [
            529.0,
            819.0,
            3027.0,
            863.0
          ],
          "confidence": 0.9908768534660339
        },
        {
          "text": "rights relating to the protection of trade secrets, know-how or confidential information; and (d) rights in any trade names, trademarks,",
          "bbox": [
            529.0,
            875.0,
            3025.0,
            917.0
          ],
          "confidence": 0.9968334436416626
        },
        {
          "text": "service marks, domain names, logos, trade dress and brand features.",
          "bbox": [
            531.0,
            934.0,
            1794.0,
            970.0
          ],
          "confidence": 0.9873893857002258
        },
        {
          "text": "1.15.",
          "bbox": [
            357.0,
            981.0,
            450.0,
            1029.0
          ],
          "confidence": 0.9999510049819946
        },
        {
          "text": "Net Revenue is defined on Exhibit A.",
          "bbox": [
            531.0,
            989.0,
            1214.0,
            1025.0
          ],
          "confidence": 0.9963054656982422
        },
        {
          "text": "1.16.",
          "bbox": [
            361.0,
            1042.0,
            450.0,
            1084.0
          ],
          "confidence": 0.9996989369392395
        },
        {
          "text": "Patent Rights means all patents, patent applications and inventions on which patent applications are filed and all patents issuing",
          "bbox": [
            526.0,
            1036.0,
            3029.0,
            1091.0
          ],
          "confidence": 0.982984721660614
        },
        {
          "text": "therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations, divisionals, continuations-",
          "bbox": [
            529.0,
            1100.0,
            3027.0,
            1142.0
          ],
          "confidence": 0.995895504951477
        },
        {
          "text": "in-part, re-examination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable",
          "bbox": [
            529.0,
            1157.0,
            3027.0,
            1199.0
          ],
          "confidence": 0.9949788451194763
        },
        {
          "text": "patent law or other law), provisional rights and certificates of inventions..",
          "bbox": [
            527.0,
            1210.0,
            1885.0,
            1255.0
          ],
          "confidence": 0.9974363446235657
        },
        {
          "text": "1.17.",
          "bbox": [
            359.0,
            1263.0,
            451.0,
            1310.0
          ],
          "confidence": 0.9312731027603149
        },
        {
          "text": "Potentially Serious Complaint shall mean any information coming to the notice of Qualigen or Sekisui which might relate to a Serious",
          "bbox": [
            529.0,
            1268.0,
            3027.0,
            1310.0
          ],
          "confidence": 0.9972066879272461
        },
        {
          "text": "Incident (as hereinafter defined), or to a significant lapse in the quality of the Products, or might lead to significant adverse public or",
          "bbox": [
            529.0,
            1325.0,
            3027.0,
            1367.0
          ],
          "confidence": 0.9978949427604675
        },
        {
          "text": "media comment, or otherwise significantly, adversely affect the reputation or business of Sekisui or Qualigen.",
          "bbox": [
            529.0,
            1380.0,
            2561.0,
            1422.0
          ],
          "confidence": 0.9933378100395203
        },
        {
          "text": "1.18.",
          "bbox": [
            357.0,
            1431.0,
            450.0,
            1478.0
          ],
          "confidence": 0.9999502301216125
        },
        {
          "text": "Products shall mean all of Qualigen's current and future products, including without limitation those listed on Exhibit D, for sale under",
          "bbox": [
            529.0,
            1434.0,
            3029.0,
            1478.0
          ],
          "confidence": 0.9926795959472656
        },
        {
          "text": "the trade names listed with such products, including any improvements thereto.",
          "bbox": [
            529.0,
            1491.0,
            2014.0,
            1533.0
          ],
          "confidence": 0.9983309507369995
        },
        {
          "text": "1.19.",
          "bbox": [
            357.0,
            1542.0,
            448.0,
            1590.0
          ],
          "confidence": 0.9832305908203125
        },
        {
          "text": "Qualigen Retained Customers shall mean certain of Qualigen's existing direct sales customers, all as listed on Exhibit E.",
          "bbox": [
            529.0,
            1548.0,
            2733.0,
            1590.0
          ],
          "confidence": 0.9966022968292236
        },
        {
          "text": "1.20.",
          "bbox": [
            361.0,
            1603.0,
            450.0,
            1645.0
          ],
          "confidence": 0.9994433522224426
        },
        {
          "text": "Regulatory Approval shall mean the approval of the applicable Regulatory Authority required for the promotion, marketing.",
          "bbox": [
            527.0,
            1603.0,
            3021.0,
            1648.0
          ],
          "confidence": 0.9971389770507812
        },
        {
          "text": "distribution and/or sale of the Products in any territory in which they are being sold, including any Product registration or license, and",
          "bbox": [
            531.0,
            1659.0,
            3027.0,
            1703.0
          ],
          "confidence": 0.9954867362976074
        },
        {
          "text": "any supplement, amendment or variation thereto, required before the commencement of commercial sales of the Products in such",
          "bbox": [
            529.0,
            1718.0,
            3027.0,
            1760.0
          ],
          "confidence": 0.9954943656921387
        },
        {
          "text": "territory, and export and import approvals for the Products..",
          "bbox": [
            529.0,
            1773.0,
            1622.0,
            1813.0
          ],
          "confidence": 0.9963735342025757
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            1829.0,
            1669.0,
            1869.0
          ],
          "confidence": 0.9996826648712158
        },
        {
          "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
          "bbox": [
            332.0,
            4437.0,
            1504.0,
            4479.0
          ],
          "confidence": 0.9938833713531494
        }
      ],
      "multi_page": true,
      "part_of": 2
    }
  ]
}